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Nephrotoxicity is a serious side effect of many drugs due to the kidney being one of the major 
sites for their excretion. In vitro models of nephrotoxicity are therefore paramount in drug 
development process, which would be used to detect early stages of drug-induced toxicity. 
Most current proximal tubule models have their limitation, not only due to the lack of 
expression of some of the major drugs transporters, but also the lack of species-specific 
properties. This study investigates the use of human and rat primary proximal tubule cells as 
in vitro models of nephrotoxicity.   
Human and rat proximal tubule cells (PTCs) were isolated and cultured from cortical tissues of 
the kidney. The cells form highly polarised monolayers that were exposed to polymyxin B, 
gentamicin and cisplatin – all well-known nephrotoxins. Cell viability and LDH-based cell death 
were measured, alongside the production of renal toxicity biomarkers, KIM-1, NGAL and 
clusterin.  
As expected, cell viability of the monolayers after polymyxin B, gentamicin and cisplatin 
challenge deceased. The proportion of cells alive was dependent on the concentration and 
period of exposure of the nephrotoxin. For example, the cell viability of rat PTCs treated with 
gentamicin for 48h decreased by 41% than control cells (P < 0.01). Similarly, human PTCs 
treated with cisplatin showed a significant decrease (39%, P < 0.01) in cell viability when 
compared with non-treated cells. This relationship was also observed in LDH-based cell 
viability. Higher levels of KIM-1, NGAL and clusterin secretion were detected when human and 
rat PTCs were treated with nephrotoxins. All three biomarkers were predominately secreted 
across the apical membrane of the PTCs monolayers. For instance, KIM-1 level across the apical 
membrane was 5.25±1.01 ng/ml after polymyxin B treatment for just 24h, which was 
significantly higher than across the basolateral membrane at 0.81±0.31 ng/ml. The levels of 
biomarkers secretion were also found to be dependent on concentrations of nephrotoxin and 
period of exposure. For example, rat PTCs treated with 250 µg/ml polymyxin B for 24h 
produced 9.8±1.2 ng/ml of KIM-1, which increased to 25.8±2.5 ng/ml with 48h challenge, an 
increase of more than 2-fold (P <0.01).  
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The mechanisms of toxicity were also investigated by pre-treating the PTCs with supposedly 
nephron-protectant, rosuvastatin, cilastatin and cimetidine, prior to nephrotoxin exposure. 
While 50 µM rosuvastatin did not change the cell viability nor KIM-1 expression levels in human 
and rat PTCs, the pre-treatment of rosuvastatin with polymyxin B increased cell viability by 15 
% when compared to polymyxin-B only treatment. Similarly rat PTCs treated with 250 µg/ml 
gentamicin and 40 µM cilastatin for 48h showed KIM-1 at levels of 28.8±0.27 ng/ml, compared 
with 28.7±0.5 ng/ml in cells treated with only gentamicin, giving a decrease of 29 % (P < 0.001). 
Another instance showed human PTCs treated with 250 µg/ml polymyxin B and 50 µM 
rosuvastatin for 24h produced clusterin at significantly lower level than cells treated with 
polymyxin B alone (42.3±12.2 ng/ml and 95.6±18.1 ng/ml, P < 0.001, respectively). These data 
suggest mechanisms of the aminoglycoside uptake could be via megalin/cubilin receptors, 
which were inhibited by rosuvastatin and cilastatin.  
Another goal of this project was to investigate the influence of cisplatin treatment on p53, 
caspase 3, caspase 8 and caspase 9 in human and rat PTCs. These factors are important in the 
induction of apoptosis and would provide mechanistic data of nephrotoxicity. The activity and 
mRNA levels of the caspases in PTCs were increased after cisplatin treatment. For example, 
human PTCs treated with cisplatin, mRNA level of caspase 3 appeared to be increased 
significantly (P< 0.01) with the treatment of cisplatin (3.51±0.34%) compared to control. The 
co-treatment of cimetidine with cisplatin did decrease caspase 3 mRNA levels significantly to 
(2.45±0.32, P< 0.05) when compared only cisplatin treatment. These data revealed the 
mechanism of how cisplatin may cause nephtoxocitiy in these PTCs.  
Taken together, these data show the utility of human and rat PTCs as in vitro models for the 
study of nephrotoxicity, and their potential in elucidating the mechanisms of action of 
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1.1 The kidney 
The kidney is an organ that carries out several important functions, such as the clearance of 
metabolites and drugs. A pair is located towards the back of the abdomen of many mammals 
and the tissue can be divided into three regions; the cortex, the medulla, and the renal pelvis. 
The anatomy of a human kidney can be seen in Figure 1.1. The functional unit of the kidney is 
the nephron [1], each beginning with the glomerulus, which carries out the infiltration of the 
blood [2], and continues as tubule where reabsorption and active secretion occurs. The tubules 
of the nephron and their contents then open up to the bladder via the collecting duct, where 
waste product is stored temporally before expelled [3].  
The importance of the kidney in drug clearance is illustrated in a study which identified that, 
out of a sample of 330 clinically relevant drug molecules, around 30 % undergo renal clearance 
[4]. With such high proportion of drugs cleared by the kidneys, and the increase in use of 
prescription drugs, it is not surprising that the incidence of chronic and acute kidney injury are 
spiking [5, 6].  
The process of renal clearance is a result of three mechanisms: glomerular filtration, tubular 
secretion and tubular reabsorption. Filtration is the movement of fluid from blood into the 
lumen of the nephron. Reabsorption is the process of moving substances in the filtrate from 
lumen of the tubule back into the blood. Secretion removes selected molecules from the bold 
and adds them to the filtrate in the tubule lumen [7]. Secretion is a more selective process that 
usually uses membrane proteins to move molecules across the tubule epithelium. It is 
considered a two-step process consisting of uptake of the molecule across the basolateral 
membrane into the cell followed by exit across the apical membrane [8]. This uptake process 
is often mediated by the solute carrier (SLC) transporter superfamily, of which members 
include organic cation transporters (OCT) and organic cation transporters (OAT). The efflux of 
molecules across the apical membrane of proximal tubule cells is typically mediated by the ATP 
binding cassette (ABC) superfamily of transporters, such as breast cancer resistance protein 
(BCRP), multidrug resistance protein 1 (MDR1), and multidrug-resistance associated protein, 
although SLC transporters may also be involved.  
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These transporters undoubtedly play an important role in the clearance of drugs. However, 
they also contribute to the accumulation of the drugs in the proximal tubule, which can lead 
to nephrotoxicity [9, 10]. Indeed, approximately 20% of nephrotoxicity incident is induced by 
drugs, and some potent medicine such as those used in chemotherapy or cancer treatment 




Figure 1.1: Anatomy of the human kidney. 
On the surface of a bisected human kidney the cortex and medulla are distinct. The pyramids' 
apexes have little openings leading into the calyzes of the renal pelvis which drains the urine 
that is produced through the ureter into the bladder. For rat, only single renal pyramids are 
found in the medulla of their kidneys.   
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1.2 Drug transporters 
The renal proximal tubule plays a vital role in the excretion of a wide range of xenobiotics and 
endogenous metabolites. Tubular secretion can be regarded as a two-stage process consisting 
of xenobiotic absorption across the basolateral membrane into the cell followed by exit across 
the apical membrane[13]. The uptake of molecules from circulation across the basolateral 
membranes of proximal tubular cells is often mediated by the members of the solute carrier 
(SLC) superfamily, whereas the efflux of molecules across proximal tubule cells apical 
membrane is typically mediated by both ABC and SLC transporters. A summary of most of the 
characterised transporters of human and rat PTCs are shown in Figure 1.2 and Figure 1.3. 
1.2.1 MATE  
Multidrug and MATE proteins are widely distributed across mammalian tissues[14]. Bacterial 
MATE transporters were well known as cationic / H+ or Na+ exchangers, but mammalian MATE 
proteins were only described in recent years [15]. There are two highly expressed MATE 
proteins found in the human kidneys–MATE1 and MATE2-K [14, 16]. MATE2-K is an isoform of 
MATE2 that is unique to the human kidney. Another MATE2 isoform is found in the brain 
exclusively and is referred to as MATE2-B[16] . In rat tissues, rat Mate1 is also abundantly 
expressed, but curiously not in the liver [17, 18]. There is also no Mate2 mRNA detected while 
rat Mate1 is found in the kidney[19]. Human MATE1, MATE2-K and rat Mate1 are located on 
the apical membrane of the proximal tubular cells [14, 18]and are therefore considered to be 
significant toxicity barriers. Human MATE1 and MATE2-K, and rat Mate1 are H+-coupled 
organic cation transporters found in the proximal tubular cell apical membrane. They can 
transport a variety of organic cations and share substrate close to OCT including TEA, MPP+, 
metformin, and cimetidine [20, 21]. These also bear certain organic anions, including estrone 
sulphate [22]. 
Affinities of MATE1 and MATE2-K for cationic substrates also vary from those of OCTs. For 
example, when metformin was introduced to MDCK cells transfected with OCT2 only, 
metformin accumulation was higher when compared with OCT2 and MATE1 doubly-
transfected cells. However, metformin was not saturated in transfected cellsOCT2/MATE1 
over a variety of concentrations, indicating efflux capacity by MATE1 [23]. Cimetidine was also 
shown to be a more active metformin transport receptor by MATE1 compared with OCT2 [24]. 
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This drug interaction with cimetidine may result in metformin uptake in proximal tubular cells, 
since drug use by OCT2 inhibits MATE less efficiently than efflux throughout the apical 
membrane. Therefore, OCTs and MATE's in renal proximal tubules are believed to form organic 
cation transport systems. 
1.2.2 MRP 
The multidrug resistance-associated protein (MRP) family is another subgroup of the ABC 
family involved in substrate efflux in the proximal tubule. Members of this family include nine 
structurally-related (MRP1-9) proteins with a wide distribution [25]. Every member works as 
lipophilic anion efflux conveyor and is expressed either on the epithelial apical or basolateral 
membrane[26]. In the drug-resistant lung cancer cell line H69AR, MRP1 was first identified, 
suggesting that this carrier has a role in drug resistance in cancer cell. MRP1 was found in the 
basolateral membrane of the distal and collecting tubular cells in the mouse kidney but not in 
the proximal tubule cells [27]. Subsequently MRP2, MRP3, MRP4 and MRP5 were identified in 
several cancer cell lines and tissue samples, and many medicines including anticancer and 
antiviral agents have demonstrated as substrates of MRPs [28]. 
1.2.3 MDR1 
Another member of the ABC superfamily is the multidrug resistance protein 1 (MDR1). It 
carries a wide variety of substrates including drug molecules and, like BCRP, MDR1 expression 
in the cells gives multidrug resistance[29]. In humans, one gene encodes MDR1[30, 31], 
whereas in rats there are two gene isoforms; Mdr1a and Mdr1b[32]. Human MDR1 can be 
found in different tissues, including the kidney in the apical surface of the proximal tubular 
cells [33]. Likewise, Mdr1a and b rats are widespread in all tissues.  
1.2.4 OCT 
Transport in a kidney of the OCT family's organic cations is an important way of removing blood 
from the urine. Like several OATs, rats Oct1 and Oct2 were initially identified and cloned from 
rat kidneys prior to the identification of human versions. Human OCT1 is mainly present in 
liver, while rat Oct1 is omnipresent in both liver and kidney and low in other tissues. In the 
human kidney, another member of the transport family (OCT3). The basolateral membrane of 
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the proximal tubules is located in all three transporters[34]. OCT3 is found in the kidney of 
humans and transport cations; but its role in nephrotoxicity is still unknown[35].  
1.2.5 OAT 
The main movement for organic anions (OAs) is happening the proximal tubule, which are 
extracted from the blood and passed into the urine[36]. OAs are secreted in at least two stages 
in PTCs, namely exogenous substrates (e.g. drugs) and endogenous substrates (e.g. urate)[37]. 
A well-known group of uptake transporter is that of the organic anion transport (OAT) family, 
which is focused on basolateral membranes in human proximal tube cells, including OAT1, 
OAT2 and OAT3[38]. 
1.2.6 Megalin/Cubilin  
Megalin is a transmembrane protein of (600 kDa) from the family of low density lipoprotein 
receptors[39]. The extracellular domain of megalin consists of four clusters of repeats rich in 
cysteine, which are thought to be involved in ligand binding, and a variety of ligands have been 
identified. Megalin contains a single domain of transmembrane (23 amino acids), and the 
receptor has a cytoplasmic tail of 209 amino acids intracellular C-terminal. Megalin cytoplasmic 
domain regulates the trafficking of receptors and endocytosis [40]. Megalin is highly expressed 
on the apical membrane of PTCs. 
In particular, it is located in the brush border, endocytic vesicles, dense apical tubules and in 
lysosomes to some extent[41]. Clinical markers for the endocytic function of megalin are 
glomerular-filtered low-molecular weight proteins, such as α1-microglobulin, β2- 
macroglobulin and liver-type fatty acid binding protein[42]. Megalin also mediates the 
absorption of nephrotoxic substances by PTCs, which lead to the development of chronic 
kidney disease and acute kidney injury[43]. 
Cubilin is a large extracellular 460 kDa glycosylated protein composed of 27 C-terminal CUB 
domains (C1r/C1s complement, and bone morphogenic protein 1), which is thought to be 
responsible for ligand binding[39].The cubilin N-terminal part consists of eight repeats of the 
epidermal growth factor and a stretch of 110 amino acids. Cubilin is an extracellular protein 
and interacts for membrane localization and endocytosis with other membrane proteins[44]. 
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It is believed that the proximal tubule cubilin interacts with megalin and forms a multireceptor 





Figure 1.2: A summary of the uptake and efflux transporters expressed within human renal 




Figure 1.3: A summary of the uptake and efflux transporters expressed within rat renal 





Nephrotoxicity refers to the continuous accumulation of the toxin concentration inside the 
kidney, and as a result affects the normal functioning of the kidney renal[7]. While medications 
generate approximately 20% of nephrotoxicity, older medicine raises the incidence of 
nephrotoxicity to 66% as the average lifetime increases. It is therefore imperative noting that 
nephrotoxicity may take place as a result of various forms of drug intake as the excessive 
accumulation of drugs without creating an effective path for eliminating them may affect the 
normal functioning of the renal in one way or another. It is worth noting that nephrotoxicity is 
caused by substances known as the nephrotoxins[7]. The level of the nephrotoxicity advances 
or worsens with the stage of any form of kidney failure. General nephrotoxicity pathways 
include changes in glomerular hemodynamics, toxicity of tubular cells, inflammation, crystal 
nephropathy, rhabdomyolysis, and thrombotic microangiopathy [45]. In concentration and 
reabsorption by glomerulus, PTCs are exposed to drugs and are affected by drug Toxicity[46]. 
Drug include one of the major substances that may lead to the occurrence of the 
nephrotoxicity. For instance, heroine, as well as pamidronate are famous for leading to the 
glomerulosclerosis focal segmentation.    
1.4 Kidney biomarkers 
Due to the limitation of serum creatinine, it is important to develop and establish new 
biomarkers to detect early stages of kidney injuries. A biomarker is a characteristic that is 
measured and evaluated as an indicator of normal biological or pathogenic processes, or 
pharmacologic response. Biomarkers should show the relationship and differences between 
diseases state [10]. An example of a class of kidney injury biomarkers is the urinary enzymes. 
These enzymes are normally found in the tubular epithelial cells and released into urine during 
cellular stress, which may be an indication of nephrotoxicity. Thus, enzyme detection in the 
urine provides valuable information not only to the site of tubular injury (proximal or distal 
tubule) but also the severity of injury [45]. These enzymes include alanine aminopeptidase, 
alkaline phosphatase, α-glutathione-S-transferase, γ-glutamyl transpeptidase, π-glutathione-
S-transferase, and N-acetyl-D-glucosaminidase [12]. Alongside the enzymes, high molecular 
weight protein also can be detected in urine, which is a sign of damaged glomerulus and can 




Kidney injury molecule-1(KIM-1 also named TIM-1 and HAVCR-1) is a glycoprotein (104 kDa) 
cell membrane type I, which is highly preserved in rodents, dogs, primates and humans[47]. 
KIM-1 is also a receptor of phosphatidylserine found in renal epithelial cells, which recognizes 
apoptotic cells and enables phagocytosis to clear them[48]. In normal kidney tissue, KIM-1 is 
not detectable, but is inducible by ischemic and toxic insult[49]. KIM-1 expresses in high 
amounts in the apical membrane of surviving proximal tubule epithelial cells and is detectable 
in the urine[50]. KIM-1 mRNA is up-regulated during proximal tubular injury and the 
ectodomain of KIM-1 protein (90 kDa) is transferred from the membrane of the brush border 
into the urine[51]. Many studies have shown that patients with subclinical AKI show an 
increase in urinary KIM-1 levels depending on time. However, the clinical relevance of changes 
in subclinical AKI in KIM-1 is not entirely clear[48]. 
1.4.2 NGAL  
The NGAL gene encodes a small protein (25 kDa) linked to gelatinase from human neutrophils 
and a lipocalin superfamily member with different immunological functions[52]. It is expressed 
in inflammatory responses, but it is also expressed in different tissue epithelial cells[53]. NGAL 
was significantly induced in the mice's kidneys in a transcriptomic study to identify ischemia- 
related genes[53]. Plasma NGAL was found to be an accurate marker of AKI in human patients 
undergoing cardiac surgery[54]. Usually, urinary NGAL is expressed in low concentrations, but 
renal tubular epithelial injury induces its expression[55]. Further work has shown that NGAL is 
up- regulated and enriched in proliferating mouse proximal tubule cells after ischemia[56]. 
Recently, the secretion of NGAL protein in the urine has gained interest in the use of AKI as a 
biomarker[55]. In patients already affected by chronic nephropathies, NGAL may eventually 
have prognostic value in predicting not only acute but also chronic deterioration in renal 
function[57].  
1.4.3 Clusterin 
Clusterin is also another glycoprotein that is useful in the assessment of nephrotoxicity. 
Clusterin was first isolated from rat testes fluid by Blaschuk, Burdzy, and Fritz in 1983. It is 
found in the proximal convoluted tubule, as well as towards the end of the distal convoluted 
tubule. As such, it can be used as an important biomarker as it can be detected in the patients’ 
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urine, especially those suffering from acute injury of their kidneys. Clusterin had been 
measured using radioimmunoassay, and it’s had been correlated with the increase of serum 
creatinine in a gentamicin-induced renal injury model in rats [58], although in another study 
clusterin mRNA and protein level did not rise until day 5 of treatment with cisplatin in some 
renal models [59].  
1.4.4 Cystatin C 
Cystatin C (Cys C) is one of the all nuclear cells within the cystine proteinase inhibitor family. 
Cystatin C was proposed as an alternative filtration marker to creatinine, a small non-
glycosylated 13 kDa basic protein. All nuclear cells and proximal tubule cells secrete CysC and 
98% of this protein is absorbed by renal tubules. Cys C has been reported as an early kidney 
injury marker. Cys C has no influence on muscle mass or diet and can thus better correlate than 
creatinine to GFR measured. It is believed that Cys C is less affected by age, sex and race than 
creatinine.  
1.5 Nephrotoxins drugs  
Nephrotoxic drugs are kidney-harming compounds that could cause renal damage. In this 
study 3 nephrotoxins drugs used (gentamicin, polymyxin B and cisplatin).  
1.5.1 Cisplatin 
Cisplatin, an effective chemotherapeutic drug, used in the treatment of many solid tumors, 
such as testicular, ovaries, esophageal, head and throat, and bladder tumors[60]. Because of 
its side effects, especially nephrotoxicity, it has limited use in medical practice[61]. About 25 
% -40% of patients in clinical practice have renal dysfunction following cisplatin 
treatment[62].The mechanisms involved in cisplatin are still unclear, cellular damages, renal 
tubular cell apoptosis, vascular dysfunction, inflammatory response and oxidative damage may 
be causing them[60]. The first animal study report of nephrotoxicity in 1971 showed 
histopathological changes of acute necrosis and azotemia. In 14% to 100% of the cumulative 
doses, early clinical usage cisplatin saw dose-related acute renal failure in 14% to 100% of the 
patients[63]. Cisplatin clearance occurs primarily in the kidney through both glomerular and 
tubular filtration. Cisplatin concentration in the kidney exceeds its plasma concentration, 
indicating that the drug is accumulated in renal cells[64]. Two different transporters have been 
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identified in recent years, namely copper transporter 1 (Ctr1) and organic cation transporter 2 
(OCT2), as responsible for the active transport of cisplatin to mammalian cells[65]. 
Downregulation of Ctr1 in kidney cells attenuates the accumulation and subsequent toxicity of 
the cisplatin which indicates that Ctr1 partially at least mediates the accumulation of the 
cisplatin to the kidney cells[66]. However, it has not been studied whether Ctr1 plays a role in 
cisplatin - induced nephrotoxicity in vivo. OCT2 is mainly located in renal proximal tubular cells, 
as opposed to the universal expression of Ctr1. Initially the transport of other OCT2 substrate 
into kidney cells was suppressed by cisplatin[67]. Some OCT2 gene mutations are associated 
with a reduced risk of nephrotoxicity caused by cisplatin in patients [68]. 
1.5.2 Polymyxin B  
Polymyxin B were discovered 1950s from Paenibacillus polymyxa (Bacillus 
polymyxa), however their toxicity has restricted their use[69]. Polymyxin B was prescribed for 
life-threatening gram-negative bacterial infections on its own or in combination with other 
antimicrobials[70]. Polymyxin B is classified as an antibiotic cyclic lipopeptide and includes a 
decapeptide sequence containing a polycationic heptapeptide ring and a fatty acyl tail. 
Polymyxin B amphipathic chemistry for antibacterial activity is essential[71]. The nephrotoxic 
effects of polymyxin B include mechanisms that kill bacteria through lipid an interactions, 
disrupting the Ca2+ and Mg2 + bridges, which destabilize the molecules of lipopolysaccharide 
in the bacterial membrane[70]. The nephrotoxicity of polymyxin B therefore appears to be due 
to effects on the content of D-amino and fatty acid components that increase membrane 
permeability and cation influx[69]. Recent in vitro and in vivo studies showed at least three 
main pathways of apoptosis — mitochondrial, endoplasmic reticulum and death receptor— 
which play key roles in polymyxin B induced nephrotoxicity[72]. A study showed, 73 patients 
used polymyxin B, almost 60% developed acute renal injury (AKI). The acute tubular necrosis 
or tubular epithelial cell apoptosis has been characterized by polymyxin B nephrotoxicity[70]. 
In vitro, polymyxin B intake into proximal tubular epithelial cells was demonstrated to be 
saturable and showed a strong affinity to megalin, a low- density lipoprotein receptor, 
expressed on the proximal tubules apical membrane. Therefore, megalin is assumed to play 
an important role in the absorption of polymyxin B into renal tubular cells; the identification 
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of an effective antagonist off megalin will be a new direction in preventing polymyxin B 
nephrotoxicity [73]. 
1.5.3 Gentamicin  
Gentamicin is a widely used and highly effective antibiotic of aminoglycosides[74]. It is usually 
used to treat patients with gram-negative bacterial infections[75]. Gentamicin effectively links 
to prokaryotic ribosomes and mistranslates the inhibition of protein synthesis leading to 
bacterial death[74]. The clinical use of gentamicin is limited because of it is serious 
complications such as nephrotoxicity and ototoxicity. Gentamicin nephrotoxicity clinical 
symptoms are renal tubular injury and glomerular filtration dysfunction[76]. Approximately 
10-25% of patients with a single dose of gentamicin show signs of nephrotoxicity. Gentamicin 
causes tubular damage by necrosis of tubular epithelial cells, mainly in the proximal tubule, 
and changes in the function of the main cellular components involved in water transport and 
solutes[76]. Treatment of animals with gentamicin is associated with apoptosis and tubular 
epithelial cell necrosis. The increased accumulation of gentamicin in proximal tubules is 
associated with the expression of protein and cation (megalin and cubilin complex) transport 
molecules in apical membrane of the proximal tubules[75]. This complex is known to be 
responsible for the transportation of gentamicin by endocytosis[75]. The glomerular filtration 
actively eliminates gentamicin. Approximately 3 to 5% of the entered gentamicin is actively 
reabsorbed in proximal tubules and cause necrosis of the proximal tubules segmentS1-S2[77]. 
The accumulation of undigested phospholipids in lysosomes is closely linked to genetically 
modified nephrotoxicity. Gentamicin acts directly and indirectly on mitochondria in cytoplasm 
and activates the intrinsic apoptosis pathway, breaks the respiratory chain, reduces the 
synthesis of ATP and leads to oxidative stress by creating superoxide anion and hydroxyl 
radical, which leads to cell death. The indirect mitochondrial effect is mediated by increased 
levels of protein X (Bax) associated with Bcl-2 by inhibiting proteasomal degradation. In vitro 
studies have shown that the main aspect of gentamicin cytotoxicity is its cytoplasm 
concentration, not the accumulation of lysosomes as previously thought[75].  
1.6 Limitation of current clinical methods to measure nephrotoxicity 
Current clinical method to access renal function or nephrotoxicity is to measure the creatinine 
levels in the serum and/or urine. Creatinine is a waste product from the body that comes from 
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muscle activity. It is normally removed from blood by kidneys, but when kidney function 
decreases, the creatinine level in the blood increases. The Glomerular Filtrate Rate (GFR) is 
another important assessment method of the level of effectiveness of the kidney in filtering 
the blood [1]. The blood urea nitrogen (BUN) level is also deemed another important method 
for measuring the level of waste in the blood. Higher level of BUN is a clear indication of low 
level of functioning of the kidney while the reverse means the vice versa [78], as the kidney is 
expected to regulate the amount of nitrogen or urea in the blood.  
Whilst serum creatinine level and BUN are established methods to measure renal function, 
they are limited in providing early signs of chronic kidney diseases. For instance, the level of 
creatinine production is corresponding to body weight, and it reduces with age and is slower 
in females than in males, meaning there is no physiologically normal level to be used as a 
baseline [79]. Kidney damage can be found with small rise or no change in serum creatinine 
because of the instability of the normal response to protein change; tubular secretion of 
creatinine rises after a protein meal healthy people, but not in patients with renal diseases 
[80]. Also, Tomlanovich et al. found heart transplant patients receiving cyclosporine (CsA), a 
known nephrotoxin had their creatinine level increased only after GFR has become depressed 
below normal values by two thirds or more [81].  
1.7 Project aims 
There is a pressing challenge for the pharmaceutical industry to develop less nephrotoxic drugs 
in recent years. However, assessment of nephrotoxicity remains difficult and usually detected 
late in the development pipeline due to lack of good pre-clinical models. Therefore, it is 
important to find a model that can be more physiologically relevant in terms of drug handling 
and nephrotoxicity. Most models of transporters in the kidney have been used are from human 
and animal cells. However, they have several limitations, one of which is that they lose the 
expression of many inherent renal transporters. For example, HK-2 proximal tubule cells do 
not express SLC22 transporters (e.g. OAT1, OAT3, and OCT2) at the mRNA level, which are 
ubiquitous in the proximal tubule. Similarly, ABCG1 (BCRP) is also not detected. This suggests 
HK-2 cells are limited in vitro model of drug transporter expression in the human proximal 
tubule [82]. In contrast, primary PTCs has been shown to be a good renal model for xenobiotic 
handling, due to the cells maintaining their full complement of endogenous renal transporters 
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at the protein levels (reference). The cells appear to be more physiologically relevant and 
better indicator of what happens in vivo. The renal PT is therefore could be an ideal in vitro 
model for nephrotoxicity tests.  
With that in mind, the purpose of this study is to characterise and validate primary proximal 
tubule cells from human and rat kidney as in vitro models for drug safety and nephrotoxicity 
studies. Proximal tubule cells will be isolated from human and rat kidneys as outlined in Brown 
et al. (2008), and characterise the cells in the presence of various nephrotoxins. Firstly, to 
ensure the models retain their differentiated functions, the treated monolayers will be 
assessed at the mRNA and functional expression levels for important transporters of the ABC 
and SLC families. Secondly, the expression of several nephrotoxicity biomarkers (KIM-1, NGAL 
and clusterin), along with cell viability, will be measured in the models when they are exposed 
to the nephrotoxins to determine their use in predicting nephrotoxicity. In addition to the 
above mentioned, it is also necessary to highlight the differences in human and rat proximal 




2 Materials and Methods  
2.1 Materials 
Cell culture reagents used in this project included high-glucose Dulbecco’s modified eagles 
medium (HG-DMEM), Ham’s F-12 nutrient mixture, Roswell Park Memorial Institute (RPMI)-
1640 medium, foetal calf serum (FCS), penicillin, streptomycin, L-glutamine, trypsin with 0.02% 
ethylenediaminetetraacetic acid (EDTA), collagen, Dulbecco’s phosphate-buffered saline (PBS) 
and mouse epidermal growth factor (EGF) purchased from Sigma-Aldrich (UK). Percoll was 
bought from GE Healthcare Life Sciences (UK), type 2 collagenase from Worthington 
Biochemicals (USA), and 10X Hanks’ balanced salt solution (HBSS) from Invitrogen (USA). Renal 
epithelial cell growth medium (REGM) SingleQuot kit supplements and growth factors 
(containing insulin, hydrocortisone, gentamycin amphotericin-B (GA) - 1000, adrenaline, tri-
iodothyronine (T3), transferrin, FCS and human EGF) were procured from Lonza (Switzerland). 
Cells were grown on various cell culture vessels bought from Corning (UK). These included 24-
well Transwell® permeable insert cell culture plates (with a surface area of 0.33 cm2 per insert 
and polycarbonate filter pore size of 0.4 µm), plastic 96-well plates (0.33 cm2 surface area), 
plastic 12-well plates (3.8 cm2 surface area), T25 flasks (surface area 25 cm2) and T75 flasks 
(surface area 75 cm2).  
Direct-zol RNA MiniPrep kit by Zymo Research Ltd, USA was used to isolate total cell RNA. 
Moloney murine leukaemia virus (M-MLV) reverse transcriptase, M-MLV 5x reaction buffer, 
RNasin, magnesium chloride, deoxyribonucleotide triphosphate (dNTP) mix, 5x Green GoTaq® 
reaction buffer, GoTaq polymerase, and pGem-T-easy cloning vector kit (consisting of T4 DNA 
ligase, pGem®-T vector, 2x ligation buffers) were procured from Promega (UK). Random 
hexamers were obtained from GE Healthcare Life Sciences, and MiniElute PCR purification kit 
from Qiagen. Agarose, EDTA, boric acid, ethidium bromide were bought from Sigma Aldrich, 
UK. Bespoke primers were ordered from IDT DNA (Belgium). 
2.2 Isolation of proximal tubule cells 
Human primary proximal tubule cells (PTCs) were isolated from healthy, transplant quality 
human kidneys with at least a glomerular filtration rate of 60 ml/min, supplied by a UK licensed 
Tissue Bank with full ethical approval for commercial use for drug development and safety 
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screening. Rat PTCs were isolated from kidneys of 8 to 12-week-old male Sprague-Dawley rats 
after they had been humanely euthanised. All cell culture work was performed in a class II 
vertical laminar flow hood to ensure sterility. All kidneys were first decapsulated before thin 
cortical slices were taken with a sharp scalpel. This process was repeated until the medulla was 
reached, and the cortical slices finely chopped to around 1 mm3 pieces. 25 ml of isolation 
medium was used to suspend every 1 g of minced tissue. The composition of the isolation 
medium can be found in Table 1. Type 2 collagenase (activity of ≈300 units/mg, working 
concentration of 1 μg/ml) was added to the suspension to initiate the digestion of the tissue. 
The suspension was kept shaken for 2 hours at 37 °C before cell separation. To separate the 
cells, the suspension was passed through a 40 μm nylon sieve to remove undigested material 
and then centrifuged gently at 240 relative centrifugal force (RCF) for 10 minutes. In this and 
all subsequent centrifugation steps the temperature was maintained at 4 ˚C. The resulting cell 
pellet was resuspended in fresh isolation medium before the cells were pelleted again by 
centrifugation (this is considered the wash step). The cell pellet was then loosened and gently 
resuspended again in fresh isolation medium. 
 
Supplements Final concentration 
RPMI-1640 Medium - 
FCS 5 % 
Penicillin/Streptomycin 200 units/mL, 200 
µg/mL respectively. 
Table 1: Composition of isolation medium used in the isolation of human and rat PTC. 
 
To isolate the proximal tubule cells, the cell suspension was loaded on top of discontinuous 
Percoll gradients with densities of 1.04 g/ml and 1.07 g/ml, and centrifuged at 1500 RCF for 25 
minutes. After centrifugation, PTCs at the intersection of the gradients were aspirated and 
washed as previously described. The cells were resuspended in warm renal epithelial growth 
medium (REGM). The compositions of human and rat REGM are shown in Table. The cell yield 
was estimated using Cellometer Auto T4 Cell Counter (Nexcelom Bioscience LLC, USA) after 
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passing the cell suspension through a large bore needle three times to separate aggregated 
cells. 
Isolated cells were seeded on to 24-well Transwell inserts (surface area of 0.33 cm2), at a 
density of 75,000 cells in 200 µl of REGM per insert, and the inserts submerged in 700 µl of 
REGM. PTCs were also seeded on to 24-well cell culture plates at 18,000 cells per well with 500 
µl of REGM, 96-well cell culture plates at 7200 cells per well with 200 µl of REGM, and T25 cell 
culture flasks at a density of 1.875 million cells in 5 ml of REGM. The medium was refreshed 
after 24 hours of initial seeding, and thereafter every two days. PTCs were maintained in a 
humidified incubator at 37 ˚C with 5 % CO2 and 95 % air.  
Monolayers were then used for experiment as and when they achieve confluency as 
determined by their TEER values. This usually was around 5-6 days after culture for rat, and 6-
7 days for human. The monolayers used within these days did not show donor to donor 





DMEM/Ham’s F-12 (1:1) 500 mL 
Supplements  
L-Glutamine 2.5 mL 
Mouse EGF 0.5 mL 
Insulin 0.5mL 
Hydrocortisone 0.5 mL 
GA 0.5 mL 
FCS 2.5 mL 
Adrenaline 0.5 mL 
T3 0.5 mL 
Transferrin 0.5 mL 
Penicillin/Streptomycin 2.5 mL 
Table 2: The composition of rat REGM. 
 
2.3 Transepithelial electrical resistance (TEER)  
Confluency of the cells was determined by visual inspection of the cell culture flask under a 
phase contrast microscope. Growing PTCs on uncoated Transwell plates improve the 
differentiated status with an expression of a variety of functional drugs transporters. A study 
showed improved protein expression and functionality of many drug transporters when 
primary human PTCs were grown on Transwell filter plates. The polycarbonate philtre is 
calculated to allow the cells to be polarised and bathed in a medium from the apical and 
basolateral sides, to replicate the physiology of the in vivo cells and thus to maintain their 
differentiated state. In our project, PTCs growth was monitored by microscopic examination 
and also TEERs value was measured as well. In other studies, to characterize PTCs, examination 
of alkaline phosphatase activity (the proximal tubule brush border enzyme) and AGT mRNA 
expression was used to proof of growing PTCs [83]. The transepithelial electrical resistance 
(TEER) was used as an indicator of monolayer confluency on the Transwell inserts. The 
monolayer resistance, which comprises the resistance of the filter and cell monolayer, was 
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measured using an electric voltohmmeter (EVOM, World Precision Instruments, UK). The TEER 
of the monolayers, with the unit of Ω.cm2, was calculated by subtracting the base resistance 
created by the filter submerged in culture medium (90 Ω) and then multiplying it by the surface 
area (0.33 cm2) of the filter. Only monolayers with TEERs greater than 80 Ω.cm2 were used in 
experiments.  
2.4 CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) 
We used cellTiter 96® AQueous One solution cell proliferation assay to quantify the live cells 
(Promega, Madison, WI, USA; #G3582). The MTS tetrazolium compound is reduced by cells to 
a coloured formazan product that is soluble in the tissue culture medium. This conversion is 
carried out by NADPH or NADH in metabolically active cells produced by dehydrogenase 
enzymes. Human and rat PTCs were treated with different nephrotoxins to quantify the cell 
viability. Confluent PTCs seeded onto 96-well plates were cultured with a concentration of the 
nephrotoxins in the REGM for a period of 24 or 48 hours. Spent media were collected and the 
cells were washed with warmed modified-Krebs buffer three times before equilibrated with 
100 µl of modified-Krebs buffer for 30 minutes. The composition of the modified-Krebs buffer 
used is shown in  Table 3. After equilibration of the cells to the buffer, 20 µl of MTS was added 
and the plates covered to prevent photo-bleaching of the compounds. The entire set-up was 
maintained at 37 °C by placing the plates on thermostat-controlled heated platforms. The 
change in colour of MTS was monitored spectrophotometrically by taking absorbance readings 













Tris Base ad hoc to pH 7.4 
                                         Table 3: Composition of modified-Krebs buffer. 
 
2.5 CellTiter-Glo® Luminescent Cell Viability Assay 
Cell viability was measured using CellTiter-Glo Luminescent Cell Viability Kit (Promega, 
Madison, WI, USA; #G7570) by measurement of intracellular adenosine triphosphate (ATP), an 
indicator of metabolically active cells. Human and rat PTCs were treated with nephrotoxins for 
24h and 48h. Cells were cultured in white 96-well plate to decrease luminescence loss. We 
added equal volume of CellTiter-Glo® Reagent to the volume of cell culture medium present 
in each well (50µl of reagent to 50µl of medium). Incubated for 10 min at room temperature. 
The luminescence signal were recorded using a microplate reader (BMG Labtech, Germany).  
2.6 Lactate dehydrogenase (LDH) Cytotoxicity Assay 
The amount of LDH released from human and rat PTCs after nephrotoxins treatment were 
quantify damaged cells as a biomarker for cellular cytotoxicity  by using Pierce™ LDH 
Cytotoxicity Assay Kit (Thermo fisher,IL, USA;TG267605). Release of LDH in the cell culture 
medium, it reduces NAD+ to NADH and H+ through the oxidation of lactate to pyruvate. Later, 
the catalyst (diaphorase) then transfers H/H+ from NADH + H+ to the tetrazolium salt INT to 
form the red colored formazan salt. According to the kit protocol (absorbance at 450 nm, 
background absorbance at the reference wavelength of 600 nm). The average absorbance 
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values of the control and samples, each in 3 repeats, were calculated by subtraction of the 
background absorbance from the measured absorbance.  The cytotoxicity (% of LDH release) 
was calculated as: (treated cells – mean of lysis control cells) × 100.  
2.7 Enzyme-Linked Immunosorbent Assay (ELISA) 
The amount of KIM-1 and NGAL produced by rat PTCs after nephrotoxins treatments were 
quantified. In addition, the amount of KIM-1, NGAL and clusterin were quantified after treated 
human PTCs with different nephrotoxins.  The spent media collected from the above section 
were used in KIM-1, NGAL and clusterin ELISA kits sourced from R&D Systems, USA. The 
protocol for the assay was followed as recommended by the manufacturer.  A 96 well plate 
was coated with a 1/100 solution of capture antibody. The plate was incubated overnight at 
room temperature (RT). The contents of the plate were discarded and wells were washed three 
times using 200µl wash buffer per well (0.05% Tween 20 in 1X phosphate buffer solution (PBS), 
pH 7.2-7.4). Then blocked with 1.0% bovine serum albumin (BSA) solution in 1X PBS for one 
hour at RT.  The plate contents was aspirated and washed three, 100µl of standards diluted in 
100µl of PBS or 100µl of cell culture media were added in duplicate. The plate was incubated 
for two hours at RT and the washing stage was repeated. 100µl of detection antibody was 
added to each well and the plate was incubated for two hours at RT. After another washing 
step was done, 100μl of streptavidin horseradish peroxidase (HRP) diluted in 1.0% BSA was 
added to each well and incubated for 20 minutes out of direct light at RT. A substrate solution 
(1:1 mixture of reagent A (H202) and reagent B (tetramethylbenzidine)) was added to each 
well (100µl) and the plate was incubated away from direct light for a further 20 minutes at RT. 
The addition of 50µl stop solution (2N H2 SO4) was required for each well for 20 minutes. The 
optical density (OD) of the contents was determined was taken using a microplate reader (BMG 
Labtech, Germany) set at 540 nm. The biomarkers levels were normalised to amount of live 
cells based on MTS data. 
2.8 Caspase-Glo 3/7 assay. 
The Caspase-Glo 3/7 assay reagent (Promega, Madison, WI) was used for caspase 3/7 
measurement in treated human PTCs with different nephrotoxins.  The kit provides a 
proluminescent caspase-3/7 substrate, which contains the tetrapeptide sequence DEVD, in 
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addition to a luciferase and a cell-lysing agent. The addition of the Caspase-Glo 3/7 reagent 
directly to the cells well results in cell lysis, followed by caspase cleavage of the DEVD 
substrate, and the generation of luminescence. The level of luminescence is proportional to 
the amount of caspase activity in the PTCs after nephrotoxins treatment and apoptotic renal 
cell death. Luminescence readings were recorded with a microplate reader (BMG Labtech, 
Germany). 
2.9 Quantification of RNA 
Key drug transporters were detected at the mRNA level in human and rat PTC monolayers by 
using endpoint PCR. In addition, the effects of cisplatin on caspas3, caspase8, caspase9 and 
p53in human and rat PTCs were assessed at the mRNA level by using qPCR. Nephrotoxins 
treated PTCs, were washed with PBS before lysed with TRI-reagent and cell total RNA extracted 
using column-based Direct-zol RNA MiniPrep kit by Zymo Research Ltd, USA. The 
manufacturer’s protocol was followed to ensure maximum yield. RNA yield was quantified 
using NanoDrop (Thermofisher, UK), which also provided the A260/280 and A260/230 ratios. 
Only samples with ratios of 1.8-2.2 were used for downstream applications.  
Prior to the start of endpoint PCR and qPCR, the RNA samples were reversed transcribed to 
cDNA. Briefly, this involved incubating 1 µg of cell total RNA with of 0.5 mg/ml random 
hexamers to a total volume of 13 µl at 65 for 5 minutes to ensure denaturing of RNA and 
annealing of primers. A reaction mixture of 12 µl comprising MMLT-RT at 200 units/µl, reaction 
buffer, 2 mM dNTPs and RNasin at 40 units/µl, were added to the RNA samples and incubated 
at 42 ˚C for 2 hours followed by 10 minutes at 90 ˚C for 3 minutes. 
Endpoint PCRs were carried out for genes of interest using GoTaq DNA polymerase (Promega, 
UK). A typical endpoint PCR consisted of 0.25 µl GoTaq DNA polymerase at activity of 5 units/µl, 
2 µl 2 mM dNTPs, 0.5 µM of each primer of the gene of interest, 4 µl of 5X Green GoTaq buffer, 
1.5 µl of cDNA template and molecular grade water to make up to a volume of 20 µl. The 
amplification protocol was as follows: 95 ˚C for 2 minutes, 35 cycles of 95 ˚C for 30 seconds, Ta 
˚C for 30 seconds and 72 ˚C degree for 30 seconds, then an end stage of 72 ˚C for 10 minutes. 
The PCR products were separated by size on a 1.5% agarose gel and visualized with safe view 
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and an UV-transilluminator and verified by sequence analyses. The sequences of the primers 














F: ATT GAT GGC ACA GGA AGA GA 






F:TGA AGG TGT GGG CAG GAA C 






F:ACC TGG TGA TCT ACA ATG GCT 













F: CAC CAT CAT GGA CAG TGACAA GG 






















57  179 
Rat OCT2 NM_031584.
2 
F:ATC CCT GAT GAT CTA CAG TGG 




F:ATG CTG TGG TTT GCC ACT AGC 




NM81855.1 F:GTC AAG GAA GCC AAT GCC 






F:GTT CTC GTC CTG GAA GAA GC 
R:TTC AGC AGC TGA GGA TTC AG 
57 170 
Table 4: Sequences of primers used in endpoint PCR for the amplification of human and rat 




2.10 Quantitative PCR 
The effects of cisplatin on caspas3, caspase8, caspase9 and p53in human and rat PTCs were 
assessed at the mRNA level by using qPCR. Diluted cDNA produced earlier was mixed with 
SYBR-green Master Mix, 10 µM primer mix of gene of interest and molecular grade water to a 
volume of 10 µl in a well of a 96-well format qPCR plate. PCR has run in a Roche LightCycler 
480 (Roche, UK) with the following protocol: 95 ˚C for 10 minutes, 45 cycles of 95 ˚C for 10 
seconds, Ta ˚C for 20 seconds and 72 ˚C for 10 seconds, followed by melt curve step (cooling 
to 65 ˚C followed by heating to 97 ˚C), and a cooling step. Ta represents the annealing 
temperature of the primers used in the reaction. The primers for the genes of interest were 
designed using the Primer-Blast tool on the National Centre for Biotechnology Information 
website (www.ncbi.nlm.nih.gov). Either forward or reverse primer is intron spanning.  The 
primer sequences are summarised in Table 5. 
The PCR cycle and its corresponding fluorescence from each sample were logged by the 
software LightCycler 480 (version 1.5, Roche, UK). The software calculated the fluorescence 
baseline during the first 15 cycles of the PCR to create a common starting fluorescence 
intensity for all the samples. A threshold level of fluorescence intensity was also defined by an 
algorithm where it was significantly above the background fluorescence but still within the 
linear phase of amplification. The cycle at which a sample produces fluorescence intensity that 
crosses the threshold is termed the threshold cycle (Ct), and is correlated to the starting 
concentration of the cDNA template; the greater the amount of starting cDNA, the earlier the 


































































Table 5: Sequences of primers used in qPCR for the amplification of human and rat PTCs 
caspase3, 8, 9 and p53.  
 
2.11 Transport of Albumin–fluorescein isothiocyanate conjugate (FITC)-albumin 
Human and rat PTCs cultured on 24-well Transwell filter support were used to investigate the 
functional expression of megalin and cubilin using FITC-albumin as the fluorescence substrate 
probe. Culture medium was first aspirated from the insert wells and washed three times with 
warm modified-Krebs buffer. The inserts were then placed in a clean 24-well plate and we 
added 200µl of modified-Krebs buffer to each insert well and 500µl of modified-Krebs were 
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added to each plate well from the original plate to equilibrate the cells for an hour. For the 
objective of this experiment, the insert wells are referred to as the apical membrane and the 
plate wells are referred to as the basolateral membrane. We used a thermostatically controlled 
heated platform to keep the temperature at 37 ˚C. Experiment was started when apical and 
basolateral solutions were replaced with 30µg/ml albumin in three wells, 30 µg/ml albumin 
and 250µg/ml polymyxin B in another three wells and 30 µg/ml albumin plus 50µM of 
rosuvastatin in three wells too, and incubated for two hours. After that, we washed the inserts 
and plate wells with cold modified- Krebs buffer. We added 0.01% SDS to lysis the cells in both 
side (apical and basolateral) and incubated for 30 min and transferred into a clean 96-well 
plate. The FITC- albumin was measured by using a microplate reader. The raw values are 
expressed as absorbance unit (AU). 
2.12 Transepithelial flux of creatinine and PAH 
The rate of movement of a substrate through a membrane can be measured, and is termed 
flux. When conducted under certain controlled environments, a flux experiment can be used 
to determine the mechanisms upon which the substrate moves across the membrane. In this 
study, the movement of creatinine and PAH from the extracellular environment through the 
apical or basolateral membranes of human and rat PTC monolayers into the cells and vice versa 
under a series of conditions over a period of time was conducted. This would allow the 
identification of the membrane transporters responsible for its movement. 
The flux of creatinine and PAH in the apical-to-basolateral direction is referred to as the 
absorptive flux (JA-B). The movement of creatinine in the opposite direction of basolateral-to-
apical is referred to as the secretory flux (JB-A). In addition to the fluxes, the movement of 
creatinine and PAH from the extracellular environment across either the apical membrane or 
basolateral membrane into the cells in a fixed period of time was also investigated, and 






Figure 2.1: Schematics of transepithelial flux of creatinine and PAH by PTC monolayers.  
JA-B denotes the movement of a substrate in the absorptive direction of apical to basolateral, 
whereas JB-A denotes the movement of a substrate in the secretory direction of basolateral to 
apical. In this instance, the brush-border membrane of the PTC monolayers faces the apical 
chamber, which is the equivalent of the tubule lumen in vivo, and the basolateral membrane 
faces the interstitial space/blood.  
 
Culture media were first aspirated from the insert wells before sequential transfer of the 
inserts into three beakers of around 100 ml warm modified-Krebs buffer. The monolayers were 
then equilibrated with differential pH across the apical and basolateral membrane. The inserts 
were placed in a clean 24-well plate, each well containing 1000 µl warm modified-Krebs buffer 
of pH 7.4, and 200 µl of pH 6.8 was added to the insert’s well. For the purpose of this study, 
the insert wells are referred to as the apical chamber and the plate wells are referred to as the 
basolateral chamber. The temperature of the whole set up was kept at 37 °C by placing the 
plates on a thermostat-controlled heated platform. 
Prior to the initiation of flux of creatinine and PAH, monolayers were pre-incubated for at least 
30 minutes with Krebs buffer containing a specified concentration of the TA or inhibitor in one 
or both chambers. This was to investigate potential drug-drug interactions of the TA or 
inhibitors with creatinine. Control monolayers were pre-incubated with Krebs buffer with no 
inhibitor. Master stocks of all TAs or inhibitors were reconstituted with DMSO. The amount of 
solvent incorporated into the final working solutions were not more than 0.5 %.  
At the end of the pre-incubation period, flux was initiated when the Krebs buffer was aspirated 
from the apical or basolateral chambers and replaced with equal volume of 10 µM creatinine 
and PAH. This flux solution also contained the TA/inhibitor at the concentration used during 
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the pre-incubation step, and mannitol at the same concentration of creatinine. The presence 
of the inhibitor during creatinine flux ensured sustained interaction of the membrane 
transporters with the inhibitor. The addition of mannitol at the same time and solution with 
creatinine allowed the measurement of paracellular flux. The chambers with the flux solutions 
are referred to as the donor chamber. Radiolabelled creatinine (with 14C isotope) was included 
in the flux solutions at activity of 0.5 µCi/ml to trace the movement of the substrate. Mannitol 
movement was traced with 3H isotope at 0.1 µCi/ml.  
Sampling of 50 µl from the contralateral chamber (referred to as the receiver chamber) at 
predetermined time points of 120 minutes after experiment initiation was carried out. After 
each sampling, equal amount of fresh Krebs with the appropriate pH and substrate was 
replaced. At the last sampling, the reaction terminated by sequentially transferring the inserts 
into four beakers of ice-cold Krebs buffer and left to dry. The samples from the receiver 
chambers were placed into scintillation vials. The filters of the inserts, on which the 
monolayers were adhered, were then excised out and also transferred to scintillation vials. The 
filter samples provided the amount of creatinine accumulated at over the 120 minutes flux 
period, which was indicative of the uptake of the substrates from across either the apical or 
basolateral membrane of the monolayers. 
Radioactivity in all samples was determined by liquid scintillation spectrophotometry after 2 
ml of Optiphase Hisafe 2 scintillation solvent (Perkin Elmer, UK) was added. Radioactivity in 
terms of disintegration per minute was detected using TriCarb 2910 liquid scintillation counter 
(Perkin Elmer, UK). The liquid scintillation counter was serviced annually, with the last service 
and calibration performed in August 2018 by Isocount ltd, UK. 5 µl of donor samples at flux 
initiation were also put through the scintillation counter to be used as the reference. 
Background activity was counted using a vial containing only 2 ml scintillation fluid and this 
value was automatically deducted from the counts. 
The raw data provided by the liquid scintillation counter were expressed in disintegration per 
minute (DPM) and was able to distinguish between 14C-labelled and 3H-labelled substrates. To 
convert the counts to flux or paracellular flux of a substrate (i.e. amount of radiolabeled 
substrate moving from the donor to the receiving chamber), the following equation was used: 
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Amount of substrate =  
𝚨𝚨STD
DPMSTD
× 𝟑𝟑 × DPMSPL 
where ASTD represents the amount of substrate in 5 μl in the donor chamber, DPMSTD 
represents the DPM of the radiolabeled substrate in 5 µl of the dosing solution, and DPMSPL 
represents the DPM of 50 µl from the receiver chamber. The constant 3 was used to express 
the result in cm2 (surface area of a Transwell insert was 0.33 cm2). All calculations were 
performed using Microsoft Excel for Office 365. The corrected flux of the substrate was 
determined by subtracting the mannitol paracellular flux from the calculated flux and 
expressed as nmol/cm2/hr or pmol/cm2/hr.  
2.13 Data analysis 
All data presented in the results are expressed as mean ± standard error of mean (SEM) of 
three technical replicates. One-way Analysis of Variance (ANOVA) statistical test was 
performed to compare significance of difference in data conditions. This test was used because 
we are comparing between different conditions within the same cells. GraphPad Prism 8.0 





3 Characterising renal proximal tubule cells model 
3.1 Introduction  
The absence of a decent model of the human proximal tubule has impaired the understanding 
of kidney drug handling in human. Current in vitro drug screens depend on immortalized renal 
epithelial cells, which poorly predict in vivo setting. Several studies on characterization of renal 
epithelial cells lines have also noted that these cells lack drug and metabolic enzyme 
expressions, fail to maintain microvilli at the brush border or cannot create confluent 
monolayers with tight junctions, although the cells can be transfected steadily to express 
missing transporters. The expression of the transporters in these cell lines however does not 
represent the physiological level of expression of the transporters as they are powered by the 
transmission machinery and vector promoters.  
An alternative is to use primary proximal tubule cells. The protocol most frequently used to 
isolate fresh proximal tubule cell cultures involves the enzyme dispersion of tubular cells from 
the kidney cortex, followed by differential sieving (via Percoll gradients centrifugation), and 
fluorescent surface marker antibody labelling and cell sorting via FACS [8, 84]. Cells are also 
chosen using cultured growth medium that encourages interest cell growth compared to other 
cell types after isolation.  
The acquisition of tissues from which the primary cells are isolated is a challenge. The supply 
of human kidney cortex is far a few in between, not least due to the short fall in organ donation 
and the lengthy waiting list for transplants. It is therefore vital that an effective isolation 
protocol is carried out to maximize the primary cell yield, when tissues are available. Rat 
kidneys are more accessible, on the other hand.  
This chapter highlights the results from the characterisation of human and rat proximal tubule 
cells (PTCs). Freshly isolated PTCs are seeded on to Transwell inserts, which allow for the 
formation of monolayers. Transepithelial electrical resistance (TEER) measurement is used to 
assess the barrier function and properties of filter-grown PTCs. The expression of several key 
transporters is investigated using endpoint PCR. The functional expressions of several 




3.2 Cell culture and morphology of rat PTCs 
PTCs have been isolated from rat kidney cortex and seeded onto multiple platforms of cell 
culture. Figure 3.1 shows the cells cultured over a 5-day period on a T75 cell culture flask. 
The morphology for freshly isolated PTCs of rat showed single cells not more than 40 μm in 
diameter, although depending on the isolation efficiency, clumps of cells (tubules) were still 
identifiable. Rat PTCs appeared to adhere within the first 24 hours of seeding, with visible 
lamellipodia at the cell edges. By day 3, (Figure 3.1C) defined regions of flattened cells in loose 
contact can be seen. Clusters of cuboidal forms or islets of rounded cells were seen at day 4 
and 5 of culture (Figure 3.1D and E). The cells were seen proliferating and the typical 
















Figure 3.1: Phase contrast images of T75 cell culture flask seeded with rat PTCs over 5 days 
of culture. 
Phase contrast images of rat PTCs seeded onto T75 cell culture flask with initial seeding density 
of 300,000 cells per ml on (A) day 1, (B) day 2, (C) day 3, (D) day 4, and (E) day 5 of culture. 
Cells appeared to adhere to the flask within the first 24 hours of seeding, and formed confluent 
monolayer by day 4/5. Confluent monolayer of rat PTCs was observed at day 5 of culture. 
Images were taken with a phase contrast microscope at 200 X magnification. This is a 
representative of 12 experiments.   
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3.3 Cell culture and morphology of human PTCs 
PTCs were isolated from human kidney cortex and seeded onto multiple platforms of cell 
culture. Figure 3.2 shows the cells cultured over a 6-day period on a T75 cell culture flask. 
Similar to the rat, the morphology for isolated human PTCs was primarily individual cells with 
a diameter of not more than 40 μm. Most cells can be recognized with lamellipodia at the 
edges of the cell within the first 24 hours. On day 4 to 6 of culture, clusters of cuboidal forms 
or islets of rounded cells were observed. The cells then spread, and it was possible to observe 

















Figure 3.2: Phase contrast images of T75 cell culture flask seeded with human PTCs over 5 
days of culture.  
Phase contrast images of human PTCs seeded onto T75 cell culture flask with initial seeding 
density of 300,000 cells per ml on (A) day 1, (B) day 2, (C) day 3, (D) day 4, (E) day 5, and (F) 
day 6 of culture. Cells appeared to adhere to the flask within the first 24 hours of seeding, and 
formed confluent monolayer by day 6.  Images were taken with a phase contrast microscope 




3.4 Transepithelial electrical resistance of rat PTC monolayers 
Isolated rat PTCs were also cultured on Transwell semi permeable filter inserts to recapitulate 
the formation of a monolayer with distinct apical and basolateral differentiation. The 
resistance of the monolayers were evaluated throughout the culture period, and the 
transepithelial electrical resistance calculated (the average basal resistance of the filter inserts 
was 90 Ω), which are summarised in Figure 3.3.  
On day 1 of culture (data not shown) produced negligible TEER. An average TEER of 28.9 ± 7.4 
Ω.cm2 was measured on day 2, however. The TEER rose to 72.7 ± 8.3 Ω.cm2 on day 3, 96.4 ± 
17.3 on day 4 and peaked at 100.9 ± 14.5 Ω.cm2 on day 5. Thereafter, the TEER declined to 
80.9 ± 11.1 on Day 6. The TEER reduced further to 40.8 ± 15.6 Ω.cm2 and 23.2 ± 5.7 Ω.cm2 on 






































Figure 3.3: TEERs of rat PTC monolayer cultured on Transwell filter support. 
The rat PTC monolayers TEER was negligible on day 1, and peaked to 100.8 ± 14.5 Ω.cm2 on 
day 5. Thereafter, the TEER reduced to 23.2 ± 5.7 Ω.cm2 on day 8. Each bar represents the 





3.5 Transepithelial electrical resistance of human PTC monolayers 
Human PTCs were also cultured on Transwell filter inserts to recapitulate monolayer 
formation. During the culture period, the resistances of the monolayers were measured and 
TEERs calculated. Figure 3.4 shows the TEERs of the human PTC monolayers over their culture 
period. 
The resistance on day 1 of culture was negligible (the outcome not shown), but an average 
TEER of 42.1 ± 8.2 ± Ω.cm2 was measured on day 2. The TEER increased to 73.6 ± 10.7 Ω.cm2 
on day 3, and 97.9 ± 11.5 Ω.cm2 on day 4, and 126.3 ± 14.2 Ω.cm2 on day 5. The TEER was 136.3 
± 16.7 on Day 6, with the highest TEERs observed at 139.8 ± 20.1 Ω.cm2 and 137.7 ± 17.9 Ω.cm2 
on day 7 and 8, respectively. In contrast to the rat PTC monolayers, subsequent days of culture 
did not see a significant decrease in TEERs. For example, on day 9 and 10, the TEER was 139.55 































Figure 3.4: TEERs of human PTC monolayer cultured on Transwell filter support.  
The resistance of the human PTC monolayers was negligible at day 1 of culture (result not 
shown). However, an average of 42.1 ± 8.2 ± Ω.cm2 was measured on day 2. The TEER increased 
to a high of 139.77 ± 20.14 Ω.cm2 on day 7, with no significant change in TEERs over the 





3.6 mRNA expression of small and large molecule transporters in rat and human 
PTCs 
Several key transporters expression at the mRNA level were investigated using endpoint PCR. 
Total cells RNA from freshly isolated rat and human PTCs were isolated and reverse transcribed 
before used in end-point PCRs. The PCR products were then visualised on 1.5 % agarose gels 
stained with ethidium bromide. A negative control was used no confirm there is no 
contamination in the master mix. Figure 3.5 shows the separation of PCR products on the gels, 
with clear bands in the lanes where megalin, cubilin, OCT2, OAT1 MRP2 and MDR1 primers 
were used. This signified the expression of these key transporters in the PTCs of rat and human. 
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Figure 3.5: 1.5 % agarose gel showing separation of PCR products.  
Clear bands in the agarose gel from (A) rat and (B) human PTC samples demonstrated the 




3.7 FITC-albumin concentration range uptake by human and rat PTCs  
The functional expressions of megalin and cubilin in rat and human PTCs were investigated 
using FITC-albumin as the fluorescence substrate probe. It will show the importance of these 
surface receptors in the PTCs as they provide the mechanism of movement of larger molecules 
in the kidney. Rat and human PTC monolayers were incubated with a range of concentrations 
of FITC-albumin (10, 30, 60 and 90 μg/ml) for a period of 1, 2, 4 or 5 hours. Figure 3.6 shows 
the uptake of FITC-albumin over this time period. The uptake of FITC-albumin had been 
normalised to the amount of protein (relative number of cells). 
The cells waited to be confluence and incubated with albumin and polymyxin B at the same 
time. For rat the experiment started at day 5 and human at day 7.  Both rat and human PTC 
monolayers showed a concentration dependent uptake of FITC-albumin – uptake of FITC-
albumin increased in greater dosing concentration of FITC-albumin. For examples, rat PTC 
monolayers saw an uptake of 73,662.1 ± 7,597.1 AU with 10 µg/ml dosing concentration of 
albumin but increased to 128,890.7 ± 17,532.7 AU with 60 µg/ml dosing concentration the 2-
hour time point. 
Interestingly, both rat and human PTC monolayers did not exhibit a time dependent increase 
in FITC-albumin uptake. Uptake was significantly higher at the 2 hour time point when FITC-
albumin dosing concentration was above 60 µg/ml for rat PTC monolayers, and when FITC-


































Figure 3.6: Uptake of FITC albumin by rat and human PTC monolayers.  
Albumin uptake by (A) rat PTC monolayers and (B) human PTC monolayers were measured over 
time and dosing concentrations, normalised to protein concentrations. Both species saw 
concentration dependent uptake of albumin. Interesting, uptake was not time-dependent, as 
both species saw significantly more uptake at 2-hour time point than any other periods. Graphs 
are representatives of three independent experiments (N = 3). Each point represents the mean 
± S.E.M of the 3 experiments. AU is absorbance unit.  
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3.8 FITC-albumin uptake by rat and human PTC monolayers in the presence of 
polymyxin B or rosuvastatin 
The uptake of FITC-albumin by rat and human PTCs in presence of 250 µg/ml polymyxin B or 
50 µM rosuvastatin was investigated, to demonstrate the potential interaction of large 
molecules with megalin/cubilin mediated-uptake (FITC-albumin) in the kidney. Polymyxin B 
dose was the same dose used for biomarkers levels measurement. Based on previous results 
(Figure 3.6), the uptake of 50 µg/ml FITC-albumin in the presence of the two large molecules 
over a period of 2 hours. The uptake of FITC-albumin was normalised to the respective protein 
concentration, and summarised in Figure 3.7.  
In rat PTC monolayers, the amount of FITC-albumin decreased significantly in the presence of 
polymyxin B, from 633,501.1 ± 82,995.3 to 498,337.9 ± 122,370.7 AU (P < 0.05). The presence 
of rosuvastatin also caused a significant decrease in FITC-albumin uptake to 381,585.8 ± 
95,978.1 AU (P < 0.001). 
Similarly, the amount of FITC-albumin taken up by human PTC monolayers also changed 
significantly in the presence of polymyxin B, which decreased from 758,277.7 ± 170,859 to 
482,451.1 ± 62,023.9 AU (P <0.001) when compared to the control alone. The presence of 
rosuvastatin also caused a significant decrease in FITC-albumin level when compared to the 




































































Figure 3.7: Uptake of FITC-albumin by rat and human PTCs in the presence of polymyxin B or 
rosuvastatin.  
Uptake of albumin by (A) rat PTC monolayers and (B) human PTC monolayers saw significant 
decrease in the presence of polymyxin B or rosuvastatin. For example, a 20 % decrease in 
albumin uptake was observed compared to control cells. Each bar represents the mean ± SEM 
of 3 replicates. One-way ANOVA test was performed to determine statistical significance. * P < 
0.5, ** P < 0.1, ***, P < 0.01. AU is absorbance unit.  
47 
 
3.9 Creatinine uptake by rat and human PTCs monolayers  
To investigate the differential functional expression of OCT2 across the apical and basolateral 
membrane, creatinine uptake was performed using rat and human PTC monolayers. Uptake of 
creatinine across the apical and basolateral membranes was determined from the amount of 
intracellular accumulation of creatinine in the PTC monolayers after a period of time, and also 
in the presence of OCT2 specific inhibitor, dolutegravir. The results are showed in Figure 3.8.   
Uptake of creatinine across the basolateral membrane was higher than across the apical 
membrane in both species of monolayers. For instance, uptake of creatinine by rat PTC 
monolayers were (1.10 ± 0.19 pmol/cm2/hr) across the basolateral membrane, almost 2 times 
more than across the apical membrane at 0.56 ± 0.05 pmol/cm2/hr. Similarly, uptake of 
creatinine by human PTC monolayers were 4.59 ± 0.58 pmol/cm2/hr across the basolateral 
membrane, a 3 times higher than across the apical membrane at 1.73 ± 0.11 pmol/cm2/hr. 
However, monolayers treated with 100 µM dolutegravir saw significantly inhibition of uptake. 
For example, 60.0 % decrease in uptake across the basolateral membrane (from 4.6 ± 0.3 
pmol/cm2/hr to 1.9 ± 0.2 pmol/cm2/hr, P < 0.01) when compared to control cells was seen in 
human PTC monolayers. In rat PTC monolayers, creatinine uptake across the basolateral 
membrane was also decreased from 1.1 ± 0.1 pmol/cm2/hr to 0.6 ± 0.2 pmol/cm2/hr in the 














































Figure 3.8: Creatinine uptake by rat and human PTC monolayers. 
Apical and basolateral uptake of creatinine by (A) rat and (B) human PTC monolayers, in the 
presence and absence of 100 µM dolutegravir. Uptake of creatinine were significantly higher 
across the basolateral membrane then across the apical membrane in both species of 
monolayers. Basolateral uptake was significantly decreased in the presence of dolutegravir. For 
instance, human PTC monolayers saw a 60.0 % decrease (4.6 ± 0.3 pmol/cm2/hr to 1.9 ± 0.2 
pmol/cm2/hr). Each bar represents the mean ± SEM of 3 replicates. One-way ANOVA test was 
performed to determine statistical significance. * P < 0.5, ** P < 0.1, ***, P < 0.01.  
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3.10 PAH uptake by rat and human PTCs monolayers 
To investigate the functional expression of OAT1 in rat and human PTC monolayers, the uptake 
of PAH by the monolayers were performed. The differences in apical and basolateral PAH 
uptake magnitudes were also compared to PAH uptake in the presence of OAT1 inhibitor, 
probenecid. Figure 3.9 shows the results. 
As expected, the basolateral uptake of PAH was greater in magnitude across the basolateral 
membrane of both species of monolayers. For example, uptake of PAH by rat PTC monolayers 
were (1.69 ± 0.28 pmol/cm2/hr) across the basolateral membrane, and the apical membrane 
at 1.15 ± 0.39 pmol/cm2/hr. Similarly, uptake of PAH by human PTC monolayers were 7.65 ± 
0.82 pmol/cm2/hr across the basolateral membrane, which was 2 times higher than across the 
apical membrane at 3.04 ± 0.62 pmol/cm2/hr. 
PAH uptake measured in the presence of 200 µM probenecid saw significant decrease in 
uptake across the basolateral membrane of human PTC monolayers, which went from 7.65 ± 
0.48 pmol/cm2/hr to 4.14 ± 0.54 pmol/cm2/hr (P < 0.01). Similarly in rat PTCs, PAH uptake 
across the basolateral membrane with 200 µM probenecid treatment declined compared to 





















































Figure 3.9: PAH uptake by human PTC monolayers in the presence of 200 µM probenecid.  
Apical and basolateral uptake of PAH by (A) rat and (B) human PTC monolayers, in the presence 
and absence of 200 µM probenecid. Uptake of PAH was significantly higher across the 
basolateral membrane then across the apical membrane in both species of monolayers. 
Basolateral uptake was significantly decreased in the presence of probenecid. For instance, 
human PTC monolayers saw a 40 % decrease in uptake from 7.65 ± 0.48 pmol/cm2/hr to 4.14 
± 0.54 pmol/cm2/hr. Each bar represents the mean ± SEM of 3 replicates. One-way ANOVA test 




One key property of the primary renal cell model is its ability to express transport proteins 
located in the basolateral and apical membranes of the cells. This makes the model more 
physiologically relevant and therefore better in renal handling. In this chapter, human and rat 
PTCs were cultured on Transwell filter inserts for the initial characterisation of the cells, which 
focused on expression of a range of key proximal tubule transporters at the mRNA level. This 
was followed by a study of the functional expression of some transporters expressed in the 
human and rat proximal tubule. 
3.11.1  Measurements of TEERs value 
Numerous in vitro models for studying molecular transport across barrier tissues consisting 
mainly of epithelial and endothelial layers were developed[85]. There is no concern about 
changing in phenotypic stability over time in culture is because fresh cells were used each time 
and no passaging is done. In addition, the time of culture is short and the chance of the PTC 
differentiating to another cell type is low. One of the advantages of growing PTCs on Transwells 
plates is the ability to allow PTC monolayers to differentiate wth apical and basolateral 
membranes. However, it requires an effective monitoring technique to determine their 
cultural quality. The TEERs measurement was in consistent with morphological features of 
PTCs grown in this project. Primary proximal tubule cells TEER value are between (120–
150 Ω*cm2 in 24-Transwell plates). Low TEER is widely assumed to imply poor growth of PTCs. 
When PTCs are treated with nephrotoxins drugs, the TEERs value is decreasing because the 
effect of those drugs to the integrity of the PTCs. The PTCs are leaking and after that die.      
3.11.2 mRNA expression of transporters in human and rat PTCs 
The mRNA detection of several transporters in human and rat PTCs were examined. The 
expression of all tested transporters has been identified by endpoint PCRs conducted with a 
cDNA template that was transcribed from RNA isolated from human and rats PTC cultures. 
Visualization of the PCR products on the agarose gels showed that in each of the lanes there 
was only one product. This showed the specificity of the primers used because only the interest 
gene was amplified. An agarose gel band intensity is a qualitative measure of PCR product 
quantity. For a quantitative measure of the amount of mRNA level, real-time quantitative PCR 
is a better technique.  
52 
 
There is consensus that primary tubular cells are better at retention of drug transporter 
expressions than other renal cell lines [86, 87].  Caki-1 cells, for instance, do not have mRNA 
from various organic transporters of anion and organic cation, including OAT1, OAT2, OCT1 
and OCT2[88]. Rat cell line NRK-52E, and swine cell line LLC-PK1 lack mRNA expression of these 
transporters as well [89, 90].  In addition, LLC-PK1, which is often used to evaluate renal drug 
transport, also lack proximal brush-border enzymes compared with those in primary cultured 
PTCs[86].  
It has been demonstrated that the preservation of the differentiated condition of primary cells 
and incidentally their brush-bound enzyme activity is largely affected by the composition of 
the culture medium [91, 92].  Furthermore, it has been demonstrated that bathing epithelial 
cells on both the apical and basolateral sides improves their capacity to stay differentiated, 
thus repeating in vivo physiology[93]. The data from section 1.6 showed expression of drug 
transporters in culture primary PTCs. However, the results do not show the location of those 
drugs transporters and further investigation is needed.   
3.11.3 Functional expression of megalin and cubilin using FITC-albumin: 
The experiments mentioned had been performed on human and rat PTCs cultured on 
Transwell filter inserts and demonstrated the functional expression of megalin and cubilin 
receptors by using albumin-FITC as a tracer substrate. Uptake was also carried out in the 
presence of polymyxin B and rosuvastatin to identify megalin and cubilin mediated uptake.  
The results showed that the uptake of FITC-albumin was concentration dependent, but not 
time dependent. For instance, in both species of monolayers, 2 hours of incubation appeared 
to give significantly higher uptake of FITC-albumin than 3 or 4 hours.   
The presence of polymyxin B, and to an extend rosuvatstain, decreased the ability of PTCs in 
albumin uptake.  Our data is compatible with another study done with OK cells line, the 
observation of albumin uptake was noticed after the incubation of OK cells with 3 different 
statins (rosuvastatin, pravastatin, and simvastatin). In addition, ATP levels was measured and 
normalised to protein levels. The levels of ATP were stable even with high concentration of 
statins. That is mean the reduction of albumin uptake was not because the toxicity of the 
statins[94].   
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3.11.4  Functional expression of OCT2/MATE1 and OAT1/3 using creatinine and PAH  
Creatinine is excreted primarily in urine through glomerular filtration and partially secreted via 
transport, which, depending on the renal function, account for 10–40 % of the complete 
creatinine clearance[95]. Creatinine is a substrate for OCT2 and MATE1.  Genome-wide 
association studies show that OCT2 and MATE1 genetic mutations influence the clearance of 
creatinine [96]. Dolutegravir is an OCT2 clinically appropriate inhibitor that causes serum level 
increases by inhibition the tubular secretion, and therefore used as an inhibitor of OCT2 in this 
study [97].  
For most anionic drugs, the urinary excretion mechanism includes active tubular secretion and 
glomerular filtration in the kidney[98].  The main kidney transporters responsible for 
basolateral uptake of multiple organic anions, including pharmaceuticals and uremic toxins, 
are regarded to be organic anion carriers OAT1 and OAT3[99]. OAT1 plays a significant part in 
uptake of  hydrophilic and small organic anions such as PAH, 2,4 dichlorophenoxyacetate and 
acyclic nucleotide phosphonate while OAT3 is more specific in substrate than OAT1 and 
accepts organic anions and even organic cations (cimetidine) and zwitterion 
(fexofenadine)[100]. The urinary excretion mechanisms of drugs have been characterized by 
probenecid. Probenecid is both a powerful inhibitor of OAT1 and OAT3 and probenecid co-
administration at a therapeutic dose leads to significant inhibition of OAT1 and OAT3 
substrates tubular secretion [101].  
Our data showed that creatinine uptake was reduced significantly after incubation with 
dolutegravir in human PTC, but it didn’t change in rat PTC. This may be because creatinine 
handling by the kidneys is different between human and rat. It has also been shown that OCT2 
may not be the only transporter responsible for creatinine uptake in human [102]. Similarly, 
PAH uptake was reduced in the basolateral membrane after treatment with probenecid but 
this time the change was notice in both human and rat PTCs.        
This chapter has shown the expression of several significant drug transporters by human and 
rat PTCs at mRNA level. Also, the functional expression and location of some of the 
transporters on polarized human and rat PTC monolayers. These data highlight the capacity of 
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human and rat PTCs to reflect proximal tubules in vivo, it would be necessary to investigate 




4 Human Biomarkers 
4.1 Introduction  
The kidneys are responsible for maintaining circulatory fluid homeostasis and serve as the 
main organ for xenobiotic elimination and detoxification and receive approximately 25% of all 
heart blood flow[103]. The nephron with about 1 million nephrons per kidney is the functional 
filtration unit of the kidney[104]. The nephron has three key functional components, namely 
the passive blood filtration by the glomeruli and the active absorption and secretion by tubular 
epithelia. PTCs are enriched by membrane proteins that facilitate and activate the transport of 
compounds within a cell at significantly higher concentration rates than those observed in 
circulation[103]. The main driver behind xenobiotic nephropathy, leading to observable acute 
kidney damage (AKI), was considered to be intracellular accumulation.  
The ability to accurately predict toxic kidney damage, for both existing and new 
pharmaceutical prescription medicines or for risk assessment due to environmental exposures 
of xenobiotics is a major current challenge[103]. To respond to this concern, new, more 
sensitive, biomarkers of nephrotoxicity have been identified. One of the biomarkers have been 
used in this chapter is KIM-1. In 2002, the first KIM-1 human subjects studies  were 
released[105]. The study indicated that a significant enhanced expression of KIM-1 in patients 
with acute tubular necrosis from renal biopsy samples. Another study detected KIM-1 protein 
by staining after taking kidney biopsy from 102 patients with different kidney diseases and 
showed that positive KIM-1 staining was associated with tubulo-interstitial fibrosis and 
inflammation in dedifferentiated proximal tubular cells[106].  
Another biomarker used in this study was NGAL. A study done showed NGAL measurements is 
an early AKI biomarker in paediatric intensive care environment that can be predicted about 2 
days prior to serum creatinine increase [107]. In adult intensive care patient research, 
measuring plasma NGAL levels were a very useful biomarker for AKI extension within the next 
2 days [108]. 
Clusterin, another biomarker was investigated in this chapter. A study discovered that the 
expression of clusterin mRNA levels in damaged rat renal tubular epithelial cells of unilateral 
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ureteral obstruction was considerably enhanced while its urination content decreased 
simultaneously, indicating clusterin could act as an early biomarker of AKI [109]. 
One of the nephrotoxic drugs we used is Cisplatin. Cisplatin accumulates in the kidney during 
glomerular filtration and tubular secretion[110]. Nephrotoxicity caused by cisplatin is dose-
dependent and includes kidney cell necrosis, apoptosis and necroptosis [111]. Cisplatin is 
transported by OCT2 [112] this is why it is a good nephrotoxic molecule to test in our PTCs 
model.  
Another drug used in this study is gentamicin, causing tubular injury by: 1) tubular epithelial 
cell necrosis, predominantly in the proximal segment, and 2) altering the function of the 
primary cellular components engaged in water and solute transport [113].  Tubular cytotoxicity 
is the key element of gentamicin nephrotoxicity. The enhanced accumulation of gentamicin in 
PTCs is linked to (megalin/cubilin) receptors in the apical membrane of PTCs [114]. These two 
receptors transports gentamicin by endocytosis. The drug is then transferred into lysosomes, 
Golgi and endoplasmic reticulum[115]. 
This study’s purpose is therefore to identify and substantiate the use of human primary 
proximal tubule cells (PTCs), from the kidney, as suitable models in the study of nephrotoxicity 
and to further the cause of drug related nephrotoxicity. The cells would be isolated from the 
kidneys, as Brown et al. (2008) described, and subsequently characterised on exposure to 
different nephrotoxins, namely polymyxin B, gentamicin and cisplatin. These three compounds 
were chosen as they represent prototypic large (polymyxin B and gentamicin) and small 
(cisplatin) molecules the kidney would encounter. Measuring the expression of different 
biomarkers of nephrotoxicity, such as KIM-1, NGAL and clusterin, upon exposure to those 




4.2 Large molecule nephrotoxin – Gentamicin 
Before the biomarker expression was quantified by ELISA, human PTCs were treated with 
gentamicin, a recognized nephrotoxin. Because of the well characterized and related toxicities 
of gentamicin in vivo, Gentamicin's monolayer PTC impacts are important. 
4.2.1 MTS cell viability after treatment in presence of range of concentration of gentamicin 
To determine the nephrotoxicity of gentamicin, human PTCs were treated with a range of 
concentration of gentamicin for 24, 48 and 72 hours. The viability of the human PTCs was 
determined by measuring the mitochondrial activity using MTS assay. The obtained results are 
presented Figure 4.1 
The results of the MTS assay showed the effect of gentamicin on cell viability in human PTCs. 
With a rise in gentamicin concentration, cell viability reduced continuously. For example, after 
24h treatment with 100 µg/ml gentamicin the cell viability was 23% less than the nonrated 
cells. The percentage of live cells was less than 50% after 250 µg/ml gentamicin treatment for 
24h. 
 The percentage of live cells decreased with the rise of the gentamicin dose after 48h 
incubations.  For instance, after 300 µg/ml gentamicin the percentage of live cells was 44%. 
The live was less more than 40% after 400 µg/ml gentamicin treatment.   
After 72h treatment with a range of gentamicin concentrations, cell viability decreased 
significantly. After 100 µg/ml gentamicin treatment, live cells reduced was 71%. In addition, 




































Figure 4.1: Cell viability in human PTCs treated with range concentrations of gentamicin for 
24, 48 and 72 hours.  
MTS assay was used to measure the cell viability. Gentamicin showed a time and 
concentrations dependent after 24, 48 and 72 hours treatment. For example, the cell viability 
after 250 µg/ml gentamicin for 24h was 56.5% and the percentage dropped to 47% after 48h. 
In addition, cell viability after 300 µg/ml gentamicin treatment for 72h was 39% and after 500 
µg/ml gentamicin the cell viability decreased to 21%. Each point represent mean ± S.E.M values 
of each gentamicin concentration. Each data point is expressed as a percentage of the negative 




4.2.2 KIM-1 production after treatment of human PTCs in presence of a range 
concentration of gentamicin  
The effects of a range of gentamicin concentrations on KIM-1 levels produced by human PTCs 
were investigated. The level of the biomarker was normalised to the cell viability. The results 
are shown in Figure 4.2. 
The KIM-1 levels after 24h treatment of gentamicin increased significantly compared to non-
treated cells. For instance, the level of KIM-1 production was 24.11±7.21 ng/ml at 250 μg/ml 
gentamicin, compared with the control 1.60±0.28 ng/ml. The level of KIM-1 increased   as the 
concentration of gentamicin increased up to 600 μg/ml. 
The levels of KIM-1 also increased significantly in comparison with the non-treated cells after 
48h of gentamicin treatment. The level of KIM-1 was 14.70±2.53 ng/ml after 100 μg/ml 
gentamicin treatment, and increased further to 55.43±17.72 ng/ml with 300 μg/ml gentamicin 
treatment. 
The KIM-1 levels after 72h treatment of gentamicin increased significantly compared to non-
treated cells.  For instance, KIM-1 levels were elevated significantly by 250 μg/ml gentamicin 
concentrations (62.15±14.30 ng/ml). The level of KIM-1 production reached the peak at 500 




























Figure 4.2: Measurement of KIM-1 production by human PTCs treated with gentamicin for 
24, 48 and 72 hours.  
Levels were normalised to MTS absorbance value to account for cell numbers after nephrotoxin 
treatments. Human PTCs were treated with a range of gentamicin concentration (50 to 600 
µg/ml). For example, KIM-1 production after 100 µg/ml gentamicin treatment for 24h was 
3.1±0.3 ng/ml and after 250 µg/ml the level of KIM-1 increased to 7.6±1.5 ng/ml. The level of 
KIM-1 after 400 µg/ml gentamicin treatment for 48h was 43.9±10.1 ng/ml and after 72h the 
level increased to 74.5±26.1 ng/ml. Statistical analysis was conducted using repeated-
measures-paired-one-way ANOVA the data are representative of three independent 
experiments (n=3). Each point mean ± S.E.M values of each group. (*p < 0.05, **p < 0.01, ***p 
< 0.001).  
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4.2.3 NGAL production after treatment of human PTCs in presence of a range concentration 
of gentamicin  
The effects of a range of gentamicin concentrations on NGAL levels produced by human PTCs 
were investigated. The biomarker levels were normalised to cell viability. The results are 
showed in Figure 4.3. 
There was a significant increase in NGAL levels after 24h treatment of gentamicin compared 
to non-treated cells. NGAL levels were elevated significantly by 50 to 600 μg/ml gentamicin 
concentrations. The level of NGAL production at 300 μg/ml gentamicin was 65.81±4.89 ng/ml 
compared with the control 8.45±2.66 ng/ml and then the level of NGAL increased as the 
concentration of gentamicin increases up to 600 μg/ml.  
In comparison to non-treated cells, the levels of NGAL increased significantly after gentamicin 
treatment for 48h. For example, the level of NGAL after 250 μg/ml gentamicin treatment was 
180.49±43.59 ng/ml. The level of NGAL after 400 μg/ml gentamicin treatment was 
230.86±60.42 ng/ml.  
NGAL concentrations rose considerably relative to non-treated cells after 72 hours of 
gentamicin treatment.  For example, NGAL level was 153.31±29.97 ng/ml after 100 μg/ml 
gentamicin treatment. The level of NGAL production after 500 μg/ml gentamicin treatment 

































Figure 4.3: Measurement of NGAL production from human PTCs treated with gentamicin for 
24, 48 and 72 hours. 
Levels were normalised to MTS absorbance value to account for cell numbers after nephrotoxin 
treatments. Human PTCs were treated with a range of gentamicin concentration (50 to 600 
µg/ml). For example, NGAL production after 300 µg/ml gentamicin treatment for 24h was 
65.8±4.7 ng/ml and after 500 µg/ml the level of NGAL increased to 131.4±19.5 ng/ml. The level 
of NGAL after 250 µg/ml gentamicin treatment for 48h was 180.4±43.5 ng/ml and after 72h 
the level increased to 307.8±35.7 ng/ml. Statistical analysis was conducted using repeated-
measures-paired-one-way ANOVA the data are representative of three independent 





4.2.4 Clusterin production after treatment of human PTCs in presence of a range 
concentration of gentamicin  
The impacts of a range of gentamicin concentrations generated by human PTCs on clusterin 
levels were studied. The biomarker levels were normalised to cell viability. The results are 
shown in Figure 4.4. 
Clusterin concentrations rose considerably relative to non-treated cells after 24h incubation 
with range of gentamicin concentrations. The level of clusterin production after 250 μg/ml 
gentamicin was 53.67±23.58 ng/ml compared with the control 8.85±2.94 ng/ml and then the 
level of clusterin increased as the concentration of gentamicin increases up to 600 μg/ml. 
The levels of clusterin increased significantly in comparison with non-treated cells after 48h of 
gentamicin treatment. The clusterin levels increased by 50 to 600 μg/ml gentamicin treatment. 
The highest level of clusterin, compared to control 25.84±1.1 ng/ml, was after 600 μg/ml 
gentamicin treatment at 380.40±55.44 ng/ml.  
After 72h of gentamicin treatment, clusterin levels considerably increased relative to non-
treated cells. For instance, the level of clusterin after 100 μg/ml gentamicin treatment to 
118.1±23.36 ng/ml compared with the control 82.78±15.93 ng/ml and then the production of 









































Figure 4.4: Measurement of clusterin production from human PTCs treated with gentamicin 
for 24, 48 and 72 hours.  
Levels were normalised to MTS absorbance value to account for cell numbers after nephrotoxin 
treatments. Human PTCs were treated with a range of gentamicin concentrations (50 to 600 
µg/ml). For example, clusterin production after exposure to 250 µg/ml gentamicin for 24h was 
53.6±23.5 ng/ml and after 500 µg/ml the level of clusterin increased to 142.7±28.8 ng/ml. The 
level of clusterin after 300 µg/ml gentamicin treatment for 48h was 207.7±19.8 ng/ml and after 
72h the level increased to 316.2±38.6 ng/ml. Statistical analysis was conducted using repeated-
measures-paired-one-way ANOVA the data are representative of three independent 
experiments (n=3). Each point mean ± S.E.M values of each group. (*p < 0.05, **p < 0.01, ***p 
< 0.001).  
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4.2.5 MTS and ATP cells viability assays 
The cell viability was measured after treatment of human PTCs for 24 and 48 hours with 250 
µg/ml gentamicin. The cell viability was also measured in the presence of cilastatin co-
treatments. Both CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (MTS) and 
RealTime-Glo™ MT Cell Viability Assay (ATP) were used to assess cell viability. Both the MTS 
and ATP assays were used to calculate viability from the same plate. The results revealed no 
significant difference between the two assessment methods. The results are shown in Figure 
4.5. 
After 24h, the results revealed that cell viability reduced significantly in response to exposure 
to gentamicin to (65±3.4%, P < 0.01) of control. The cilastatin co treatment did not affect the 
cell viability (95.71±3.44% live cells). The treatment of gentamicin with cilastatin increased the 
live cells compared to only gentamicin (76.1±3%).  
The cell viability was reduced significantly by gentamicin (56.90±5%, P < 0.01) after 
48h.However, the cell viability did not change with cilastatin (95±3.70%). The cell viability after 











































































































Figure 4.5: Cells Viability of human PTCs after treatment of gentamicin for 24 and 48 hours. 
 MTS and ATP assays were used to measure the cell viability. Viability is measured as a 
percentage of the control. For example, MTS percentage after gentamicin treatment for 24h 
was 65% and ATP percentage was 68.3%. In addition, the co-treatment of cilastatin with 
gentamicin for 48h showed, the percentage of MTS was 74.1% and ATP percentage was 76.3%.      
Statistical analysis was conducted using repeated-measures-paired-one-way ANOVA the data 
are representative of three independent experiments (n=3). Bars represent mean ± S.E.M values 
of each group. (*p < 0.05, **p < 0.01, ***p < 0.001).  
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4.2.6 Lactate dehydrogenase (LDH) cytotoxic assay 
The measurement of cytoplasmic enzymes released by damaged cells is a common method for 
determining cytotoxicity. Lactate dehydrogenase (LDH) is a stable enzyme found in all cellular 
systems. In this experiment, we treated human PTCs for 24 and 48 hours with 250 µg/ml 
gentamicin and LDH was measured. In addition, we measured the LDH after cilastatin co 
treatment. The results is consistent with cell viability data. Result shown in Figure 4.6 
After 24h, the results revealed that LDH increased significantly in response to exposure to 
gentamicin to 32.28±2.8%. The cilastatin co treatment did not change the LDH (13.74±1.41%). 
The treatment of gentamicin with cilastatin decreased the LDH compared to only gentamicin 
(27.38±2.21%). 
The LDH was increased significantly by gentamicin (45.58±5.47%) after 48h.However, the LDH 
did not change with cilastatin (14±1.29%). The LDH after gentamicin with cilastatin was lower 































































Figure 4.6: LDH of human PTCs after treatment of gentamicin for 24 and 48 hours. 
 LDH is measured as a percentage of the control. LDH percentage after gentamicin treatment 
for 24h was 36.2% and after 48h the percentage increased to 45.5%. In addition, LDH 
percentage decreased after cilastatin co-treatment with gentamicin for 48h to 30.7% Statistical 
analysis was conducted using repeated-measures-paired-one-way ANOVA the data are 
representative of three independent experiments (n=3). Bars represent mean ± S.E.M values of 




4.2.7 KIM-1 production after treatment of human PTCs in the presence of gentamicin +/- 
cilastatin 
The amount of KIM-1 produced after treatment of human PTCs for 24 and 48 hours in the 
presence of gentamicin was measured, and also PTCs co-treated with cilastatin. The 
concentrations of KIM-1 was normalised to the cell viability as determined from their MTS 
absorbance, results of which were therefore expressed as ng/ml. The results are shown in 
Figure 4.7. 
With 24h treatment of gentamicin, the amount of KIM-1 in the apical membrane change 
significantly from the control (12.19±1.93 ng/ml, P < 0.01). However, the presence of cilastatin 
did not change KIM-1 level 4.73±1.05 ng/ml compared to control (4.71±1.11 ng/ml). The co-
treatment of gentamicin with cilastatin caused a significant decrease in KIM-1 in the apical 
membrane (8.16±1.39 ng/ml, P < 0.0001) compared to only gentamicin. KIM-1 levels in the 
basolateral membrane were low compared to apical membrane.  
With 48h treatment of gentamicin, the amount of KIM-1 in the apical membrane did change 
significantly from the control (30.49±5.69 ng/ml, P < 0.01). However, when we added   
cilastatin did not change KIM-1 level 13.45±3.71 ng/ml compared to control 13.32±3.21 ng/ml. 
The co-treatment of gentamicin with cilastatin caused a significant decrease in KIM-1 in the 
apical membrane (24.1±5.28 ng/ml, P < 0.0001) compare to only gentamicin. KIM-1 levels in 
































































































Figure 4.7: The amount of KIM-1 produced after treatment of human PTCs for 24 and 48 
hours in presence of gentamicin +/- cilastatin. 
ELISA was used to measure KIM-1 production. For example, KIM-1 production in the apical 
membrane is significantly higher than basolateral membrane. The amount of KIM-1 in the 
apical membrane change significantly from the control (12.19±1.93 ng/ml, P < 0.01) after 24h 
gentamicin treatment. After co-treatment with cilastatin, KIM-1 level decreased to (8.16±1.39 
ng/ml, P < 0.0001) compared to only gentamicin. The level of KIM-1 after 48h treatment was 
more than 1 fold compared to 24h. Statistical analysis was conducted using repeated-
measures-paired-one-way ANOVA the data are representative of three independent 
experiments (n=3). Bars represent mean ± S.E.M values of each group. (*p < 0.05, **p < 0.01, 
***p < 0.001, ++++p < 0.0001).  
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4.2.8 NGAL production after treatment of human PTCs in the presence of gentamicin +/- 
cilastatin 
NGAL production for 24 and 48 hours in the presence of gentamicin following treatment of 
human PTCs. In the presence of cilastatin co-treatment, levels of NGAL were also measured. 
NGAL concentrations had been normalized to cell viability based on the MTS absorption of the 
PTCs, resulting in ng/ml. The results are shown in Figure 4.8. 
With 24h treatment of gentamicin, the amount of NGAL in the apical membrane did increase 
significantly from the control (230.49±85.20 ng/ml, P < 0.01). However, the presence of 
cilastatin did not change NGAL level 30.39±6.1 ng/ml compared to control 23.72±3.32 ng/ml 
in the apical membrane. The co-treatment of gentamicin with cilastatin caused a significant 
decrease in NGAL in the apical membrane (125.79±28.1 ng/ml, P < 0.0001) compared to only 
gentamicin. Compared to apical membrane, NGAL levels in the basolateral membrane were 
low.  
After 48 hour treatment of gentamicin, the amount of NGAL in the apical membrane did 
increase significantly from the control (439.69±109.81 ng/ml, P < 0.01). However, the presence 
of cilastatin did not change NGAL level 89.18±27.90 ng/ml compared to control 90.43±31.21 
ng/ml in the apical membrane. The co-treatment of gentamicin with cilastatin caused a 
significant decrease in NGAL in the apical membrane (303.32±81.99 ng/ml, P < 0.0001) 
compared to only gentamicin. Compared to apical membrane, NGAL levels in the basolateral 

































































































Figure 4.8: The amount of NGAL produced after treatment of human PTCs for24 and 48 hours 
in presence of gentamicin +/- cilastatin. 
ELISA was used to measure NGAL production. For example, NGAL production in the apical 
membrane is significantly higher than basolateral membrane. The amount of NGAL in the 
apical membrane change significantly from the control (230.49±85.20 ng/ml, P < 0.01) after 
24h gentamicin treatment. After co-treatment with cilastatin, NGAL level decreased to 
(125.79±28.1 ng/ml, P < 0.0001) compared to only gentamicin. The level of NGAL after 48h 
treatment was more than 1 fold compared to 24h. Statistical analysis was conducted using 
repeated-measures-paired-one-way ANOVA the data are representative of three independent 
experiments (n=3). Bars represent mean ± S.E.M values of each group. (*p < 0.05, **p < 0.01, 
***p < 0.001, ++++p < 0.0001).  
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4.2.9 Clusterin production after treatment of human PTCs with gentamicin +/- cilastatin 
Clusterin production 24 and 48 hours after treatment of human PTCs in the presence of 
gentamicin. In the presence of cilastatin co-treatment, levels of clusterin were also measured. 
Clusterin concentrations had been normalized to cell viability based on the MTS absorption of 
the PTCs, resulting in ng / ml. The results are shown in Figure 4.9.   
With 24h treatment of gentamicin, the amount of clusterin in the apical membrane did 
increase significantly from the control (277.40±100.63 ng/ml, P < 0.01). However, the presence 
of cilastatin did not change clusterin level 35.52±8.94 ng/ml compared to control 35.87±10.92 
ng/ml. The co-treatment of gentamicin with cilastatin caused a significant decrease in clusterin 
in the apical membrane (135.70±25.03 ng/ml, P < 0.0001) compared to only gentamicin. 
Compared to apical membrane, clusterin levels in the basolateral membrane were low.  
With 48h treatment of gentamicin, the amount of clusterin in the apical membrane did change 
significantly from the control (476.16±143.1 ng/ml, P < 0.01). However, when we added 
cilastatin did not change clusterin level 79.26±12.89 ng/ml compared to control 79.20±23.29 
ng/ml. The co-treatment of gentamicin with cilastatin caused a significant decrease in clusterin 
in the apical membrane (316.75±82.60 ng/ml, P < 0.0001) compare to only gentamicin. 


























































































Figure 4.9: The amount of clusterin produced after treatment of human PTCs for 24 and 48 
hours in presence of gentamicin +/- cilastatin. 
ELISA was used to measure clusterin production. For example, clusterin production in the apical 
membrane is significantly higher than basolateral membrane. The amount of clusterin in the 
apical membrane change significantly from the control (35.87±10.9 to 277.40±100.63 ng/ml, P 
< 0.01) after 24h gentamicin treatment. After co-treatment with cilastatin, clusterin level 
decreased to (135.70±25.03 ng/ml, P < 0.0001) compared to only gentamicin. The level of 
clusterin after 48h treatment was more than doubled compared to 24h. Statistical analysis was 
conducted using repeated-measures-paired-one-way ANOVA the data are representative of 
three independent experiments (n=3). Bars represent mean ± S.E.M values of each group. (*p 
< 0.05, **p < 0.01, ***p < 0.001, ++++p < 0.0001).  
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4.3 Large molecule nephrotoxin – Polymyxin B 
Human PTCs were treated with polymyxin B before biomarker expression was quantified by 
using ELISA. The effects of polymyxin B on PTCs were important as the toxicity of polymyxin B 
was already nephrotoxic in vivo. 
4.3.1 MTS cell viability after treatment in presence of range of concentrations of polymyxin 
B 
The cell viability was measured after treatment of human PTCs with a range of concentration 
of polymyxin B (50 to 600 µg/ml) for 24, 48 and 72 hours.  CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay (MTS) was used to assess cell viability. The MTS absorbance 
show as a percentage normalised to non-treated cells. The results are shown in Figure 4.10. 
The impact of polymyxin B on cell viability in human PTCs was found in the outcome of the 
MTS assay.  The cell viability decreased steadily with an increase in polymyxin B concentration. 
For example, after 24h treatment with 250 µg/ml polymyxin B the cell viability was 17% less 
than the nonrated cells. The percentage of live cells was less than 50% after 300 µg/ml 
polymyxin B treatment. 
 After 48h incubation with polymyxin B the percentage of live cells decrease as the dose of 
polymyxin B increase.  For instance, at 300 µg/ml polymyxin B the percentage of live cells was 
40%. The live was less more than 70% after 400 µg/ml polymyxin B.   
There were a major drop in cell viability after 72h treatment with a range of concentration of 
polymyxin B. after 100 µg/ml polymyxin B treatment, live cells reduced more than 35%. In 































Figure 4.10: Cell viability in human PTCs treated with range concentrations of polymyxin B 
for 24, 48 and 72 hours.   
MTS assay was used to measure the cell viability. Polymyxin B showed a time and 
concentrations dependent. For example, the cell viability after 250 µg/ml polymyxin B 
treatment for 24h was 58.6% and the percentage dropped to 43.1% after 48h. In addition, cell 
viability after 300 µg/ml polymyxin B treatment for 72h was 31.7% and after 500 µg/ml 
polymyxin B the cell viability decreased to 7.7%.  Each point represent mean ± S.E.M values of 




4.3.2 KIM-1 produced after treatment of human PTCs in presence of a range concentration 
of polymyxin B 
The effect on human PTCs treated with a range concentration of polymyxin B were 
investigated. The level of KIM-1 was normalised to the cell viability. The results are shown in 
Figure 4.11. 
 KIM-1 concentrations increased significantly relative to non-treated cells after 24h polymyxin 
B treatment. KIM-1 levels were elevated significantly and gradually by 50 to 600 μg/ml 
polymyxin B concentrations. The production of KIM-1 after 250 μg/ml polymyxin B treatment 
was 24.11±7.21 ng/ml compared with the control 1.59±0.28 ng/ml and then the level of KIM-
1 was the same as the concentration of polymyxin B increases up to 600 μg/ml. 
 KIM-1 concentrations rose considerably after 48h of polymyxin B treatment compared to non-
treated cells. The level of KIM-1, compared to control 3.47±0.47 ng / ml, was after 300 μg / ml 
polymyxin B treatment at 55.43±17.72 ng / ml, and then the KIM-1 level, with the polymyxin B 
treatment rising up to 600 μg / ml, increased significantly. 
The levels of KIM-1 after 72h treatment of polymyxin B increased significantly compared to 
non-treated cells.  For instance, KIM-1 production after 250 μg/ml polymyxin B treatment was 
62.15±14.30 ng/ml compared with the control 9.81±1.1 ng/ml and then the level of KIM-1 





























Figure 4.11: Measurement of KIM-1 production from human PTCs treated with range 
concentrations of polymyxin B for 24, 48 and 72 hours.  
Levels were normalised to MTS absorbance value to account for cell numbers after nephrotoxin 
treatments. Human PTCs were treated with a range of polymyxin B concentration (50 to 600 
µg/ml). The levels of KIM-1 showed, polymyxin B is time and concertation dependent. For 
example, KIM-1 production after 100 µg/ml polymyxin B treatment for 24h was 7.7±1.7 ng/ml 
and after 250 µg/ml the level of KIM-1 increased to 24.1±7.2 ng/ml. The level of KIM-1 after 
400 µg/ml polymyxin B treatment for 48h was 73.6±14.1 ng/ml and after 72h the level 
increased to 129.3±24.4 ng/ml.  Statistical analysis was conducted using repeated-measures-
paired-one-way ANOVA the data are representative of three independent experiments (n=3). 





4.3.3 NGAL produced after treatment of human PTCs in presence of a range concentration 
of polymyxin B  
The NGAL production after treated human PTCs with a range concentration of polymyxin B 
were investigated. The concentrations of NGAL was normalised to the cell viability. The results 
are shown in Figure 4.12.  
There were a significant increase in NGAL levels after 24h treatment of polymyxin B compared 
to non-treated cells. NGAL levels were elevated significantly by (50 to 600) μg/ml polymyxin B 
concentrations. For example, the level of NGAL production was at 100 μg/ml polymyxin B to 
16.37±2.96 ng/ml compared with the control 6.1±0.45 ng/ml and then the level of NGAL 
remained the same as the concentration of polymyxin B increases up to 600 μg/ml.  
The levels of NGAL increased significantly in comparison with non-treated cells after 48h of 
gentamicin treatment. The maximum level of NGAL was after 600 μg / ml polymyxin B 
treatment 426.18±130.72 ng / ml compared to the control 18.78±3.1 ng / ml.  
The NGAL levels after 72h treatment of polymyxin B increased significantly compared to non-
treated cells.  For example, the level of NGAL production after 250 μg/ml polymyxin B 
treatment was 306.19±65.39 ng/ml compared with the control 40.95±3.84 ng/ml and then the 




























Figure 4.12: Measurement of NGAL production from human PTCs treated with range 
concentrations of polymyxin B for 24, 48 and 72 hours.  
Levels were normalised to MTS absorbance value to account for cell numbers after nephrotoxin 
treatments. Human PTCs were treated with a range of polymyxin B concentration (50 to 600 
µg/ml). For example, NGAL production after 300 µg/ml polymyxin B treatment for 24h was 
50.7±0.3 ng/ml and after 500 µg/ml the level of NGAL increased to 68.7±15.4 ng/ml. The level 
of NGAL after 250 µg/ml polymyxin B treatment for 48h was 195.32±24.4 ng/ml and after 72h 
the level increased to 306.1±65.3 ng/ml.  Statistical analysis was conducted using repeated-
measures-paired-one-way ANOVA the data are representative of three independent 
experiments (n=3). Each point mean ± S.E.M values of each group. (*p < 0.05, **p < 0.01, ***p 
< 0.001).  
81 
 
4.3.4 Clusterin produced after treatment of human PTCs in presence of a range 
concentration of polymyxin B  
The impact of a range of polymyxin B concentrations on clusterin levels produced by human 
PTCs were investigated. The concentrations of the biomarker was normalised to the cell 
viability. The results are shown in Figure 4.13. 
Clusterin concentrations rose considerably in comparison with non-treated cells 
concentrations after 24 h polymyxin B incubation. Clusterin levels were increased gradually 
and significantly by 50 to 600 μg/ml polymyxin B concentrations treatment. The level of 
clusterin after 300 μg/ml gentamicin treatment was 64.92±5.30 ng/ml compared with the non-
treated cells 6.43±0.49 ng/ml and then the level of clusterin remained at stable as the 
concentration of polymyxin B increases up to 600 μg/ml. 
After 48h of polymyxin B incubation, clusterin concentrations significantly increased compared 
with non-treated cells. The highest production of clusterin, compared to control 26.52±2.82 
ng / ml, was after 250 μg / ml polymyxin B treatment at 203.25±30.81 ng / ml, and then the 
clusterin level, with the polymyxin B rising up to 600 μg / ml, remained almost the same.  
The clusterin production after 72h treatment of polymyxin B increased significantly compared 
to non-treated cells.  For instance, clusterin levels were gradually elevated by 50, 100, 250 and 
300 μg/ml polymyxin B concentrations. The level of clusterin after 300 μg/ml polymyxin B 



























Figure 4.13: Measurement of clusterin production from human PTCs treated with a range of 
concentrations of polymyxin B for 24, 48 and 72 hours.  
Levels were normalised to MTS absorbance value to account for cell numbers after nephrotoxin 
treatments. Human PTCs were treated with a range of polymyxin B concentration (50 to 600 
µg/ml). For example, clusterin production after 250 µg/ml polymyxin B treatment for 24h was 
54.8±2.3 ng/ml and after 500 µg/ml the level of clusterin increased to 85.6±19.7 ng/ml. The 
level of clusterin after 300 µg/ml polymyxin B treatment for 48h was 223.7±30.8 ng/ml and 
after 72h the level increased to 307.8±69.4 ng/ml. Statistical analysis was conducted using 
repeated-measures-paired-one-way ANOVA the data are representative of three independent 
experiments (n=3). Each point mean ± S.E.M values of each group. (*p < 0.05, **p < 0.01, ***p 
< 0.001).  
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4.3.5 MTS and ATP cell viability assays 
After 24 and 48 hours treatment with 250 μg / ml polymyxin B, cell viability was measured. 
The cell viability was also measured in the presence of rosuvastatin co-treatments. The cell 
viability from the same plate was assessed using both MTS and ATP assays. The results showed 
no significant difference between the two methods used for cell viability. The results are 
shown in Figure 4.14. 
After 24h of treatment, the results revealed that cell viability decreased significantly in 
response to exposure to polymyxin B to 74.52±4.88% of control. The rosuvastatin co treatment 
did not change the cell viability (96.16±2.85% live cells). The treatment of polymyxin B with 
rosuvastatin increased the live cells compared to only polymyxin B (87.25±4.26%).  
The cell viability was reduced significantly by polymyxin B (65.55±8.1%) after 48h of treatment. 
However, the cell viability did not change with rosuvastatin (94.99±2.94 %). The cell viability 













































































































Figure 4.14: Cells Viability of human PTCs after treatment of polymyxin B for 24 and 48 hours.  
MTS and ATP assays were used to measure the cell viability. Viability is measured as a 
percentage of the control. For example, MTS percentage after polymyxin B treatment for 24h 
was 74.5% and ATP percentage was 69.2%. In addition, the co-treatment of  rosuvastatin  with 
polymyxin B for 48h showed, the percentage of MTS was 77.6% and ATP percentage was 74.1%.      
Statistical analysis was conducted using repeated-measures-paired-one-way ANOVA the data 
are representative of three independent experiments (n=3). Bars represent mean ± S.E.M values 
of each group. (*p < 0.05, **p < 0.01, ***p < 0.001).  
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4.3.6 Lactate dehydrogenase (LDH) cytotixicy assay 
LDH released by damaged cells was measured.  In this experiment, we treated human PTCs for 
24 and 48 hours with 250 µg/ml polymyxin B and LDH was measured. In addition, we measured 
the LDH after rosuvastatin co treatment. The results are consistent with cell viability data. 
Result is shown in Figure 4.15 
After 24h, the results revealed that LDH increased significantly in response to exposure to 
polymyxin B to 40.62±4.17%. The rosuvastatin co treatment did not change the LDH 
(12.1±0.27%). The treatment of polymyxin B with cilastatin decreased the LDH compared to 
only polymyxin B (27.38±2.21%). 
The LDH was increased significantly by polymyxin B (47.91±5.1%) after 48h treatment. 
However, the LDH did not change with rosuvastatin (12.41±0.95%). The LDH after polymyxin B 



































































Figure 4.15: LDH of human PTCs after treatment of polymyxin B for 24 and 48 hours.  
LDH is measured as a percentage of the control. LDH percentage after polymyxin B treatment 
for 24h was 40.6% and after 48h the percentage increased to 47.9%. In addition, LDH 
percentage decreased after rosuvastatin co-treatment with polymyxin B for 48h to 33.1% 
Statistical analysis was conducted using repeated-measures-paired-one-way ANOVA the data 
are representative of three independent experiments (n=3). Bars represent mean ± S.E.M values 




4.3.7 KIM-1 production after treatment of human PTCs in presence of polymyxin B +/- 
rosuvastatin 
The quantity of KIM-1 produced after human PTCs were exposed for 24 and 48 hours with 250 
μg / ml polymyxin B were investigated. The levels of KIM-1 was also measured in the presence 
rosuvastatin co-treatments. The concentrations of KIM-1 was normalised to the cell viability 
as determined from their MTS absorbance’s, expressed as ng/ml. The results are shown in 
Figure 4.16. 
After 24h treatment of polymyxin B, the amount of KIM-1 in the apical membrane did change 
significantly from the control (1.73±0.51 to 5.25±1.01 ng/ml, P < 0.01). However, the presence 
of rosuvastatin did not change KIM-1 level to 1.71±0.55 ng/ml compared to control 1.73±0.51 
ng/ml. The co-treatment of polymyxin B with rosuvastatin caused a significant decrease in KIM-
1 in the apical membrane (2.44±0.81 ng/ml, P < 0.0001) compared to only polymyxin B. In 
comparison with apical membrane, basolateral membrane levels of KIM-1 were undetectable. 
The amount of KIM-1 on the apical membrane changed significantly from the control after 48h 
of treatment with polymyxin B (20.80±5.08 ng/ml, P < 0.01). However, when we added   
rosuvastatin did not change KIM-1 level 6.98±1.28 ng/ml compared to control 6.77±1.18 
ng/ml. The co-treatment of polymyxin B with rosuvastatin caused a significant decline in KIM-
1 in the apical membrane (13.01±3.55 ng/ml, P < 0.0001) compare to only polymyxin B. In 






























































































Figure 4.16: The amount of KIM-1 produced after treatment of human PTCs for 24 and 48 
hours in presence of polymyxin B +/- rosuvastatin. 
ELISA was used to measure KIM-1 production. For example, KIM-1 production in the apical 
membrane is significantly higher than basolateral membrane. The amount of KIM-1 in the 
apical membrane change significantly from the control (5.25±1.01 ng/ml, P < 0.01) after 24h 
polymyxin B treatment. After co-treatment with rosuvastatin, KIM-1 level decreased to 
(8.16±1.39 ng/ml, P < 0.0001) compared to only polymyxin B. The level of KIM-1 after 48h 
treatment was more than 3 fold compared to 24h. Statistical analysis was conducted using 
repeated-measures-paired-one-way ANOVA the data are representative of three independent 
experiments (n=3). Bars represent mean ± S.E.M values of each group. (*p < 0.05, **p < 0.01, 
***p < 0.001, ++++p < 0.0001).  
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4.3.8 NGAL production after treatment of human PTCs in presence of polymyxin B +/- 
rosuvastatin 
NGAL production for 24 and 48 hours in the presence of 250 µg/ml polymyxin B following 
treatment of human PTCs. In the presence of rosuvastatin co-treatment, levels of NGAL were 
also measured. NGAL concentrations had been normalized to cell viability based on the MTS 
absorption of the human PTCs, resulting in ng / ml. Figure 4.17 shows the results.  
In 24h treatment of polymyxin B, the amount of NGAL in the apical membrane did increased 
significantly from the control (70.16±18.28 ng/ml, P < 0.01). However, the presence of 
rosuvastatin did not change NGAL level 20.52±5.60 ng/ml compared to control 20.41±5.56 
ng/ml. The co-treatment of polymyxin B with rosuvastatin caused a significant decrease in 
NGAL in the apical membrane (43.75±15.54 ng/ml, P < 0.0001) compared to only polymyxin B. 
NGAL concentrations in the basolateral membrane were very low compared to apical 
membrane. 
After 48h treatment of polymyxin B, the amount of NGAL in the apical membrane did increase 
significantly from the control (178.28±49.36 ng/ml, P < 0.01). However, the presence of 
rosuvastatin did not change NGAL level 38.83±15.78 ng/ml compared to control 38.72±14.58 
ng/ml. The co-treatment of polymyxin B with rosuvastatin caused a significant decrease in 
NGAL in the apical membrane (108.20±9.45 ng/ml, P < 0.0001) compared to only polymyxin B. 










































































































Figure 4.17: The amount of NGAL produced after treatment of human PTCs for 24 and 48 
hours in presence of polymyxin B +/- rosuvastatin. 
ELISA was used to measure NGAL production. For example, NGAL production in the apical 
membrane is significantly higher than basolateral membrane. The amount of NGAL in the 
apical membrane change significantly from the control (70.16±18.28 ng/ml, P < 0.01) after 24h 
polymyxin B treatment. After co-treatment with rosuvastatin, NGAL level decreased to 
(43.75±15.54 ng/ml, P < 0.0001) compared to only polymyxin B. The level of NGAL after 48h 
treatment was more than 2 fold compared to 24h. Statistical analysis was conducted using 
repeated-measures-paired-one-way ANOVA the data are representative of three independent 
experiments (n=3). Bars represent mean ± S.E.M values of each group. (*p < 0.05, **p < 0.01, 
***p < 0.001, ++++p < 0.0001).  
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4.3.9 Clusterin production after treatment of human PTCs for in presence of polymyxin B 
+/- rosuvastatin 
Clusterin production in the presence of 250 μg / ml of polymyxin B was measured after 24 and 
48 hours of human PTC treatment using ELISA. Clusterin levels were also measured in the 
presence of rosuvastatin co-treatment. Levels of clusterin were normalized to cell viability 
based on the PTCs ' MTS absorption, resulting in ng / ml. The results are shown in Figure 4.18. 
After 24h treatment of polymyxin B, the amount of clusterin in the apical membrane did 
increase significantly from the control (95.63±18.11 ng/ml, P < 0.01). However, the presence 
of rosuvastatin did not change clusterin level 19.22±5.29 ng/ml compared to control 
19.28±8.64 ng/ml. The co-treatment of polymyxin B with rosuvastatin caused a significant 
decrease in clusterin in the apical membrane (42.42±12.12 ng/ml, P < 0.0001) compared to 
only polymyxin B. The levels of clusterin in the basolateral membrane were low compared to 
the apical membrane. 
After 48h of polymyxin B treatment, the amount of clusterin in the apical membrane changed 
significantly from control (411.27±147.69 ng/ml, P < 0.01). However, when we added 
rosuvastatin did not change clusterin level 76.25±10.72 ng/ml compared to control 
76.88±12.14 ng/ml. The co-treatment of polymyxin B with rosuvastatin caused a significant 
decrease in clusterin in the apical membrane (240.29±78.68 ng/ml, P < 0.0001) compare to 











































































































Figure 4.18: The amount of clusterin produced after treatment of human PTCs for 24 and 48 
hours in presence of polymyxin B +/- rosuvastatin.  
ELISA was used to measure clusterin production. For example, clusterin production in the apical 
membrane is significantly higher than basolateral membrane. The amount of clusterin in the 
apical membrane change significantly from the control (95.63±18.11 ng/ml, P < 0.01) after 24h 
polymyxin B treatment. After co-treatment with rosuvastatin, clusterin level decreased to 
(42.42±12.12 ng/ml, P < 0.0001) compared to only polymyxin B. The level of clusterin after 48h 
treatment was more than 3 fold compared to 24h. Statistical analysis was conducted using 
repeated-measures-paired-one-way ANOVA the data are representative of three independent 
experiments (n=3). Bars represent mean ± S.E.M values of each group. (*p < 0.05, **p < 0.01, 
***p < 0.001, ++++p < 0.0001).  
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4.4 Small molecule nephrotoxin – Cisplatin 
Before quantifying the expression of biomarkers using ELISA, human PTCs were treated with 
cisplatin, a known nephrotoxin. The uptake of cisplatin in human PTC is regulated by OCT2 
transporter in the basolateral membrane. The effects of cisplatin on human PTC monolayers 
were important as toxicity induced by cisplatin is already well characterized and can be 
compared in vivo. 
4.4.1 MTS cell viability after treatment in presence of range of concentrations of cisplatin 
After cisplatin concentration ranges (5 to 40 μM) were used for 24, 48 and 72 hours for human 
PTCs, the cell viability was measured.  MTS assay was used to assess cell viability. The MTS 
absorbance show as a percentage normalised to non-treated cells. The results are shown in 
Figure 4.19.   
The findings from MTS assay show the impact of cisplatin on human PTCs.  With the rise in 
cisplatin concentration, cell viability reduced significantly. For example, after 24h treatment 
with 20 µM cisplatin the cell viability was 67.83% compared to non-treated cells. The 
percentage of live cells was less than 30% after 30 µM cisplatin treatment. 
 After 48h, the cisplatin dose decreases the percentage of live cells. For instance, at 25 µM 
cisplatin the percentage of live cells was 59%. The live cells was less than 55% after 35 µM 
cisplatin.   
There was a major decrease in cell viability after 72h treatment with a range of concentration 
of cisplatin. After 15 µM cisplatin treatment, live cells reduced more than 30%. In addition, 




































Figure 4.19: Cell viability in human PTCs treated with range concentrations of cisplatin for 
24, 48 and 72 hours.   
MTS assay was used to measure the cell viability. Cisplatin showed a time and concentrations 
dependent after 24, 48 and 72 hours treatment. For example, the cell viability after 25 µM 
cisplatin for 24h was 64.5% and the percentage dropped to 59.1% after 48h. In addition, cell 
viability after 10 µM cisplatin treatment for 72h was 80.8% and after 20 µg/ml cisplatin the cell 





4.4.2  KIM-1 production after treatment of human PTCs in presence of a range 
concentration of cisplatin 
The effects of a range of cisplatin concentrations on KIM-1 levels produced by human PTCs 
were explored. The concentrations of the biomarker was normalised to the cell viability. The 
results are shown in Figure 4.20. 
KIM-1 concentrations rose considerably after 24h of cisplatin treatment compared to non-
treated cells.  For instance, the level of KIM-1 production at 20 μM cisplatin to 58.11±9.92 
ng/ml compared with the control 2.40±0.83 ng/ml and then the level of KIM-1 increased as the 
concentration of cisplatin increases up to 40 μM. 
The levels of KIM-1 increased significantly in comparison with non-treated cells after 48h of 
cisplatin treatment. The KIM-1 levels have been considerably increased by 5 to 30 μM cisplatin 
treatment. Compared to control 4.21±0.39 ng / ml, the peak level of KIM-1 was at 83.41±9.94 
ng / ml after 30 μM cisplatin treatment, and then the KIM-1 level increased, with cisplatin 
levels rising to 40 μM. 
The KIM-1 levels increased significantly compared to non-treated cells after 72h of cisplatin 
treatment.  For instance, KIM-1 levels were elevated significantly by 5, 10, 15 and 20 μM 
cisplatin concentrations. The level of KIM-1 production reached the peak at 20 μM cisplatin 
treatment to 98.62±10.74 ng/ml compared with the control 19.1±5.13 ng/ml and then the 




































Figure 4.20: Measurement of KIM-1 production from human PTCs treated with range 
concentrations of cisplatin for 24, 48 and 72 hours.   
Levels of KIM-1 were normalised to MTS absorbance value to account for cell numbers after 
nephrotoxin treatments. Human PTCs were treated with a range of cisplatin concentration (5 
to 40 µM). For example, KIM-1 production after 10 µM cisplatin treatment for 24h was 4.5±0.7 
ng/ml and after 25 µM the level of KIM-1 increased to 7.8±1.1 ng/ml. The level of KIM-1 after 
30 µM cisplatin treatment for 48h was 26.7±7.7 ng/ml and after 72h the level increased to 
114.8±27.6 ng/ml. Statistical analysis was conducted using repeated-measures-paired-one-
way ANOVA the data are representative of three independent experiments (n=3). Each point 





4.4.3 NGAL production after treatment of human PTCs in presence of a range concentration 
of cisplatin 
After treatment of human PTCs with a range of cisplatin concentrations, NGAL production was 
explored. NGAL concentrations were normalized to the viability of the cell. The results are 
shown in Figure 4.21. 
NGAL concentrations have increased significantly relative to non-treated cells after 24h 
cisplatin treatment. NGAL levels were elevated significantly by (5 to 30) μM cisplatin 
concentrations. The highest level of KIM-1 production was at 30 μM cisplatin to 345.60±93.1 
ng/ml compared with the control 30.22±5.86 ng/ml and then the level of NGAL decreased as 
the concentration of cisplatin increases up to 40 μM.  
NGAL levels increased significantly after 48h of cisplatin treatment compared to non-treated 
cells. The NGAL levels increased by 5 to 35 μM cisplatin. The level of NGAL reached the peak 
after 35 μM cisplatin treatment 460.23±137.88 ng / ml compared to the control 45.45±11.38 
ng / ml. 
The NGAL levels increased significantly in comparison with non-treated cells after 72h of 
cisplatin treatment. For example, the level of NGAL production at 25 μM cisplatin treatment 
was 412.78±143.1 ng/ml compared with the control 83.16±17.40 ng/ml and then the level of 






































Figure 4.21: Measurement of NGAL production from human PTCs treated with range 
concentrations of cisplatin for 24, 48 and 72 hours.   
Levels of NGAL were normalised to MTS absorbance value to account for cell numbers after 
nephrotoxin treatments. Human PTCs were treated with a range of cisplatin concentration (5 
to 40 µM). For example, NGAL production after 20 µM cisplatin treatment for 24h was 
207.1±56.1 ng/ml and after 30 µM the level of NGAL increased to 345.6±93.1. The level of NGAL 
after 25 µM cisplatin treatment for 48h was 343.3±24.4 ng/ml and after 72h the level increased 
to 412.7±143.1 ng/ml. Statistical analysis was conducted using repeated-measures-paired-
one-way ANOVA the data are representative of three independent experiments (n=3). Each 





4.4.4  Clusterin production after treatment of human PTCs in presence of a range 
concentration of cisplatin  
The effects of a range of cisplatin concentrations on clusterin levels produced by human PTCs 
were investigated. The concentrations of the biomarker was normalised to the cell viability. 
The results are shown in Figure 4.22. 
The level of clusterin considerably increased relative to non-treated cells after 24h cisplatin 
treatment.   The level of clusterin reached the peak at 15 μM cisplatin to 211.23±17.75 ng/ml 
compared with the control 26.56±10.22 ng/ml and then the level of clusterin decreased slightly 
as the concentration of cisplatin increases up to 40 μM. 
The levels of clusterin increased significantly in comparison with non-treated cells after 48h of 
cisplatin treatment. The clusterin levels increased by 5 to 25 μM cisplatin treatment. The 
highest clusterin level compared to 37.63±10.83 ng / ml was at 274.97±56.20 ng / ml after 25 
μM cisplatin treatment, and then the clusterin level slightly decreased with a cisplatin level of 
up to 40 μM. 
The clusterin production after 72h treatment of cisplatin increased significantly compared to 
non-treated cells.  For instance, clusterin levels were gradually elevated by 5 to 25 μM cisplatin 
concentrations. Clusterin production peaked at 25 μM cisplatin to 356.53±59.95 ng / ml in 
comparison with the 72.98±13.41 ng / ml control, and then the clusterin production rose with 



































Figure 4.22: Measurement of clusterin production from human PTCs treated with range 
concentrations of cisplatin for 24, 48 and 72 hours.   
Levels were normalised to MTS absorbance value to account for cell numbers after nephrotoxin 
treatments. Human PTCs were treated with a range of cisplatin concentration (5 to 40 µM). For 
example, clusterin production after 25 µM cisplatin treatment for 24h was 129.4±33.9 ng/ml 
and after 40 µM the level of clusterin decreased to 53.3±9.6 ng/ml. The level of clusterin after 
30 µM cisplatin treatment for 48h was 196.9±6.1 ng/ml and after 72h the level increased to 
621.9±174.1 ng/ml. Statistical analysis was conducted using repeated-measures-paired-one-
way ANOVA the data are representative of three independent experiments (n=3). Each point 




4.4.5 MTS and ATP cells viability assays 
The cell viability was measured after treatment of human PTCs for 24 and 48 hours with 25 µM 
cisplatin. In the presence of cimetidine co-treatment, cell viability was also measured. Both 
MTS and ATP assays were used to assess cell viability from the same plate. No major difference 
was discovered between the two methods of assessment. The results are shown in Figure 4.23. 
After 24h, the results showed that cell viability was considerably reduced to 71.25±2.98% as a 
result of exposure to cisplatin. The co-treatment with cimetidine hasn't altered cell viability 
(93.79±3.1% live cells). The treatment of cisplatin with cimetidine increased the live cells 
compared to only cisplatin (83.11±1.83%).  
The cell viability was reduced significantly by cisplatin (61.18±3.76%) after 48h treatment. 
However, the cell viability did not change with cimetidine (93.44±1.36%). Cisplatin with 
































































































Figure 4.23: Cells Viability of human PTCs after treatment of cisplatin for 24 and 48 hours. 
MTS and ATP assays were used to measure the cell viability. Viability is measured as a 
percentage of the control. For example, MTS percentage after cisplatin treatment for 24h was 
71.2% and ATP percentage was 72.5%. In addition, the co-treatment of cimetidine with 
cisplatin for 48h showed, the percentage of MTS was 74.4% and ATP percentage was 75.1%.      
Statistical analysis was conducted using repeated-measures-paired-one-way ANOVA the data 
are representative of three independent experiments (n=3). Bars represent mean ± S.E.M values 
of each group. (*p < 0.05, **p < 0.01, ***p < 0.001).  
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4.4.6  Lactate dehydrogenase (LDH) cytotixicy assay 
A common method for determining cytotoxicity is the measurement of cytoplasmic enzymes 
released by damaged cells. Treatment of human PTCs for 24 and 48 hours with 25 µM cisplatin 
and then LDH was measured. In addition, we measured the LDH after cimetidine co treatment. 
The results is consistent with cell viability data. Result shown in Figure 4.24. 
After 24h, the results revealed that LDH increased significantly in response to cisplatin 
exposure to 34.38±2.72%. The cimetidine co treatment did not change the LDH (14.88±1.58%). 
The treatment of cisplatin with cimetidine decreased the LDH compared to only cisplatin 
(24.49±2.01%). 
The LDH was increased significantly by cisplatin (47.1±1.67%) after 48h.However, the LDH did 
not change with cimetidine (18.89±1.39%). The LDH after cisplatin with cimetidine was lower 

























































Figure 4.24: LDH of human PTCs after treatment of cisplatin for 24 and 48 hours.  
LDH is measured as a percentage of the control. LDH percentage after cisplatin treatment for 
24h was 34.3% and after 48h the percentage increased to 47.1%. In addition, LDH percentage 
decreased after cimetidine co-treatment with cisplatin for 48h to 32.5% Statistical analysis was 
conducted using repeated-measures-paired-one-way ANOVA the data are representative of 
three independent experiments (n=3). Bars represent mean ± S.E.M values of each group. (*p 




4.4.7 KIM-1 production after treatment of human PTCs in presence of cisplatin +/- 
cimetidine 
The quantity KIM-1 generated after 24 and 48 hours of human PTC treatment in the presence 
of 25 μM cisplatin were investigated. In presence of cimetidine co-treatments, the levels of 
KIM-1 were also measured. The concentrations of KIM-1 was normalised to the cell viability as 
determined from their MTS absorbance’s, expressed as ng/ml. The results are shown in Figure 
4.25. 
After 24h treatment of cisplatin, the amount of KIM-1 in the apical membrane did change 
significantly from the control (3.55±1.07 ng/ml, P < 0.01). However, the presence of cimetidine 
did not change KIM-1 level 0.074±0.22 ng/ml compared to control 0.077±0.21 ng/ml. The co-
treatment of cisplatin with cimetidine caused a significant decrease in KIM-1 in the apical 
membrane (2.10±0.66 ng/ml, P < 0.0001) compared to only cisplatin. KIM-1 levels in the 
basolateral membrane were undetectable compared to apical membrane. 
After 48h treatment of cisplatin, the amount of KIM-1 in the apical membrane did increase 
significantly from the control (14.61±3.49 ng/ml, P < 0.01). However, when we added   
cimetidine did not change KIM-1 level 4.49±0.61 ng/ml compared to control 4.96±1.48 ng/ml. 
The co-treatment of cisplatin with cimetidine caused a significant decrease in KIM-1 in the 
apical membrane (8.99±1.95 ng/ml, P < 0.0001) compare to only cisplatin. Compared to apical 

























































































Figure 4.25: The amount of KIM-1 produced after treatment of human PTCs for 24 and 48 
hours in presence of cisplatin +/- cimetidine.  
ELISA was used to measure KIM-1 production. For example, KIM-1 production in the apical 
membrane is significantly higher than basolateral membrane. The amount of KIM-1 in the 
apical membrane change significantly from the control (3.55±1.07 ng/ml, P < 0.01) after 24h 
cisplatin treatment. After co-treatment with cimetidine, KIM-1 level decreased to (2.10±0.66 
ng/ml, P < 0.0001) compared to only cisplatin. The level of KIM-1 after 48h treatment was 
almost 4 fold compared to 24h. Statistical analysis was conducted using repeated-measures-
paired-one-way ANOVA the data are representative of three independent experiments (n=3). 




4.4.8 NGAL production after treatment of human PTCs in presence of cisplatin +/- 
cimetidine 
NGAL production for 24 and 48 hours in the presence of cisplatin following treatment of human 
PTCs. In the presence of cimetidine co-treatment, levels of NGAL were also measured. NGAL 
concentrations had been normalized to cell viability based on the MTS absorption of the PTCs, 
resulting in ng / ml. The results are shown in Figure 4.26. 
In 24h treatment of cisplatin, the amount of NGAL in the apical membrane did increase 
significantly from the control (489.77±120.25 ng/ml, P < 0.01). In contrast, the presence of 
cimetidine did not change NGAL level 172.32±59.59 ng/ml compared to control 170.14±5.32 
ng/ml. The co-treatment of cisplatin with cimetidine caused a significant decrease in NGAL in 
the apical membrane (254.28±82.1 ng/ml, P < 0.0001) compared to only cisplatin. Compared 
to apical membrane, NGAL levels in the basolateral membrane were low. 
After 48h treatment of cisplatin, the amount of NGAL in the apical membrane did rise 
significantly from the control (3936.2±1828.69 ng/ml, P < 0.01). However, the presence of 
cimetidine did not change NGAL level 702.46±133.38 ng/ml compared to control 
735.12±180.97 ng/ml. The co-treatment of cisplatin with cimetidine caused a significant 
decline in NGAL in the apical membrane (1207.11±442.01 ng/ml, P < 0.0001) compared to only 


























































































Figure 4.26: The amount of NGAL produced after treatment of human PTCs for 24 and 48 
hours in presence of cisplatin +/- cimetidine. 
ELISA was used to measure NGAL production. For example, NGAL production in the apical 
membrane is significantly higher than basolateral membrane. The amount of NGAL in the 
apical membrane change significantly from the control (489.77±120.25 ng/ml, P < 0.01) after 
24h cisplatin treatment. After co-treatment with cimetidine, NGAL level decreased to 
(254.28±82.1 ng/ml, P < 0.0001) compared to only cisplatin. The level of NGAL after 48h 
treatment was more than 8 fold compared to 24h. Statistical analysis was conducted using 
repeated-measures-paired-one-way ANOVA the data are representative of three independent 
experiments (n=3). Bars represent mean ± S.E.M values of each group. (*p < 0.05, **p < 0.01, 
***p < 0.001, ++++p < 0.0001).  
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4.4.9 Clusterin production after treatment of human PTCs in presence of cisplatin +/- 
cimetidine 
Human PTCs were treated for 24 and 48 hours with 25 µM cisplatin and clusterin production 
was measured. In the presence of cimetidine co-treatment, levels of clusterin were also 
measured. Clusterin concentrations had been normalized to cell viability based on the MTS 
absorption of the PTCs, resulting in ng / ml. The result is shown in Figure 4.27. 
After 24h treatment of cisplatin, the amount of clusterin in the apical membrane did elevate 
significantly compared the untreated cells (200.05±67.43 ng/ml, P < 0.01). In contrast, the 
presence of cimetidine did not change clusterin level 40.23±15.71 ng/ml compared to control 
39.62±14.27 ng/ml. The co-treatment of cisplatin with cimetidine caused a significant decline 
in clusterin in the apical membrane (119.34±23.60 ng/ml, P < 0.0001) compared to only 
cisplatin. Compared to apical membrane, clusterin levels in the basolateral membrane were 
low. 
After 48h treatment of cisplatin, the amount of clusterin in the apical membrane did increase 
significantly compared the untreated cells (613.90±286.48 ng/ml, P < 0.01). However, the 
presence of cimetidine did not change clusterin level 80.38±18.57 ng/ml compared to control 
79.57±18.16 ng/ml. The co-treatment of cisplatin with cimetidine caused a significant decrease 
in clusterin in the apical membrane (274.60±160.79 ng/ml, P < 0.0001) compared to only 



























































































Figure 4.27: The amount of clusterin produced after treatment of human PTCs for 24 and 48 
hours in presence of cisplatin +/- cimetidine.  
ELISA was used to measure clusterin production. For example, clusterin production in the apical 
membrane is significantly higher than basolateral membrane. The amount of clusterin in the 
apical membrane change significantly from the control (200.05±67.43 ng/ml, P < 0.01) after 
24h cisplatin treatment. After co-treatment with cimetidine, clusterin level decreased to 
(119.34±23.60 ng/ml, P < 0.0001) compared to only cisplatin. The level of clusterin after 48h 
treatment was more than 3 fold compared to 24h. Statistical analysis was conducted using 
repeated-measures-paired-one-way ANOVA the data are representative of three independent 
experiments (n=3). Bars represent mean ± S.E.M values of each group. (*p < 0.05, **p < 0.01, 
***p < 0.001, ++++p < 0.0001).  
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4.5 Discussion  
This chapter aims to explore how primary human PTCs might serve as in-vitro models for 
nephrotoxicity. Monolayers were subjected to established nephrotoxins - cisplatin, gentamicin 
and polymyxin B, and the expression of KIM-1, NGAL and clusterin was also determined. The 
effects of the co-administration of rosuvastatin, cilastatin and cimetidine with polymyxin B, 
gentamicin and cisplatin were invest aged in this chapter. Using primary cultured cells carries 
several benefits. Compared to some established cell lines, The primary cells kept their full array 
of expression of drug transporters, much more than many established cell lines [116]. In 
exploring the effect of toxic xenobiotics on the kidneys, primary cells are thus thought to be 
more stable.  
4.5.1 Cell viability of human PTCs  
 The MTS and ATP assays were used to assess the number of live cells. The mechanism of MTS 
assay by metabolically active mitochondria to reduce a tetrazolium salt to formazan, which is 
spectrophotometrically distinguishable from the former. On the other hand, the ATP Cell 
Viability Assay is a homogeneous method for determining the number of viable cells in culture 
based on the quantity of the present ATP, which indicates the presence of metabolically active 
cells. The first step was to evaluate the viability of cells after being treated by nephrotoxins. 
Three types of nephrotoxins were employed: cisplatin, gentamicin and polymyxin B. Those are 
known nephrotoxins and they use different transporters to cause nephrotoxicity to human 
PTCs. The result was as predicted.   
Our results observed a time and concentrations dependent after treatment human PTCs with 
gentamicin, polymyxin B and cisplatin, indicating that our in vitro model is an ideal tool to study 
renal toxicity caused by different nephrotoxins. For example, after exposure of human PTCs 
with a range concentration of cisplatin, the cell viability after 15 µM cisplatin treatment for 
24h was 82.1% and after 48h the percentage of live cells dropped to 71%. At the same time for 
example, the percentage of live cells after 72h treatment with 25 and 30 µM cisplatin were 
39% and 16% respectively.     
Another goal was to compare MTS and ATP assays results for cells that came into contact with 
nephrotoxins in similar conditions. Human PTCs following exposure to nephrotoxins, 
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similarities in the viability data from both assays were found. The effect of treating human PTC 
monolayers with cisplatin, a commonly used nephrotoxin, was then observed, with regard to 
the monolayer production of KIM-1, NGAL and clusterin. Given the identical conditions of the 
controlled experiment, similar results were expected as mitochondrial enzymes reduce the 
reagents from both MTS and ATP. These results show the reproducible of the model we are 
using to predict nephrotoxicity. We can use any assay to measure the cell viability and the 
results will be the same.    
4.5.2 LDH 
In this study, LDH assay was used to measure the cytotoxicity of human PTCs after 
nephrotoxins exposure.  The results were consistent with cell viability data. The data showed 
as the human PTCs exposed to different nephrotoxins the release of LDH is increased. A study 
used LLC-PK1 cells to measure the LDH release after treatment with 375 µM polymyxin B for 
24 and 72 hours. They found a significant increase in LDH release after exposure, indicating the 
time dependent of polymyxin B by using LDH release in LLc-PK1 cells [117].      
4.5.3 Human Biomarkers   
The monolayer production of KIM-1, NGAL and clusterin was significantly higher when treated 
with polymyxin B over 24, 48 and 72 hours, than when not subjected to this treatment in the 
control samples. The release of KIM-1 was dependent on the concentration of the polymyxin 
B, and the same was found to be true with cisplatin and gentamicin. 
NGAL concentrations after a range concentrations treatment of polymyxin B is increasing in 
very high amount compared to 24 and 48 hours treatment. This might due to polymyxin B 
needing more time to invoke the release NGAL from the apical membrane of the PTCs.        
Our data showed non-saturatable effect of cisplatin treatment to human PTCs on biomarkers 
production. This might due to physiological response to cisplatin. In this study, biomarkers 
levels were measured after 3 days of nephrotoxins treatment. It might need more time to 
reach the saturatable point. This has been shown in another study there the authors measured 
urinary KIM-1 from rat with obstructive AKI. The data showed that KIM-1 was increasing even 
at day 7 of obstruction [118].  
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Our results also showed differences in response in biomarkers concentrations after treatment 
with cisplatin. In contrast to KIM-1, the levels of NGAL and clusterin started to decrease at high 
levels of cisplatin treatment on day 2 and at day 3. This might due to delayed response of the 
biomarkers to the nephrotoxin. For instance, overloading the monolayers the proximal tubular 
cells with cisplatin has been shown to alter cell signaling pathways and gene transcription, and 
as a result the renal transporter expression and function – they are modulated to compensate 
for the loss of nutrients [119]. These changes could explain the stalling of NGAL and clusterin 
production during 24 and 48 hours, but increased significantly at the 72 hour treatment. 
Urinary KIM-1 has been reported to be specific to proximal tubular damage. In preclinical 
biomarker qualification studies, it has proven that it was a sensitive and early diagnostic 
indicator for renal injury, with superior precision and susceptibility to traditional biomarkers 
[120]. Changes of the expression of NGAL were one of the most recent effects seen in kidneys 
of animals treated with 50 or 100 mg / kg body weight gentamicin at times when epithelial 
tubular cells were affected by little histopathological changes[121]. Compared to NGAL, after 
7 days of gentamicin treatment, mRNA level of KIM-1 became more prominent. Both genes 
were considered to be related to proliferation / regeneration and repair, according to the 
histopathological changes observed after gentamicin in response to toxicity and disease[121]. 
A study showed that the excretion of urinary clusterin peaks 2 days after an ischemia insult. 
This is well connected to its production peak of 24h in the damaged of the proximal tubule as 
determined by confocal laser quantitative microscopy. It is believed that most of the excreted 
clusterin is derived from cell debris floating in the lumen so that it can be explained by the time 
it takes to clear the scarcity out of the kidney between the clusterin and the urinary excretion 
of clusterin[122].  
Cisplatin nephrotoxicity has been studied for many years and however, the cisplatin-induced 
kidney injury molecular mechanism has yet to be clarified. Nephrotoxicity results directly from 
the loss of kidney function, including serious decreases in the level of glomerular filtration, 
clearance of Creatinine (CRE) and associated rises in serum creatinine and BUN[123]. The 
effects of cisplatin are seen to be a disruption of DNA replication, and a crosslinking of DNA. It 
induces apoptosis as a result of its accumulation in the mitochondria [124, 125]. The 
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nephrotoxic action of cisplatin is therefore likely to be a result of apoptosis via the intrinsic 
pathway and the mitochondrial release of cytochrome C. This would also account for the PTCs 
being a target site of toxicity that has been induced by cisplatin, as they contain high densities 
of mitochondria [124].  
Cimetidine has been reported to inhibit cisplatin transport via OCT2 on a competitive basis and 
affect cell toxicity [126]. A study showed that, cimetidine inhibited the cytotoxicity of cisplatin 
in renal cells. Cimetidine obviously inhibits cisplatin-induced nephrotoxicity and damage to the 
kidneys without influence over cisplatin in vitro and in vivo antitumor activity. While the 
cimetidine's in vitro activities are mainly due to the injections of ROS production, both 
inhibitory reactive oxygen species(ROS) and OCT2 measures, which are intrinsically expressed 
in the kidney, appear to have an in vivo protection effect on the nephrotoxicity of 
cisplatin[127]. 
One of the aims of this study was therefore to determine whether similar protective effects 
were seen when cilastatin was administered in conjunction with gentamicin. There was seen 
to be a significant difference after 24h in the release of KIM-1 when cells were treated with 
gentamicin on its own. There was a one fold change in KIM-1 release after 48h in cells treated 
with gentamycin, compared to the untreated cells.  This suggests that, when administered with 
gentamicin with cilastatin may have a protective effect. This needs to be confirmed by further 
studies, which should also explore whether this effect is also present when cilastatin is given 
alongside other nephrotoxins.  
This is another study done by using different co-treatment studied the impact of atorvastatin 
on the nephrotoxicity of gentamicin induced rats. Gentamicin infusion significantly reduced 
the function of the kidney, enhanced oxidative stress, and tubular necrosis in the renal cortex 
was associated. The tissue and renal function have normalized the stress parameters, and tube 
necrosis in atorvastatin-treated animals has been attenuated. Atorvastatin reduced 
expressions of kinase, kappa B nuclear factor and synthase of inducible nitric oxide, which 
confirmed an anti-inflammatory and anti-oxidant action caused by statin[128]. Simvastatin has 
been found to improve gentamicin-induced changes in renal histopathology and dose 
dependent function in a similar rodent model[128]. 
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Polymyxin B is nephrotoxic and may cause renal injury. Polymyxin B antimicrobial have a small 
therapeutic window due to the necessary balance between their antibacterial activity and 
nephrotoxicity [129]. The data showed that, the treatment of human PTCs with 250 µg/ml 
polymyxin B for 24 and 48 hours increase the production of KIM-1, NGAL and clusterin. For 
instance, the level of KIM-1 produced after 24h treatment with polymyxin B was 5.2 ng/ml and 
there was a 4 fold increase after 48h treatment. In addition, rosuvastatin was used as a co 
treatment to reduce the nephrotoxicity of polymyxin B. For example, NGAL production after 
48h treatment with polymyxin B was 77.1 ng/ml and co treatment with rosuvastatin the level 
of NGAL reduced to 43.7 ng/ml, suggesting the rosuvastatin of decreasing the nephrotoxicity 
of polymyxin B.  
The protective effects of rosuvastatin have been previously shown. Studies carried out on the 
effects of statins suggest that they decrease albuminuria and oxidative stress and lessen 
epithelial dysfunction; however, it is believed that they do not directly cause the decreased 
GFR associated with nephrotoxicity [130]. In HIV patients, when they are treated with 
combined antiretroviral therapy, there is an increased incidence of nephrotoxicity, thought to 
be caused by the drugs used in the therapy [131]. The results of a study by Longenecker et al. 
(2014) revealed that if HIV patients were also administered rosuvastatin, their circulating 
cystatin C reduced and their GFR was preserved [132]. Furthermore, compared to the controls, 
serum NGAL, cystatin c and creatinine were reduced in patients who were administered a 
contrast media for coronary angiography, when rosuvastatin was given two days before and 
three days after the contrast media was administered [133].  
The biomarkers concentration were more in the apical membrane than the basolateral 
membrane. This results were expecting and reflecting what really happen in vivo. Those renal 
biomarkers are detectible in urine. NGAL is upregulated and can be detected in mice's kidney 
and urine three hours after cisplatin treatment and has been suggested a good biomarker for 
nephrotoxicity[134]. The significant in the basolateral membrane was expecting due to the 
cells leakage and lose their integrity after drugs treatment.   
Our results showed the increase production of the all 3 biomarkers used in this study after 
treatment with 3 known nephrotoxins. In addition, the use of 3 co-treatment showed a decline 
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in biomarkers levels when treated 24h before the nephrotoxins treatment.   Our human PTCs 
model could be a good model for early prediction of nephrotoxicity. It is assumed that early 
detection of nephrotoxicity biomarkers would be available for use in laboratory research and 
clinical studies relatively soon. The development of rapid, dipstick assays for KIM-1, NGAL and 
clusterin could enable a better nephrotoxins associated AKI diagnosis, also improving patients’ 
care.  Urinary biomarkers levels are elevated in nephrotoxins induced AKI and may help in the 
differential diagnosis of PTCs injuries. Although further studies are needed to explore the 
mechanisms behind nephrotoxic drugs and the role of KIM-1, NGAL and clusterin in this 
setting, those biomarkers are showing promise in early diagnosis and prognosis of AKI.   
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5 Rat biomarkers 
5.1 Introduction 
Experimental models are required for essential understanding and the underlying drug action 
mechanisms to define new therapeutic goals and create new therapeutic strategies. In the first 
few stages of drug development, animal models, including both in vivo and in vitro methods, 
are frequently used before human testing in clinical trials. In this chapter, rat PTCs were used 
as in vitro model as an early way to detect nephrotoxicity. These studies will provide an 
indication as to the suitability of human and rat PTC monolayers as in vitro models of 
nephrotoxicity and also possible mechanisms of toxicity. Rats have been selected as a source 
of PTCs because they are often used in drug development preclinical studies[135]. In parallel, 
an animal model, specifically a rat, would provide translation data to what really happen in 
vivo.   
Rat kidney have been revealed to upregulate KIM-1 gene expression and the existence of the 
KIM-1 ectodomain in the urine [136]. Moreover, the KIM-1 protein ectodomain is separated 
and released into the urine in rats and humans, after exposure to chemicals, ischemia, and 
protein overload, in a number of nephrotoxic models [137].   
Preclinical studies found that NGAL in animal models was one of the most upregulated genes 
and proteins in the kidney immediately after AKI[138]. In animal models of AKI, NGAL protein 
was identified in urine and plasma, preceding the rise in plasma creatinine levels [139]. 
In animal models and cultured cells, the majority of gentamicin enter tubular cells 
quantitatively through endocytosis mediated by the (megalin / cubilin ) [140]. Gentamicin 
moves to the endosomal compartment through pinocytosis. The drug mainly builds up in the 
lysosomes, retrogrades through the secretory path to the Golgi and endoplasmic reticula 
(ER)[141]. Gentamicin generates membrane destabilization, lysosomal aggregation, lipid 
metabolism modification, and phospholipidosis connected with cell death in the 
lysosomes[140]. 
Cisplatin movement through the renal tubular cells is from basolateral to apical[142]. It is now 
known that two main transporters are engaged in the transport of cisplatin to the tubular cells, 
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the human copper transport protein 1 (Ctr1) and the organic cation transporter 2 (OCT2)[143]. 
Once cisplatin has entered the cell, many impacts have been observed, leading to apoptosis 
and necrosis of the cell. The frequently recognized objective is to harm nuclear DNA, but about 
1% of cytosolic cisplatin is found in the nucleus [144].  
The purpose of this study is to identify and substantiate the use of rat primary proximal tubular 
cells (PTCs) as appropriate models for nephrotoxicity study. By using polymyxin B, gentamicin 
and cisplatin as a known nephrotoxins to treat our rat PTCs, measuring the expression of 




5.2 Large molecule nephrotoxin – Gentamicin 
Rat PTCs were treated with gentamicin, a known nephrotoxin, before the biomarker 
expression was quantified using ELISA. The use of gentamicin is important because of the well-
characterized and known toxicity caused by gentamicin in vivo. 
5.2.1 MTS Cell viability of rat in gentamicin concentration range 
The results of the MTS assay showed the time and concentration dependent effect of 
gentamicin on cell viability in rat PTCs. With a rise in gentamicin concentration, cell viability 
reduced significantly. For example, after 24h treatment with 100 µg/ml gentamicin the cell 
viability was 23% less than the non-treated cells. The percentage of live cells was less than 50% 
after 250 µg/ml gentamicin treatment. The results are shown in Figure 5.1. 
 The percentage of live cells decreased with the rise of the gentamicin dose after 48h 
incubations.  For instance, after 300 µg/ml gentamicin the percentage of live cells was 44%. 
The live cells were less than 40% after 400 µg/ml gentamicin treatment.   
After 72h treatment with a range of gentamicin concentrations, cell viability decreased 
significantly. After 100 µg/ml gentamicin treatment, live cells was 71%. In addition, after 500 




































Figure 5.1: Cell viability in rat PTCs treated with range concentrations of gentamicin for 24, 
48 and 72 hours.   
MTS assay was used to measure the cell viability. For example, the cell viability after 250 µg/ml 
gentamicin for 24h was 82.2% and the percentage dropped to 71.8% after 48h. In addition, cell 
viability after 300 µg/ml gentamicin treatment for 72h was 49.9% and after 500 µg/ml 
gentamicin the cell viability decreased to 20%. Each point represent mean ± S.E.M values of 




5.2.2  KIM-1 production after treatment of rat PTCs in presence of a range concentration 
of gentamicin:  
The level of KIM-1 produced after rat PTCs were treated with a range of gentamicin 
concentrations were investigated. The concentrations of the biomarker were normalised to 
the cell viability. The results are shown in Figure 5.2. 
The KIM-1 levels after 24h treatment of gentamicin increased significantly compared to non-
treated cells.  For instance, the level of KIM-1 production after 300 μg/ml gentamicin was 
7.75±2.85 ng/ml compared with the control 1.11±0.23 ng/ml and then the level of KIM-1 
started to increase slightly as the concentration of gentamicin increases up to 600 μg/ml. 
The levels of KIM-1 increased significantly in comparison with non-treated cells after 48h of 
gentamicin treatment. The KIM-1 levels increased by 50 to 600 μg/ ml gentamicin treatment. 
The highest level of KIM-1, compared to control 2.90±0.30 ng/ ml, was after 600 μg / ml 
gentamicin treatment at 31.87±936 ng/ ml. 
The KIM-1 concentrations risen considerably compared to non-treated cells after 72h of 
gentamicin treatment.  For instance, the level of KIM-1 production after 250 μg/ml gentamicin 
treatment was 34.80±6.49 ng/ml compared with the control 7.74±1.51 ng/ml and then the 


































Figure 5.2: Measurement of KIM-1 production from rat PTCs treated with range 
concentrations of gentamicin for 24, 48 and 72 hours.  
Levels were normalised to MTS absorbance value to account for cell numbers after nephrotoxin 
treatments. Rat PTCs were treated with a range of gentamicin concentration (50 to 600 µg/ml). 
For example, NGAL production after 300 µg/ml gentamicin treatment for 24h was 65.8±4.7 
ng/ml and after 500 µg/ml the level of KIM-1 increased to 131.4±19.5 ng/ml. The level of KIM-
1 after 250 µg/ml gentamicin treatment for 48h was 180.4±43.5 ng/ml and after 72h the level 
increased to 307.8±35.7 ng/ml.  Statistical analysis was conducted using repeated-measures-
paired-one-way ANOVA the data are representative of three independent experiments (n=3). 




5.2.3 NGAL production after treatment of rat PTCs in presence of a range concentration of 
gentamicin:  
After a rat PTC had been incubated with a range of gentamicin levels, NGAL production was 
examined. NGAL levels have been normalized to cell viability. The results showed the time and 
concentration dependent effect of gentamicin on rat PTCs. The results are shown in Figure 5.3.  
There were a significant increase in NGAL levels after 24h treatment of gentamicin compared 
to non-treated cells. NGAL levels were elevated significantly by (50 to 600) μg/ml gentamicin 
concentrations. The level of KIM-1 production after 400 μg/ml gentamicin was 114.62±37.32 
ng/ml compared with the control 7.66±2.18 ng/ml and then the level of NGAL remained almost 
the same as the concentration of gentamicin increases up to 600 μg/ml.  
The levels of NGAL increased significantly in comparison with non-treated cells after 48h of 
gentamicin treatment. The maximum level of NGAL was after 500 μg / ml gentamicin 
treatment 193.83±42.23 ng / ml compared to the control 20.30±3.10 ng / ml. 
The NGAL levels after 72h treatment of gentamicin increased significantly compared to non-
treated cells.  For example, the level of NGAL production after 250 μg/ml gentamicin treatment 
was 273.17±47.36 ng/ml compared with the control 47.36±1.95 ng/ml and then the level of 
































Figure 5.3: Measurement of NGAL production from rat PTCs treated with range 
concentrations of gentamicin for 24, 48 and 72 hours.   
Levels of NGAL were normalised to MTS absorbance value to account for cell numbers after 
nephrotoxin treatments. Rat PTCs were treated with a range of gentamicin concentration (50 
to 600 µg/ml). For example, NGAL production after 300 µg/ml gentamicin treatment for 24h 
was 82.3±17.4 ng/ml and after 500 µg/ml the level of NGAL increased to 122.1±47.9 ng/ml. 
The level of NGAL after 250 µg/ml gentamicin treatment for 48h was 118.5±14.9 ng/ml and 
after 72h the level increased to 273.1±47.3 ng/ml. Statistical analysis was conducted using 
repeated-measures-paired-one-way ANOVA the data are representative of three independent 





5.2.4 MTS and ATP Cells viability assays: 
The cell viability was measured after treatment of rat PTCs for 24 and 48 hours with 250 µg/ml 
gentamicin. The cell viability was also measured in the presence of cilastatin co-treatments. 
Both MTS and ATP assays were used to assess cell viability from the same plate. The results 
revealed no significant difference between the two assessment methods. The results are 
shown in Figure 5.4. 
After 24h, the results revealed that cell viability reduced significantly in response to exposure 
to gentamicin to (65.74±3.29%, P < 0.01) of control. The cilastatin co treatment did not change 
the cell viability (97.98±3.28% live cells). The treatment of gentamicin with cilastatin increased 
the live cells compared to only gentamicin (74.38±4.12%, P < 0.01).  
After 48h, the cell viability was reduced significantly by gentamicin (58.95±3.1%, P < 0.01). 
However, the cell viability did not change with cilastatin (98.66±1.86%). The cell viability after 











































































































Figure 5.4: Cells Viability of rat PTCs after treatment of gentamicin for 24 and 48 hours. 
MTS and ATP assays were used to measure the cell viability. Viability is measured as a 
percentage of the control. For example, MTS percentage after gentamicin treatment for 24h 
was 65.7% and ATP percentage was 75.1%. In addition, the co-treatment of cilastatin with 
gentamicin for 48h showed, the percentage of MTS was 70.3% and ATP percentage was 80.8%.      
Statistical analysis was conducted using repeated-measures-paired-one-way ANOVA the data 
are representative of three independent experiments (n=3). Bars represent mean ± S.E.M values 
of each group. (*p < 0.05, **p < 0.01, ***p < 0.001). 
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5.2.5  Lactate dehydrogenase (LDH) cytotixicy assay: 
The measurement of cytoplasmic enzymes released by damaged cells is a common method for 
determining cytotoxicity. In this experiment, we treated rat PTCs for 24 and 48 hours with 250 
µg/ml gentamicin and LDH was measured. In addition, we measured the LDH after cilastatin 
co treatment. The results are consistent with cell viability data. Result shown in Figure 5.5. 
After 24h, the results revealed that LDH increased significantly in response to exposure to 
gentamicin to (29.26±1.14%, P < 0.01). The cilastatin co treatment did not change the LDH 
(17.1±1.26%). The treatment of gentamicin with cilastatin increased the decreased the LDH 
compared to only gentamicin (26.72±1.23%, P < 0.01). 
After 48h, the LDH was increased significantly by gentamicin (37.91±1.90%, P < 0.01). However, 
the LDH did not change with cilastatin (19.97±0.86%). The LDH after gentamicin with cilastatin 





























































Figure 5.5: LDH released from rat PTCs after treatment of gentamicin for 24 and 48 hours. 
LDH is measured as a percentage of the control. LDH percentage after gentamicin treatment 
for 24h was 29.6% and after 48h the percentage increased to 37.9%. In addition, LDH 
percentage decreased after cilastatin co-treatment with gentamicin for 48h to 27.6%. 
Statistical analysis was conducted using repeated-measures-paired-one-way ANOVA the data 
are representative of three independent experiments (n=3). Bars represent mean ± S.E.M values 




5.2.6  KIM-1 expression after treatment of rat PTCs in presence of gentamicin +/- cilastatin  
The amount of KIM-1 produced after treatment of rat PTCs for 24 and 48 hours in presence of 
250 µm/ml gentamicin were investigated. The levels of KIM-1 was also measured in the 
presence 40 µM cilastatin co-treatments. The concentrations of KIM-1 was normalised to the 
cell viability as determined from their MTS absorbance, results of which were therefore 
expressed as ng/ml. The results are shown in Figure 5.6. 
After 24h treatment of gentamicin, the amount of KIM-1 in the apical membrane did change 
significantly from the control (3.86±0.28 to 10.31±0.72 ng/ml, P < 0.01). However, the 
presence of cilastatin did not change KIM-1 level 4.31±0.36 ng/ml compared to control 
3.86±0.28 ng/ml. The co-treatment of gentamicin with cilastatin caused a significant decrease 
in KIM-1 in the apical membrane (7.35±0.48 ng/ml, P < 0.0001) compared to only gentamicin.  
After 48h treatment of gentamicin, the amount of KIM-1 in the apical membrane did change 
significantly from the control (28.70±0.48 ng/ml, P < 0.01). However, when we added   
cilastatin did not change KIM-1 level 12.83±0.37 ng/ml compared to control 10.48±0.35 ng/ml. 
A significant reduction in KIM-1 was monitored in apical membrane (20.82±1.11 ng / ml, 
P<0.0001) compared to only gentamicin by co-treatment of cilastatin with gentamicin. 




































































































Figure 5.6: The amount of KIM-1 produced after treatment of rat PTCs for 24 and 48 hours in 
presence of gentamicin +/- cilastatin.  
ELISA was used to measure KIM-1 production. The amount of KIM-1 in the apical membrane 
change significantly from the control (3.86±0.28 to 10.31±0.72 ng/ml, P < 0.01) after 24h 
gentamicin treatment. After co-treatment with cilastatin, KIM-1 level decreased to (7.35±0.48 
ng/ml, P < 0.0001) compared to only gentamicin. The level of KIM-1 after 48h treatment was 
more than 3 fold compared to 24h. Statistical analysis was conducted using repeated-
measures-paired-one-way ANOVA the data are representative of three independent 
experiments (n=3). Bars represent mean ± S.E.M values of each group. (*p < 0.05, **p < 0.01, 
***p < 0.001, ++++p < 0.0001).  
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5.2.7 NGAL production after treatment of rat PTCs in presence of gentamicin +/- cilastatin 
NGAL production for 24 and 48 hours in the presence of gentamicin following treatment of rat 
PTCs. In the presence of cilastatin co-treatment, levels of NGAL were also measured. NGAL 
concentrations had been normalized to cell viability based on the MTS absorption of the PTCs, 
resulting in ng / ml. Figure 5.7 shows the results.  
The quantity of NGAL in the apical membrane increased significantly  after 24h incubation with 
gentamicin (146.38±21.49 ng / ml, P<0.01).However, the presence of cilastatin did not change 
NGAL level 28.42±6.16 ng/ml compared to control 28.52±5.28 ng/ml. The co-treatment of 
gentamicin with cilastatin caused a significant decrease in NGAL in the apical membrane 
(113.09±14.21 ng/ml, P < 0.0001) compared to only gentamicin. Compared to apical 
membrane, NGAL levels in the basolateral membrane were low. 
After 48h treatment of gentamicin, the amount of NGAL in the apical membrane did increase 
significantly from the control (400.65±130.9 ng/ml, P < 0.01). However, the presence of 
cilastatin did not change NGAL level 67.10±3.86 ng/ml compared to control 67.14±13.92 
ng/ml. The co-treatment of gentamicin with cilastatin caused a significant decrease in NGAL in 






































































































Figure 5.7: The amount of NGAL produced after treatment of rat PTCs for 24 and 48 hours in 
presence of gentamicin +/- cilastatin.  
ELISA was used to measure NGAL production. The amount of NGAL in the apical membrane 
change significantly from the control (146.38±21.49 ng / ml, P<0.01) after 24h gentamicin 
treatment. After co-treatment with cilastatin, NGAL level decreased to (113.09±14.21 ng/ml, P 
< 0.0001) compared to only gentamicin. The level of NGAL after 48h treatment was almost 3 
fold higher than 24h. Statistical analysis was conducted using repeated-measures-paired-one-
way ANOVA the data are representative of three independent experiments (n=3). Bars 




5.3 Large molecule nephrotoxin – Polymyxin B 
Before expression of biomarkers was quantified with ELISA, Rat PTCs were treated with 
polymyxin B. Polymyxin B impacts on PTCs were important because polymyxin B toxicity was 
already well known in vivo. 
5.3.1 MTS Cell viability of rat with polymyxin B concentration range 
The cell viability was measured after treatment of rat PTCs with a range of concentration of 
polymyxin B (50 to 600 µg/ml) for 24, 48 and 72 hours.  MTS assay was used to assess cell 
viability. The MTS absorbance show as a percentage normalised to control cells. The results 
are shown in Figure 5.8.  
The impact of polymyxin B on cell viability in rat PTCs was found in the quantity of the MTS.  
The cell viability decreased steadily with an increase in polymyxin B concentration. For 
example, after 24h treatment with 300 µg/ml polymyxin B the cell viability was 63%. The 
percentage of live cells was less than 48% after 500 µg/ml polymyxin B treatment. 
 After 48h incubation with polymyxin B the percentage of live cells decrease as the dose of 
polymyxin B increase.  For instance, at 250 µg/ml polymyxin B the percentage of live cells was 
61%. The live was less more than 65% after 400 µg/ml polymyxin B.   
There were a major decrease in cell viability after 72h treatment with a range of concentration 
of polymyxin B. after 100 µg/ml polymyxin B treatment, live cells reduced more than 40%. In 






























Figure 5.8: Cell viability in rat PTCs treated with range concentrations of polymyxin B for 24, 
48 and 72 hours.   
MTS assay was used to measure the cell viability. Polymyxin B showed a time and 
concentrations dependent. For example, the cell viability after 250 µg/ml polymyxin B 
treatment for 24h was 72.5% and the percentage dropped to 60.1% after 48h. In addition, cell 
viability after 300 µg/ml polymyxin B treatment for 72h was 43.1% and after 500 µg/ml 
polymyxin B the cell viability decreased to 28.5%.  Each point represent mean ± S.E.M values of 




5.3.2 KIM-1 production after treatment of rat PTCs in presence of a range concentration of 
polymyxin B  
The KIM-1 level was investigated after rat PTCs were treated with a range of polymyxin B 
concentrations. The results were normalised to the cell viability. The results are shown in 
Figure 5.9. 
The KIM-1 levels after 24h treatment of polymyxin B increased significantly compared to non-
treated cells. KIM-1 levels were elevated significantly and gradually by 50 to 250 μg/ml 
polymyxin B concentrations. The level of KIM-1 production at 250 μg/ml polymyxin B 
treatment was 9.79±1.25 ng/ml compared with the control 1.34±0.45 ng/ml and then the level 
of KIM-1 remained almost the same as the concentration of polymyxin B increases up to 600 
μg/ml. 
The levels of KIM-1 increased significantly in comparison with non-treated cells after 48h of 
polymyxin B treatment. The level of KIM-1, compared to control 3.89±0.93 ng / ml, was after 
300 μg / ml polymyxin B treatment at 32.14±10.59 ng / ml, and then the KIM-1 level, with the 
polymyxin B treatment rising up to 600 μg / ml, started to slightly decrease. 
The KIM-1 levels after 72h treatment of polymyxin B increased significantly compared to 
untreated cells.  For instance, KIM-1 levels were elevated significantly by 50 to 400 μg/ml 
gentamicin concentrations. The level of KIM-1 production reached the highest at 400 μg/ml 
polymyxin B treatment to 81.78±36.52 ng/ml compared with the control 10.63±1.02 ng/ml and 





























Figure 5.9: Measurement of KIM-1 production from rat PTCs treated with range 
concentration of polymyxin B for 24, 48 and 72 hours.   
Levels of KIM-1 were normalised to MTS absorbance value to account for cell numbers after 
nephrotoxin treatments. Rat PTCs were treated with a range of polymyxin B concentration (50 
to 600 µg/ml). For example, KIM-1 production after 100 µg/ml polymyxin B treatment for 24h 
was 3.3±0.4 ng/ml and after 250 µg/ml the level of KIM-1 increased to 9.7±1.2 ng/ml. The level 
of KIM-1 after 400 µg/ml polymyxin B treatment for 48h was 30.6±2.7 ng/ml and after 72h the 
level increased to 81.7±36.5 ng/ml. Statistical analysis was conducted using repeated-
measures-paired-one-way ANOVA the data are representative of three independent 





5.3.3 NGAL production after treatment of rat PTCs in presence of a range concentration of 
polymyxin B  
The production of NGAL after treated rat PTCs with a range concentration of polymyxin B were 
investigated. The NGAL levels were normalized to cell viability. The results are shown in Figure 
5.10.  
There was a significant increase in NGAL levels after 24h treatment of polymyxin B compared 
to non-treated cells. NGAL levels were elevated significantly by (50 to 600) μg/ml polymyxin B 
concentrations. For example, the level of NGAL production was at 400 μg/ml polymyxin B to 
79.1±56.1 ng/ml compared with the control 8.53±3.60 ng/ml and then the level of NGAL 
remained stable as the concentration of polymyxin B increases up to 600 μg/ml.  
The levels of NGAL increased in comparison with non-treated cells after 48h of gentamicin 
treatment. The maximum level of NGAL was after 600 μg / ml polymyxin B treatment 
332.18±76.95ng / ml compared to the control 20.79±2.58 ng / ml. 
The NGAL levels after 72h treatment of polymyxin B increased significantly compared to non-
treated cells.  For example, the level of NGAL production reached the first peak at 250 μg/ml 
polymyxin B treatment to 203.04±45.67 ng/ml compared with the control 37.98±3.26 ng/ml 




























Figure 5.10: Measurement of NGAL production from rat PTCs treated with rang 
concentrations of polymyxin B for 24, 48 and 72 hours.   
Levels of NGAL were normalised to MTS absorbance value to account for cell numbers after 
nephrotoxin treatments. Rat PTCs were treated with a range of polymyxin B concentration (50 
to 600 µg/ml). For example, NGAL production after 300 µg/ml polymyxin B treatment for 24h 
was 53.4±27.2 ng/ml and after 400 µg/ml the level of NGAL increased to 79.1±56 ng/ml. The 
level of NGAL after 250 µg/ml polymyxin B treatment for 48h was 143.9±30.1 ng/ml and after 
72h the level increased to 203.1±45.6 ng/ml.  Statistical analysis was conducted using 
repeated-measures-paired-one-way ANOVA the data are representative of three independent 





5.3.4 MTS and ATP Cells viability assays  
After 24 and 48 hours treatment with 250 μg / ml polymyxin B, the cell viability was measured. 
Cell viability was also evaluated with 50 μM of rosuvastatin co-treatment. The cell viability 
from the same plate was measured using MTS and ATP assays. The outcomes of the two cell 
viability techniques had no difference. The results are shown in Figure 5.11.  
After 24h of treatment, the results revealed that cell viability reduced significantly in response 
to exposure to polymyxin B to (74.7±4.9%, P < 0.01) of control. The rosuvastatin co treatment 
did not change the cell viability (96.2±1.9%, P < 0.01 live cells). The treatment of polymyxin B 
with rosuvastatin increased the live cells compared to only gentamicin (87.3±4.5%).  
The cell viability was reduced significantly by polymyxin B (68.3±5.8%, P < 0.01) after 48h of 
treatment. However, the cell viability did not change with rosuvastatin (94.1±2.6 %). The cell 
viability after polymyxin B with rosuvastatin was higher than only polymyxin B (76.9±4%, P < 












































































































Figure 5.11: Cells Viability of rat PTCs after treatment of polymyxin B for 24 and 48 hours.  
MTS and ATP assays were used to measure the cell viability. Viability is measured as a 
percentage of the control. For example, MTS percentage after polymyxin B treatment for 24h 
was 74.7% and ATP percentage was 71.2%. In addition, the co-treatment of  rosuvastatin  with 
polymyxin B for 48h showed, the percentage of MTS was 76.9% and ATP percentage was 73.8%.      
Statistical analysis was conducted using repeated-measures-paired-one-way ANOVA the data 
are representative of three independent experiments (n=3). Bars represent mean ± S.E.M values 
of each group. (*p < 0.05, **p < 0.01, ***p < 0.001).  
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5.3.5  Lactate dehydrogenase (LDH) cytotoxic assay 
In this experiment, rat PTCs treated for 24 and 48 hours with 250 µg/ml polymyxin B and LDH 
was measured. In addition, LDH was measured after rosuvastatin co treatment. The results is 
typically with cell viability data. Result shown in Figure 5.12. 
After 24h, the results revealed that LDH increased significantly in response to exposure to 
polymyxin B to 41.6±3.3%. The rosuvastatin co treatment did not change the LDH (10.7±1.2%). 
The treatment of polymyxin B with cilastatin increased the decreased the LDH compared to 
only polymyxin B (28.3±3.7%). 
The LDH was increased significantly by polymyxin B (49.1±4.6%) after 48h treatment. However, 
the LDH did not change with rosuvastatin (12.2±0.84%). The LDH after polymyxin B with 




































































Figure 5.12: LDH released from rat PTCs after treatment of polymyxin B for 24 and 48 hours. 
 LDH is measured as a percentage of the control. LDH percentage after polymyxin B treatment 
for 24h was 41.6% and after 48h the percentage increased to 49.1%. In addition, LDH 
percentage decreased after rosuvastatin co-treatment with polymyxin B for 48h to 33.8% 
Statistical analysis was conducted using repeated-measures-paired-one-way ANOVA the data 
are representative of three independent experiments (n=3). Bars represent mean ± S.E.M values 




5.3.6  KIM-1production after treatment of rat PTCs in presence of polymyxin B +/- 
rosuvastatin 
The level of KIM-1 produced after rat PTCs have been treated with 250 µg/ml polymyxin B for 
24 and 48 hours. KIM-1 production was also measured in the presence rosuvastatin co-
treatments. The concentrations of KIM-1 was normalised to the cell viability as determined 
from their MTS absorbance’s, expressed as ng/ml. The results are shown in Figure 5.13. 
After 24h treatment of polymyxin B, the amount of KIM-1 in the apical membrane did change 
significantly from the control (5.42±1.19 ng/ml, P < 0.01). However, the presence of 
rosuvastatin did not change KIM-1 level to 1.53±0.44 ng/ml compared to control 1.58±0.56 
ng/ml. The co-treatment of polymyxin B with rosuvastatin caused a significant decrease in KIM-
1 in the apical membrane (2.76±0.73 ng/ml, P < 0.0001) compared to only polymyxin B. In 
comparison with apical membrane, basolateral membrane levels of KIM-1 were low. 
The amount of KIM-1 on the apical membrane changed significantly from the control after 48h 
of treatment with polymyxin B (24.84±8.65 ng/ml, P < 0.01). However, when we added   
rosuvastatin did not change KIM-1 level 6.46±1.14 ng/ml compared to control 6.15±1.18 
ng/ml. The co-treatment of polymyxin B with rosuvastatin caused a significant decline in KIM-










































































































Figure 5.13: The amount of KIM-1 produced after treatment of rat PTCs for 24 and 48 hours 
in presence of polymyxin B +/- rosuvastatin.  
ELISA was used to measure KIM-1 production. The amount of KIM-1 in the apical membrane 
change significantly from the control (5.42±1.19 ng/ml, P < 0.01) after 24h polymyxin B 
treatment. After co-treatment with rosuvastatin, KIM-1 level decreased to (2.76±0.73 ng/ml, P 
< 0.0001) compared to only polymyxin B. The level of KIM-1 after 48h treatment was more than 
4 fold compared to 24h. Statistical analysis was conducted using repeated-measures-paired-
one-way ANOVA the data are representative of three independent experiments (n=3). Bars 




5.3.7  NGAL production after treatment of rat PTCs in presence of polymyxin B +/- 
rosuvastatin 
The NGAL production in 24 and 48 hours treatment of rat PTCs with 250 µg/ml polymyxin B. In 
the presence of rosuvastatin co-treatment, levels of NGAL were also measured. NGAL level 
had been normalized to cell viability based on the MTS absorption of the rat PTCs, resulting in 
ng / ml. The results are shown in Figure 5.14.  
After 24h treatment of 250 µg/ml polymyxin B, the amount of NGAL in the apical membrane 
did elevated significantly from the control (76.62±14.25 ng/ml, P < 0.01). However, the 
presence of rosuvastatin did not change NGAL level 19.18±6.28 ng/ml compared to control 
19.10±5.74 ng/ml. The co-treatment of polymyxin B with rosuvastatin caused a significant 
decrease in NGAL in the apical membrane (42.42±11.94 ng/ml, P < 0.0001) compared to only 
polymyxin B. NGAL levels were low in the basolateral membrane compared to apical 
membrane. 
After 48h treatment of polymyxin B, the amount of NGAL in the apical membrane did increase 
significantly from the control (324.28±65.52 ng/ml, P < 0.01). However, the presence of 
rosuvastatin did not change NGAL level 94.26±13.76 ng/ml compared to control 94.85±11.36 
ng/ml. The co-treatment of polymyxin B with rosuvastatin caused a significant decrease in 








































































































Figure 5.14: The amount of NGAL produced after treatment of rat PTCs for 24 and 48 hours 
in presence of polymyxin B +/- rosuvastatin.  
ELISA was used to measure NGAL production. The amount of NGAL in the apical membrane 
change significantly from the control (76.62±14.25 ng/ml, P < 0.01) after 24h polymyxin B 
treatment. After co-treatment with rosuvastatin, NGAL level decreased to (42.42±11.94 ng/ml, 
P < 0.0001) compared to only polymyxin B. The level of NGAL after 48h treatment was more 
than 4 fold compared to 24h. Statistical analysis was conducted using repeated-measures-
paired-one-way ANOVA the data are representative of three independent experiments (n=3). 
Bars represent mean ± S.E.M values of each group. (*p < 0.05, **p < 0.01, ***p < 0.001, ++++p 
< 0.0001).  
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5.4 Small molecule nephrotoxin – Cisplatin 
Rat PTCs were treated with cisplatin, a known nephrotoxin before the expression of KIM-1 and 
NGAL biomarkers were quantified using ELISA. Cisplatin's effects on rat PTC monolayers have 
been significant since cisplatin-induced toxicity is already well characterized and can be 
compared in vivo. 
5.4.1  MTS cell viability after treatment in presence of range of concentrations of cisplatin 
After cisplatin concentration ranges (5 to 40 μM) were used for 24, 48 and 72 hours with rat 
PTCs, the cell viability was measured.  CellTiter 96® AQueous Non-Radioactive Cell Proliferation 
Assay (MTS) was used to assess cell viability. The MTS absorbance show as a percentage 
normalised to control cells. The results are shown in Figure 5.15.  
The MTS assay results showed the effect of cisplatin treatment on the cell viability of rat PTCs.  
With the rise in cisplatin concentration, cell viability decreased significantly. For example, after 
24h treatment with 15 µM cisplatin the cell viability was 80.92% compared to non-treated 
cells. The percentage of live cells was less than 64% after 30 µM cisplatin treatment. 
After 48h, the quantity of live cells reduces after cisplatin treatment. For example, the 
percentage of live cells in 20 μM cisplatin was 60%. After 35 μM cisplatin, the live was less than 
45%. 
There was a major decrease in cell viability after 72h treatment with a range of concentration 
of cisplatin. After 20 µM cisplatin treatment, live cells was 44%. In addition, after 35 µM 




































Figure 5.15: Cell viability in rat PTCs treated with range concentrations of cisplatin for 24, 48 
and 72 hours.  
MTS assay was used to measure the cell viability. For example, the cell viability after 25 µM 
cisplatin for 24h was 65.3% and the percentage dropped to 53.6% after 48h. In addition, cell 
viability after 10 µM cisplatin treatment for 72h was 69.3% and after 20 µg/ml cisplatin the cell 





5.4.2 KIM-1 production after treatment of rat PTCs in presence of a range concentration of 
cisplatin:  
The production of KIM-1 from rat PTCs after treatment with a range of concentrations   of 
cisplatin were examined. The concentrations of the biomarker was normalised to the cell 
viability. The results are shown in Figure 5.16. 
The KIM-1 levels after 24h treatment of cisplatin increased significantly compared to control.  
For instance, KIM-1 levels were elevated gradually and significantly by 5 to 20 μM cisplatin 
concentrations. The level of KIM-1 after 25 μM cisplatin treatment was 42.28±5.88 ng/ml 
compared with the control 2.57±0.41 ng/ml and then the level of KIM-1 increased slightly as 
the concentration of cisplatin increases up to 40 μM. 
The levels of KIM-1 increased significantly in comparison with the control after 48h of cisplatin 
treatment. Compared to control 7.22±2.53 ng / ml, the level of KIM-1 after 20 μM cisplatin 
treatment was 62.84±0.99 ng / ml, and then the KIM-1 level remained the same, with cisplatin 
levels rising to 40 μM. 
The KIM-1 levels after 72h treatment of cisplatin increased significantly compared to control.  
For instance, the level of KIM-1 production reached the first peak at 20 μM cisplatin treatment 
to 51.13±5.82 ng/ml compared with the control 7.29±1.53 ng/ml and then the level of KIM-1 





























Figure 5.16: Measurement of KIM-1 production from rat PTCs treated with range 
concentrations of cisplatin for 24, 48 and 72 hours.   
Levels of KIM-1 were normalised to MTS absorbance value to account for cell numbers after 
nephrotoxin treatments. Rat PTCs were treated with a range of cisplatin concentration (5 to 40 
µM). The levels of KIM-1 showed, cisplatin is time and concertation dependent. For example, 
KIM-1 production after 10 µM cisplatin treatment for 24h was 11.8±3.6 ng/ml and after 25 µM 
the level of KIM-1 increased to 42.2±5.8 ng/ml. The level of KIM-1 after 30 µM cisplatin 
treatment for 48h was 127.7±28.2 ng/ml and after 72h the level increased to 360.1±113.9 
ng/ml. Statistical analysis was conducted using repeated-measures-paired-one-way ANOVA 
the data are representative of three independent experiments (n=3). Each point mean ± S.E.M 




5.4.3 NGAL production after treatment of rat PTCs in presence of a range concentration of 
cisplatin: 
The production of NGAL was investigated after treating the rat PTCs with a concentration range 
of cisplatin. NGAL concentrations were normalized to the viability of the cell. The results are 
shown in Figure 5.17. 
There was a significant increase in NGAL levels after 24h treatment of cisplatin compared to 
control. NGAL levels were elevated significantly by (20 to 40) μM cisplatin concentrations. The 
level of NGAL production after 30 μM cisplatin was 144.76±33.1 ng/ml compared with the 
control 9.64±2.1 ng/ml and then the level of NGAL increased as the concentration of cisplatin 
increases up to 40 μM.  
NGAL levels increased significantly after 48h of cisplatin treatment compared to control. The 
level of NGAL reached the peak after 25 μM cisplatin treatment 292.42±53.31 ng / ml 
compared to the control 33.55±4.77 ng / ml, and then the NGAL level remained the same, with 
the level of cisplatin rising to 40 μM. 
The NGAL levels increased in comparison with control after 72h of cisplatin treatment. For 
example, the level of NGAL production after 30 μM cisplatin treatment was 336.73±112.34 
ng/ml compared with the control 82.63±12.82 ng/ml and then the level of NGAL increased as 



































Figure 5.17: Measurement of NGAL production from rat PTCs treated with range 
concentrations of cisplatin for 24, 48 and 72 hours.   
Levels of NGAL were normalised to MTS absorbance value to account for cell numbers after 
nephrotoxin treatments. Rat PTCs were treated with a range of cisplatin concentration (5 to 40 
µM). The levels of NGAL showed, cisplatin is time and concertation dependent. For example, 
NGAL production after 20 µM cisplatin treatment for 24h was 36.1±4.1 ng/ml and after 30 µM 
the level of NGAL increased to 144.7±33.1. The level of NGAL after 25 µM cisplatin treatment 
for 48h was 292.4±53.3 ng/ml and after 72h the level increased to 413.2±39.1 ng/ml. Statistical 
analysis was conducted using repeated-measures-paired-one-way ANOVA the data are 
representative of three independent experiments (n=3). Each point mean ± S.E.M values of each 




5.4.4 MTS and ATP cell viability assays: 
After 24 and 48 hours treatment of rat PTCs with 25 μM cisplatin, cell viability was measured. 
The cell viability was also measured in the presence of cimetidine co-treatments. Both MTS 
and ATP assays were used to assess cell viability from the same plate. No major difference was 
discovered between the two methods. The results are shown in Figure 5.18. 
After 24h, the results showed that cell viability was considerably reduced to 73.29±1.43% as a 
result of exposure to cisplatin. The co-treatment with cimetidine hasn't altered cell viability 
(94.82±1.27% live cells). The treatment of cisplatin with cimetidine increased the live cells 
compared to only cisplatin (82.41±1.46%).  
The cell viability was reduced significantly by cisplatin (65.17±4.47%) after 48h treatment. 
However, the cell viability did not change with cimetidine (94.11±4.16%). Cisplatin with 



































































































Figure 5.18: Cells Viability of rat PTCs after treatment of cisplatin for 24 and 48 hours. 
 MTS and ATP assays were used to measure the cell viability. Viability is measured as a 
percentage of the control. For example, MTS percentage after cisplatin treatment for 24h was 
73.2% and ATP percentage was 75.6%. In addition, the co-treatment of cimetidine with 
cisplatin for 48h showed, the percentage of MTS was 73.7% and ATP percentage was 74.4%.      
Statistical analysis was conducted using repeated-measures-paired-one-way ANOVA the data 
are representative of three independent experiments (n=3). Bars represent mean ± S.E.M values 
of each group. (*p < 0.05, **p < 0.01, ***p < 0.001).  
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5.4.5  Lactate dehydrogenase (LDH) cytotixicy assay: 
Measuring cytoplasmic enzymes released by damaged cells is a common method for 
determining cytotoxicity. In this experiment, we treated rat PTCs for 24 and 48 hours with 25 
µM cisplatin and LDH was measured. In addition, we measured the LDH after cimetidine co 
treatment. The results are consistent with cell viability data. Result shown in Figure 5.19. 
After 24hour, the results revealed that LDH increased significantly in response to cisplatin 
exposure to 34.72±3.51%. The cimetidine co treatment did not change the LDH (14.74±2.98%) 
compared to control. The treatment of cisplatin with cimetidine increased the LDH compared 
to only cisplatin (27.15±1.15%). 
The LDH was increased significantly by cisplatin (50.72±0.40%) after treatment for 48h 
.However, the LDH did not change with cimetidine (16.85±1.58%). The LDH after cisplatin with 
































































Figure 5.19: LDH of rat PTCs after treatment of cisplatin for 24 and 48 hours. 
 LDH is measured as a percentage of the control. LDH percentage after cisplatin treatment for 
24h was 34.7% and after 48h the percentage increased to 50.7%. In addition, LDH percentage 
decreased after cimetidine co-treatment with cisplatin for 48h to 33.1% Statistical analysis was 
conducted using repeated-measures-paired-one-way ANOVA the data are representative of 
three independent experiments (n=3). Bars represent mean ± S.E.M values of each group. (*p 





5.4.6  KIM-1 production after treatment of rat PTCs in presence of cisplatin +/- cimetidine 
The amount of KIM-1 produced after 24 and 48 hours treatment of rat PTCs in the presence of 
25 μM cisplatin. The KIM-1 levels were also measured in the presence of cimetidine co-
treatments. The concentrations of KIM-1 was normalised to the cell viability as determined 
from their MTS absorbance’s, expressed as ng/ml. The results are shown in Figure 5.20. 
After 24h treatment of cisplatin, the amount of KIM-1 in the apical membrane did change 
significantly from the control (2.51±0.18 ng/ml, P < 0.01). However, the presence of cimetidine 
did not change KIM-1 level 0.59±0.12 ng/ml compared to control 0.58±0.11 ng/ml. The co-
treatment of cisplatin with cimetidine caused a significant decrease in KIM-1 in the apical 
membrane (1.34±0.24 ng/ml, P < 0.0001) compared to only cisplatin. KIM-1 levels in the 
basolateral membrane were low compared to apical membrane. 
After 48h treatment of cisplatin, the amount of KIM-1 in the apical membrane did increase 
significantly from the control (14.25±0.46 ng/ml, P < 0.01). However, when we added   
cimetidine did not change KIM-1 level 4.03±1.03 ng/ml compared to control 4.18±0.36 ng/ml. 
The co-treatment of cisplatin with cimetidine caused a significant decrease in KIM-1 in the 
apical membrane (7.53±1.99 ng/ml, P < 0.0001) compare to only cisplatin. KIM-1 levels in the 


























































































Figure 5.20: The amount of KIM-1 produced after treatment of rat PTCs for 24 and 48 hours 
in presence of cisplatin +/- cimetidine.  
ELISA was used to measure KIM-1 production. The amount of KIM-1 in the apical membrane 
change significantly from the control (0.58±0.11 to 2.51±0.18 ng/ml, P < 0.01) after 24h 
cisplatin treatment. After co-treatment with cimetidine, KIM-1 level decreased to (1.34±0.24 
ng/ml, P < 0.0001) compared to only cisplatin. The level of KIM-1 after 48h treatment was 
almost 5 fold higher than 24h. Statistical analysis was conducted using repeated-measures-
paired-one-way ANOVA the data are representative of three independent experiments (n=3). 




5.4.7  NGAL production after treatment of rat PTCs in presence of cisplatin +/- cimetidine 
NGAL production for 24 and 48 hours after treatment of rat PTCs in the presence of 25 μM of 
cisplatin. In the presence of cimetidine co-treatment, levels of NGAL were also measured. 
NGAL concentrations had been normalized to cell viability based on the MTS absorption of the 
rat PTCs, resulting in ng / ml. The results are shown in Figure 5.21.  
After 24h treatment of cisplatin, the amount of NGAL in the apical membrane did increase 
significantly from the control (330.61±22.37 ng/ml, P < 0.01). However, the presence of 
cimetidine did not change NGAL level 117.41±5.35 ng/ml compared to control 114.12±5.83 
ng/ml. The co-treatment of cisplatin with cimetidine caused a significant decrease in NGAL in 
the apical membrane (178.31±9.58 ng/ml, P < 0.001) compared to only cisplatin. Compared to 
apical membrane, NGAL levels in the basolateral membrane were low. 
After 48h treatment of cisplatin, the amount of NGAL in the apical membrane did rise 
significantly from the control (1910.42±205.1 ng/ml, P < 0.01). However, the presence of 
cimetidine did not change NGAL level 407.16±33.67 ng/ml compared to control 406.88±91.31 
ng/ml. The co-treatment of cisplatin with cimetidine caused a significant decline in NGAL in 
the apical membrane (890.28±126.72 ng/ml, P < 0.001) compared to only cisplatin NGAL 



























































































Figure 5.21: The amount of NGAL produced after treatment of rat PTCs for 24 and 48 hours 
in presence of cisplatin +/- cimetidine. 
ELISA was used to measure NGAL production. For example, NGAL production in the apical 
membrane is significantly higher than basolateral membrane. The amount of NGAL in the 
apical membrane change significantly from the control (114.12±5.83 to 330.61±22.37 ng/ml, P 
< 0.01) after 24h cisplatin treatment. After co-treatment with cimetidine, NGAL level decreased 
to (178.31±9.58 ng/ml, P < 0.001) compared to only cisplatin. The level of NGAL after 48h 
treatment was more than 6 fold compared to 24h. Statistical analysis was conducted using 
repeated-measures-paired-one-way ANOVA the data are representative of three independent 
experiments (n=3). Bars represent mean ± S.E.M values of each group. (*p < 0.05, **p < 0.01, 
***p < 0.001, ++++p < 0.0001).  
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5.5 Discussion  
Nephrotoxicity is a major adverse effect of many drugs on the market. Multiple toxic 
compound tests are used in vivo, cost-effective, practical and expedient in vitro tests that 
support the predictive early toxicity of the big amounts of compounds ahead of in vivo 
tests.[145] while many nephrotoxicity biomarkers have been assessed and implemented in 
preclinical and clinical studies, at an early screening point, they are rarely examined in vitro. 
We explored the potential of nephrotoxicity biomarkers in rat PTCs an in vitro screening model 
in this chapter and compared the predictive results of nephrotoxicity biomarkers. KIM-1 and 
NGAL were further investigated in PTCs, which were freshly isolated from rat kidney. High 
doses of gentamicin, polymyxin B and cisplatin-induced significant upregulation of KIM-1 and 
NGAL levels within 24h and 48h.  
5.5.1 MTS and ATP 
In this study, one further goal was to compare MTS and ATP assay results from rat PTCS treated 
with different nephrotoxins. Similarities in the viability data from both assays were found, 
similar results were expected as mitochondrial enzymes reduce the reagents from both MTS 
and ATP. For example, percentage of live cells using MTS assay after 250 µg/ml polymyxin B 
treatment for 24h was 74.52% and after using APT assay was 69.7%. There were only 5% 
difference between the two assays, suggesting the reproducible of our in vitro rat PTCs model 
by using different types of cell viability assays.  
5.5.2 LDH 
On the other hand, percentage of dead cells were quantified by measuring the LDH release 
from rat PTCs after nephrotoxins treatment for 24 and 48 hours. A study done showed, LDH 
release from mice primary PTCs after 50 µM cisplatin treatment was 40% compared to only 
8% of control cells and the co treatment with caspase inhibitor reduce the LHD percentage to 
13.5%[146].    
In this chapter, the viability of rat PTCS was analysed during exposure to different nephrotoxins 
for 24, 48 and 72 hours. Using our rat PTCs model, our data shows that nephrotoxins used are 
cytotoxic in vitro in a dose-and time-dependent manner and this was directly proportional to 
drug accumulation.    In the dose-response study, KIM-1 and NGAL produced from rat PTCs are 
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very sensitive to the renal injury produced by different nephrotoxins (gentamicin, polymyxin 
and cisplatin).  Gentamicin accumulates in rat PTCs, resulting in structural modifications and 
functional impairment of the plasma membrane, mitochondria and lysosome [147]. Compared 
with a recent study observing increases of KIM-1/urinary creatinine levels in patients after 72h 
of Polymyxin B exposure, they observed significant accumulation of KIM-1 and NGAL at both 
24 and 48 hours of exposure, demonstrating the sensitivity of the rat PTCs model to detect 
early injury [148]. Our results demonstrate the potential of KIM-1 as well as NGAL to be 
significantly induced for detection of nephrotoxicity in a sensitive and timely manner.  
5.5.3 Rat Biomarkers 
The cellular toxicity of gentamicin was monitor after treated rat PTCs for 24 and 48 hours. For 
example, after treatment with 250 µg/ml gentamicin for 24h, the level of KIM-1 significantly 
increased (10.31±0.72 ng/ml, P < 0.001) compared to control (3.86±0.28 ng/ml). In addition, 
after 48h the level of KIM-1 increased to 28.70±0.50 ng/ml.     
Around 80% of the gentamicin dose is excreted by glomerular filtration into the urine within 
24h. However, accumulation within the kidney cortex continues high relative to other bodies, 
particularly in the proximal tubule epithelial cells (5–10% dose)[149]. In the pathogenesis of 
nephrotoxicity, this is considered significant[150]. It has been shown that receptor-mediated 
endocytosis binding of gentamicin to the multi-ligand receptor, megalin, and cellular uptake is 
the main pathway for accumulation. The abundant adverse charges on the extracellular 
receptor domain facilitate interactions among polybasic substances like gentamicin[151]. 
After therapy with gentamicin, a study noted upregulation of mRNA expression of KIM-1 and 
NGAL in rats in the lack of impacts of nephrotoxicity on traditional clinical chemistry markers. 
These rise were apparent 1 day after gentamicin was handled and lasted 3 to 7 days. The timing 
and degree of reaction were well associated with the severity of tissue injury. 
Immunohistochemistry subsequently verified changes in protein expression. They found that 
KIM-1 and NGAL expressions occur within 1 day of gentaimcin's treatment acknowledge that 
these two biomarkers reflected renal injury quicker and more precisely than SCr and BUN[121].  
In this chapter demonstrating that cilastatin, a particular tubular brush-border DHP-I inhibitor, 
attenuates in vitro nephrotoxicity caused by gentamicin. The pre-treatment of 40 µM cilastatin 
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before treated the rat PTCs with gentamicin decrease the production of nephrotoxins 
biomarkers (KIM-1 and NGAL). For instance, NGAL production after gentamicin treatment for 
48h was 400.6 ng/ml and after co-treatment with cilastatin NGAL level decrease to 251.3 ng/ml 
suggesting the role of cilastatin of preventing the nephrotoxicity of gentamicin.   The results 
are consistent with another study suggest cilastatin inhibit the binding of megalin with 
polymyxin B and gentamicin. The same study showed that cilastatin suppresses colistin-
induced nephrotoxicity through competition for binding to megalin [73].   
Polymyxin B used as a nephrotoxic drug and the levels of KIM-1 and NGAL were measured after 
the exposure rat PTCs.  Our results showed a significant increase in biomarkers levels after 
polymyxin B treatment compared to non-treated cells. In addition, rosuvastatin used as co 
treatment against polymyxin B nephrotoxicity and the data showed the reduction in the levels 
of biomarkers production in comparison to only polymyxin B incubation. KIM-1 level after 250 
µg/ml polymyxin B treatment for 24h was 5.42 ng/ml compare to 1.58 ng/ml for control cells. 
However, after the co-treatment with rosuvastatin the production of KIM-1 reduce to 2.76 
ng/ml showing a possible protective process against polymyxin B nephrotoxicity.   
   Our hypothesis that statins, are inhibiting megalin-mediated endocytosis, would inhibit 
uptake of polymyxin B, and therefore decrease nephrotoxicity in PTCs. This hypothesis was 
tested in vitro study using an OK cell model but with gentamicin not polymyxin B[152]. The 
synthesis of cholesterol in OK cell was shown to be inhibited by statins (simvastatin, 
pravastatin, and rosuvastatin).They also led to dose dependent inhibition of gentamicin 
accumulation and cytotoxicity, which were related to the degree of GTP-binding protein 
unprenylation[152].  
One of the nephrotoxic drugs used in this study is cisplatin. Rat PTCs treated with 25 µM 
cisplatin for 24 and 48 hours and KIM-1 and NGAL biomarkers were measured. The production 
of KIM-1 after 24h treatment with cisplatin was 2.51±0.18 ng/ml and the NGAL production was 
330.6±22.3 ng/ml. Furthermore, co treatment with cimetidine was measured. The results 
showed a reduction of biomarkers production after cisplatin treated with cimetidine compared 
to only cisplatin. For example, NGAL level after cisplatin treatment for 48h was 1910.4±205.1 
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ng/ml and the level dropped significantly to 890.2±126.7 ng/ml after the co treatment with 
cimetidine.        
In the original clinical trials of cisplatin chemotherapy, nephrotoxicity was reported. The 
intracellular transport mechanism of cisplatin is not evident and vary between cells. A research 
showed that removal of Ctr1, a highly affinity copper transporter, reduces cisplatin 
intracellular accumulation in yeasts, which is linked to enhanced cisplatin toxicity 
resistance[65]. The same findings show that copper transporters are allowed for cisplatin in 
mouse cell lines, lacking either one or two Ctr1 alleles. In the renal system, however, cisplatin 
is taken by organic cation transporters (OCTs)[153]. OCTs mediate the transport of several 
cationic compounds into renal tubular cells from basolateral to apical compounds. A research 
showed that cisplatin caused greater toxicity in MDCK cells  in apical side implementation when 
applied on the basolateral side[67]. These findings show that tubular cell injury caused by 
cisplatin may be linked with OCT2. In particular, cimetidine, an OCT inhibitor, could partly stop 
cytotoxicity caused by cisplatin by decreasing transepithelial electrical resistance[110]. 
Another study showed, cimetidine obviously inhibits cisplatin-induced nephrotoxicity or 
kidney cell damage with no impact on cisplatin in vitro or in vivo antitumor activities [154]. 
Although cimetidine's in vitro actions were mainly due to inhibition the production of ROS, the 
in vivo protective impact of cimetidine on cisplatin's nephrotoxicity seems to be due to both 
inhibitory actions in ROS manufacturing and OCT2 expressed intrinsically in the kidney[127].  
The concentration of the biomarkers was more in the apical membrane than in the basolateral 
membrane. Such findings predicted and represented what's really happening in vivo. Those 
biomarkers are detectable in urine. NGAL is upregulated and can be detected in the kidney and 
urine of mice three hours after treatment with cisplatin, and a good nephrotoxicity biomarker 
has been suggested [133]. Due to the leakage of the cells, the significant in the basolateral 
membrane was expected and lost their integrity after treatment with drugs. 
These findings may reflect what is really happen in vivo. The findings suggest new possibilities 
for early prediction of nephrotoxicity by measuring the production of KIM-1 and NGAL when 
the kidney exposed to different drugs. The rat data is almost consistent with human data, this 
may show the possibility of using rat PTCs model in to investigate nephrotoxic drugs. However, 
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more drugs are still need to examine and more biomarker need to screen to confirm this 
finding. Our data showed cilastatin, rosuvastatin and cimetidine could be a good co-treatment 




6 Measurement of cisplatin apoptosis activity 
6.1 Introduction  
Nephrotoxicity of cisplatin may occur in a variety of forms, for example, distal renal tubular 
acidosis, renal concentrating defect and chronic renal failure. However, the most severe and 
frequent occurrence in 20–30 % of patients is acute renal injury (AKI) [63]. Evidence of 
basolateral to apical transportation of cisplatin has been provided in previous studies using 
kidney slices, cultures of renal epithelial cells and isolated perfuse proximal tubule 
segments[155]. The nephrotoxicity mechanisms of cisplatin are complicated and require many 
pathways and molecules. Using newly isolated or cultured renal tubular epithelial cells, cellular 
pathways of cisplatin injury to kidney cells were mainly examined in vitro [156].  In vitro, low 
cisplatin levels preferably lead to apoptotic death, whereas necrosis occurs at greater 
concentrations [111]. In vivo administration of nephrotoxic cisplatin doses results in a 
significant rise in necrosis and apoptosis in the kidney [63].  
Apoptosis is programmed cell death, includes the regulated dismantling of the intracellular 
elements while the adjacent cells are prevented from inflammation and harm[157]. Cisplatin 
has been found to cause cancer cell death by apoptosis as well as many chemical agents and 
it is interesting to determine if apoptosis is also the mechanism of cell death in a nephrotoxic 
injury[158]. Strategies can be created to minimize or stop nephrotoxicity by increasing a 
knowledge of the particular mechanisms responsible for nephrotoxic cell injury. 
P53 can be one of the pathways for cell killing triggered by cisplatin [159]. P53 can induce 
apoptosis by transcription of proapoptotic genes or by direct interaction and activation of 
existing proapoptotic molecules, as a tumour suppressing protein[160]. P53 is activated by 
cisplatin in cultured renal tubular cells[161]. P53 can upregulate proapoptotic genes including 
apoptosis-α modulator p53-upregulator, resulting in the permeability of mitochondrial outer 
membrane and release of apoptogenic factors, including cytochrome c and inducing apoptosis 
factor[162]. However, it is not clear yet how is p53 cause nephrotoxicity in vivo.   
Caspase activation is considered important in apoptosis, and a large number of stimuli activate 
caspases, including plasma membrane death receptors (caspase8) and mitochondrial 
dysfunction (caspase9)[161]. Initiator caspases include caspases 8 and 9, and activation of 
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those caspases results in activation of downstream and executioner caspases such as caspases 
3 and 7[163]. 
The goal of this chapter is the quantification of a variety of proteins that influence apoptosis 
(p53, caspase 3, caspase 8 and caspase 9) after treatment of human and rat PTCs with cisplatin. 
The expressions will be quantified at the protein and mRNA levels, using caspase-Glo® 3/7 
Assay and qPCR respectively. The results will provide an indication of the molecular mechanism 
of apoptosis in PTCs after cisplatin treatment. The purpose of this chapter is to use human and 




6.2 Caspase-Glo® 3/7 Assay 
Caspase-3/7 activity was detected using a Caspase-Glo 3/7 assay system after treated human 
PTCs with different nephrotoxins (cisplatin, polymyxin B and gentamicin) for 48h. The results 
are shown in Figure 6.1.  
The results revealed that caspase 3/7 activity increased significantly in response to exposure 
to cisplatin to 5.64±0.63% of control. The polymyxin B treatment did increase but not 
significantly the 3/7 activity (1.55±0.29%). The treatment of gentamicin increased the 3/7 


























































Figure 6.1: Caspase 3/7 activity after treated human PTCs with cisplatin, polymyxin B and 
gentamicin for 48h.  
Caspase-Glo 3/7 assay system was used to measure the caspase activity. Activity is measured 
as a percentage of the control. Caspase 3/7 activity increased significantly in response to 
exposure to cisplatin to 5.64±0.63% of control. The treatment of gentamicin increased the 3/7 
activity cells compared control (3.35±0.77%). Statistical analysis was conducted using 
repeated-measures-paired-one-way ANOVA the data are representative of three independent 
experiments (n=3). Bars represent mean ± S.E.M values of each group. (*p < 0.05, **p < 0.01, 




6.3 The mRNA level of caspase 3, 8, 9 and p53 after treatment of human PTCs with 
cisplatin +/- cimetidine 
To investigate the mRNA levels of caspase 3 in the presence of cisplatin, the cell total RNA of 
human PTCs were isolated and screened. The results are shown in Figure 6.2, which are 
normalised to the reference gene GAPDH.  
mRNA level of caspase 3 appeared to be increased significantly (P< 0.01) with the treatment 
of cisplatin (3.51±0.34%) compared to control. In addition, cimetidine did not change caspase 
3 mRNA levels significantly, its co-treatment with cisplatin did decrease caspase 3 mRNA levels 
significantly to (2.45±0.32, P< 0.05) when compared only cisplatin treatment. 
mRNA level of caspase 8 increased significantly with the treatment of cisplatin compared to 
control (3.06±1%, P< 0.01). In addition, cimetidine did not change caspase 8 mRNA levels 
significantly, its co-treatment with cisplatin did decrease caspase 8 mRNA levels significantly 
to (1.76±0.48, P< 0.05) when compared to cisplatin alone. 
mRNA level of caspase 9 increased significantly with the treatment of cisplatin compared to 
control (2.47±0.30%, P< 0.01). Furthermore, cimetidine has not changed caspase 9 mRNA level, 
its co-treatment with cisplatin has considerably reduced caspase 9 mRNA level to (1.90±0.36, 
P<0.05) compared to cisplatin alone. 
After cisplatin treatment, the mRNA level of p53 increased significantly compared to control 
(7.30±1.25%, P< 0.01). Furthermore, cimetidine has not changed p53 mRNA level, its co-
treatment with cisplatin has considerably reduced p53 mRNA level to (3.99±1.75, P<0.05) 





Figure 6.2: The mRNA level after treatment of human PTCs in presence of cisplatin +/- 
cimetidine.  
(A)  (B) Caspase 8 (C) Caspase 9 (D) p53.mRNA is measured as a percentage of the control. For 
example, after cisplatin treatment, the mRNA level of p53 increased significantly compared to 
control (7.30±1.25%, P< 0.01). Furthermore, cimetidine has not changed p53 mRNA level, its 
co-treatment with cisplatin has considerably reduced p53 mRNA level to (3.99±1.75, P<0.05) 
compared to only cisplatin treatment. Statistical analysis was conducted using repeated-
measures-paired-one-way ANOVA the data are representative of three independent 
experiments (n=3). Bars represent mean ± S.E.M values of each group. (*p < 0.05, **p < 0.01, 
+++p < 0.001).  
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6.4  The mRNA level of caspase 3, 8, 9 and p53 after treatment of rat PTCs with 
cisplatin +/- cimetidine 
The total RNA from rat PTCs was separated and screened in order to explore the mRNA 
expression of caspase 3 after cisplatin treatment. The results are shown in Figure 6.3, which 
are normalised to the reference gene GAPDH.   
mRNA level of caspase 3 appeared to be increased significantly (P< 0.001) with the treatment 
of cisplatin (3.35±0.12%) compared to control. In addition, cimetidine did not change caspase 
3 mRNA levels significantly, its co-treatment with cisplatin did decrease caspase 3 mRNA levels 
significantly to (2.19±0.51, P< 0.001) when compared to only cisplatin treatment. 
mRNA level of caspase 8 increased significantly with the treatment of cisplatin compared to 
control (4.40±1.03%, P< 0.001). In addition, cimetidine did not change caspase 8 mRNA levels 
significantly, its co-treatment with cisplatin did decrease caspase 8 mRNA levels significantly 
to (2.67±0.65, P< 0.001) when compared to cisplatin alone. 
mRNA level of caspase 9 increased significantly with the treatment of cisplatin compared to 
control (3.35±0.58%, P< 0.001). Furthermore, cimetidine has not changed caspase 9 mRNA 
level, its co-treatment with cisplatin has considerably reduced caspase 9 mRNA level to 
(1.92±0.48, P<0.01) compared to only cisplatin. 
After cisplatin treatment, the mRNA level of p53 increased significantly compared to control 
(3.19±0.44%, P< 0.001). Furthermore, cimetidine has not changed p53 mRNA level, its co-
treatment with cisplatin has considerably reduced p53 mRNA level to (2.25±0.61, P<0.05) 





Figure 6.3: The mRNA level after treatment of rat PTCs in presence of cisplatin +/- cimetidine.  
(A) Caspase 3 (B) Caspase 8 (C) Caspase 9 (D) p53. mRNA is measured as a percentage of the 
control. For example, mRNA level of caspase 3 appeared to be increased significantly (P< 0.001) 
with the treatment of cisplatin (3.35±0.12%) compared to control. In addition, cimetidine did 
not change caspase 3 mRNA levels significantly, its co-treatment with cisplatin did decrease 
caspase 3 mRNA levels significantly to (2.19±0.51, P< 0.001) when compared to only cisplatin 
treatment.  Statistical analysis was conducted using repeated-measures-paired-one-way 
ANOVA the data are representative of three independent experiments (n=3). Bars represent 
mean ± S.E.M values of each group. (*p < 0.05, **p < 0.01, +++p < 0.001).  
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6.5 Discussion  
Cisplatin is one of the most common chemotherapeutic agents to treat testes and bladder, 
head and neck, ovarian, breast, pulmonary cancers, and refractory lymphoma non-
Hodgkin[164]. Nephrotoxicity is the significant adverse effect of cisplatin use in which proximal 
cells in the kidney are particularly susceptible. Its anticancer activity is likely to depend on the 
formation of intrinsic DNA links [63].  A number of different mechanisms for kidney tubule 
cisplatin cytotoxicity were suggested, including direct DNA damage, caspase activation, 
mitochondrial dysfunction, reactive oxygen formation species, effects on the endoplasmic 
reticulum, and TNF-α apoptotic pathway activating[165]. The purpose of this chapter was to 
determine the cisplatin apoptosis mechanism by using our human and rat proximal tubule 
models.  
In this chapter, caspase 3/7 was measured after human PTCs treated with different 
nephrotoxins. Our results significant increase in caspase 3/7 activity compared to control cells 
after cisplatin and gentamicin treatments. However, there was increase after polymyxin B 
treatment. It might suggest gentamicin has the same apoptosis mechanism like cisplatin. A 
study used NRK-52E cells (rat renal proximal tubular cell line) showed after, a significant 
increase in caspase 3 and caspase 8 after gentamicin treatment, indicting  gentamicin trigger 
the apoptosis mechanism in PTCs[166].      
In order to evaluate the cisplatin apoptosis mechanism in PTCs, this chapter results detected 
the expression of caspase-3, 8, 9 and p53 at the mRNA levels after treated human and rat PTCs 
with cisplatin and we used cimetidine as a co treatment. After cisplatin exposure, the mRNA 
levels of caspase 3, 8, 9 and p53 were increased compared to no treated cells. For instance, 
mRNA expression of caspase 3 after rat PTCs treated with cisplatin was 3.35% and after the co 
treatment with cimetidine the level reduced to 2.19%. Furthermore, human PTCs cells treated 
with cisplatin and mRNA level p53 was 7.30% and with cimetidine co-treatment the mRNA 
level dropped to 3.99%.           
A study showed p53 activation by cisplatin in cultured renal tubular cells[161]. DNA damage is 
induced by cisplatin and then enzymes like telangiectasis-mutated ataxia (ATM) are activated 
to cause p53 phosphorylation[167]. Cisplatin has been discovered to reduce taurine 
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transporter gene (TauT) expression in proximal tubular kidney cells by activating p53[162]. 
TauT's overexpression also has been shown to prevent transgenic TauT's cisplatin-related 
apoptosis and renal dysfunction. By attenuating the p53-dependent pathway, functional TauT 
can stop cisplatin-induced nephrotoxicity[168]. Activated p53 is present for cisplatin-induced 
AKI and cisplatin-induced AKI for p53 inhibition may decrease. The inhibition of p53, however, 
may also boost cancer cell survival and thereby reduce cisplatin therapeutic 
effectiveness[165].  
Inhibition of caspase prevents the cultured cells from apoptosis caused by cisplatin. In vitro 
cisplatin-induced AKI, the function of caspase-3 and apoptosis is more complicated. In vivo, 
besides tubular apoptosis, cisplatin causes comprehensive acute tubular necrosis (ATN). The 
absence of a direct role of caspase- 3 mediated apoptosis as a cause of functioning disruptions 
of AKI has not been noted to protect against cisplatin-induced AKI[169].  
Recently, cisplatin therapy in kidney proximal tubular cells has shown that caspase-3 is 
activated. However, no data is provided regarding the particular functions and the underlying 
signalling pathway processes responsible for regulating downstream caspase-3 and other 
upstream caspases that may be activated in renal tubular epithelial cells during cisplatin-
induced injury. A research showed that cisplatin leads to selective and differential activation 
of caspase, not proinflammatory caspase-1, but including the executioner caspase-3 and the 
initiator caspase-8 and -9[170]. The selective activation of these caspases was significantly 
affected by their corresponding peptide inhibiting agents and suggests that these caspases 
play a significant role in a renal tubular epithelial cell injury caused by cisplatin [171]. 
Therefore, the amount of cell injury induced by the toxic agent depends on how well the toxic 
agent activates caspases and on the induction of signals of survival that block the caspase 
activation. The data presented in this chapter demonstrate that cisplatin treatment triggers 
caspase activation, but also causes increase of p53 mRNA levels in both human and rat PTCs. 
In addition, the co-treatment with cimetidine showed a reduction in mRNA levels of caspases 
and p53 in both species, suggesting the role of cimetidine for decreasing the nephrotoxicity of 
cisplatin.     
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7 Final discussion and Conclusion  
The kidney is an essential organ which the body needs to perform many important functions, 
including homeostasis sustaining, extracellular environment control, such as detoxification, 
and toxic metabolism and drugs excretion [165, 172]. The kidney can therefore be treated as 
a major target site for exogenous toxicants. Drug transporters expressed in the PTCs are 
identified as one of the key factors in the organ's ability to perform its function 
successfully[173]. There are numerous renal drug transport models in vitro, but mostly do not 
express the width of transporters to establish good correlations with in vivo [174]. In 
recognition of this issue, regulatory authorities demanded that alternative in-vitro-cell-based 
testing be established to minimize or replace existing animal testing. Nephrotoxicity is 
estimated to be 8% of pre-clinical safety failures and 9% of safety failures in the drugs clinical 
trials [175]. The aim of my PhD project is the development of rat and human primary proximal 
tubule cell models as predictive in-vitro models of proximal tubule drug handling.  
The results from chapter 3 showed, human and rat PTCs were successfully isolated and 
cultured. The mRNA and functional expressions of drug transporters, such as OCT2, Mrp2, Oat1 
and mdr1a/b, found in the native tissue were retained in the cells. In addition, the expression 
of megalin and cubilin receptors were also detected in both human and rat PTCs. This is 
important as these transporters influence renal drug disposition [176], and their expression 
would enhance the utility of the human and rat PTC as an in vitro model of renal drug transport. 
Furthermore, in chapter 3 albumin uptake was measured in human and rat PTCs to show the 
functional expression of megalin and cubilin receptors by using albumin-FITC as a tracer 
substrate. In addition FITC-albumin was measured after polymyxin B incubated for the time as 
albumin. The data showed, polymyxin B is may enter the PTCs by megalin/cubilin endocytosis 
process. The amount of FITC- albumin is significantly less after polymyxin B treatment 
compared to control cells. This results were shown in both human and rat PTCs. This may be 
due to the competitive between albumin and polymyxin B to enter the PTCs by using megalin 
and cubilin receptors. The proximal tubular re absorption of gentamicin is linked to megalin, a 
study with megalin deficient mice[177]. Another study also showed that colistin (structural 
similar to polymyxin B) is a megalin ligand and that megalin plays a major role in the uptake of 
colistin [178].   Further characterisation of the human and rat PTCs model was also performed. 
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Results of the handling of creatinine by rat PTCs monolayer. The uptake was more in the 
basolateral membrane than apical membrane, and the same was human PTCs monolayer. This 
indicated the suitability of both species as models for renal creatinine transport. However, 
after adding dolutegravir (OCT2 inhibitor), creatinine was significant in rat PTCs but not in 
human PTCs.     
Chapter 4 showed the results of exposure of human PTCs to nephrotoxins. There were two 
types of drugs used in this chapter. Large molecules include, gentamicin and polymyxin B and 
cisplatin as a small molecule. The purpose of using different sizes is to show the ability of our 
in vitro model to detect the nephrotoxicity of any drug. Furthermore, 3 biomarkers (KIM-1, 
NGAL and clusterin) were measured successfully after nephrotoxins treatment. Those 
biomarkers gives us an early prediction of nephrotoxicity. The results showed the time and 
concentrations dependant of the all 3 drugs used in this chapter. For example, after 100 µg/ml 
gentamicin for 24h the KIM-1 level was 7.7±1.7 ng/ml and after 48h incubation the level rose 
to 14.8±2.5 ng/ml. In addition, KIM-1 production after 300 µg/ml gentamicin for 72h was 
63.6±15.4 ng/ml and after 500 µg/ml gentamicin treatment increased to 235.66±12.8 ng/ml. 
To show the reproducibility of the human PTCs model, two cell viability assay (MTS and ATP) 
were used to measure the percentage of live cells after nephrotoxins treatment. When 
comparing between the results, we can see how similar the data is. For example, MTS 
percentage after 25 µM cisplatin treatment for 48h was 61.1% and ATP was 58.1%. The 
similarity between the two assays indicate that we could use any cell viability assay to measure 
number of live cells after nephrotoxins treatment. In chapter4, results showed after the use of 
co-treatment (cilastatin, rosuvastatin and cimetidine) our in vitro model could be a good model 
for finding ways to reduce the nephrotoxicity of some drugs. The results showed the reduction 
of all 3 biomarkers production after the co-treatment compared to only nephrotoxins. This 
suggest the role of these co-treatment for protecting the human PTCs from damaging by drugs. 
However, even the actual mechanism of preventing the nephrotoxicity is not clear and more 
investigation is needed.  
In chapter 5, rat PTCs were isolated and grown successfully. Gentamicin, polymyxin B and 
cisplatin used to treat our rat PTCs.  After exposure to those nephrotoxins, measuring the 
expression of different nephrotoxicity biomarkers, such as KIM-1 and NGAL were done. All 
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nephrotoxins were treated in a range of concentrations to monitor the time and concentration 
of those drugs by using our in vitro model. An example, confluent monolayers of rat PTCs were 
treated with a range concentrations of polymyxin B (50 to 600 µg/ml). After 24h of treatment 
with 250 µg/ml polymyxin B the percentage of live cells was 72.5% and after 400 µg/ml 
polymyxin B exposure the percentage dropped to 48.1%. In addition, after 100 µg/ml 
polymyxin B treatment for 48 and 72 hours the cell viability were 71.2% and 60.8% 
respectively. In addition, the measurement of KIM-1 and NGAL were quantified after 
nephrotoxins were treated for 24, 48 and 72 hours with a range of concentrations. MTS and 
ATP were measured after nephrotoxins treatment and normalised to control cells. The results 
showed the similarity between the 2 assays. This determine the reproducibility of our rat PTCs 
by using any cell viability assay. In addition, LHD were measured after nephrotoxins incubation 
to quantify the damage PTCs. The data was consistent with cell viability data. This is a good 
indication of our in vitro model, the ability of grow the rat PTCs and treat the PTC monolayers 
with different nephrotoxins and measure the live cells and the damage cells as well. In rat PTCs, 
KIM-1 and NGAL were measured but not clusterin like human PTCs. This is due to the high cost 
of rat clusterin kit and it is hard to afford it.   
The study of cisplatin nephrotoxicity mechanism has been studied in chapter 6.  The cisplatin 
concentration decides if the cells die from necrosis and apoptosis [111]. High concentrations 
of cisplatin in cell culture experiments induce necrotic cell death while lower doses result in 
apoptosis[165]. Cisplatin triggered p53 in cultured renal tubular cells[161]. mRNA were 
isolated from human and rat PTCs and expression of p53 were done after cisplatin treatment. 
Our results showed the increase expression of p53 after cisplatin treatment compared to 
control cells.  In addition, co-treatment with cimetidine showed a reduction in p53 expression, 
may suggesting the role of p53 in cisplatin apoptosis in both human and rat PTCs. Activation 
of caspases is considered a key phase in apoptosis mechanism. A research in renal cell lines 
undergoing cisplatin induced apoptosis has shown that the release of cytochromes from 
mitochondria activate the caspase 3 by caspase 9 [179]. Our data showed caspases 3, 8 and 9 
mRNA levels were significantly high compared to control cells. P53 and caspases may have a 
role in cisplatin apoptosis in human and rat PTCs and further investigation is needed.      
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  Rat and human PTC are not limited only to work on the transport of drugs and drugs 
interactions. Different studies have confirmed the suitability of rat and humans as in-vitro 
models of nephrotoxicity proximal tubular cell cultures [180, 181]. Nevertheless, the limited 
life cycle of human and rat PTCs is a drawback of their use in nephrotoxicity studies. In our 
project human and rat PTCs were grown successfully. Nephrotoxicity biomarkers were 
measured in both species. The biomarkers data is almost identical in both human and rat PTCs. 
However, this is does not mean both human and have the interaction to nephrotoxins drugs. 
In this study, only 3 drugs were used and only 3 biomarkers were measured. Further work on 
the use of human and rat PTCs in other areas of drug development is also needed. 
There are some challenges in our in vitro model in order to quantify the production of 
nephrotoxicity biomarkers. The short time life of PTCs were grown does not give us enough 
time to test out nephrotoxins drugs for longer time. The levels of biomarkers were normalised 
to the amount percentage change of live cells in compared to control cells. This is was done to 
show the production of biomarkers is based on numbers of live cells. Cell viability data were 
measure to determine the compatible with biomarkers data. The level of biomarkers produced 
after nephrotoxins exposure is different based on the physiological condition of the kidney 
used and biomarkers are produce as an immune response to a harmful. So, there is a need to 
use an internal control in each kidney used to quantify the biomarkers levels.   Equally 
important, reference values of biomarkers has to be identified for routine use in clinical 
practice, especially in the early stage of kidney damage. 
Culture cells in a 3D setting are becoming more and more involved and have been found in rat 
and human PTC culture. This includes using the flow medium to replicate what happen in vivo, 
the motion of basolateral and apical fluid. This provides an interesting expansion of the model 
for more drug transporters and drug interaction studies. Research group designed human 3D 
PTCs. There data showed that, 3D PTCs tissues could have a positive impact on the pre-clinical 
drug discovery process and help prevent costly failures in late-stage clinical trials. Treatment 
of 3D proximal tubular tissue with cisplatin resulted in dose-dependent loss of live cells and 
epithelial cells, and cimetidine rescued these results, confirming the role of the OCT2 
transporter in the nephrotoxicity caused by cisplatin. The tissue also displayed a fibrotic 
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response to TGFβ as determined by increased gene expression associated with human fibrosis 
and histological analysis of excess matrix deposition in extracellular cells [182]. 
Developing in vitro models to reliably predict the nephrotoxicity of potential pharmacological 
agents requires a solid understanding of the basic cellular targets and consequences of 
nephrotoxicants, as well as robust and reliable nephrotoxicity mechanistic biomarkers[183]. 
A golden in vitro model for nephrotoxicant evaluation has historically been represented by 
two-dimensional cultures of primary or conditionally immortalised renal epithelial cells. 
Pharmaceutical researchers have for many years concentrated on pharmaceutical metabolism 
pathways research for new molecular entities (NMEs) as a framework for studying 
pharmacokinetic processes and causes of inter-individual variation in pharmacokinetics and 
pharmacodynamics. It has recently become apparent that transporters play a major role in 
pharmacokinetics and are, together with drug-metabolizing enzymes, the main determinants 
of both the degradation of hepatic and renal drugs[184].  In our PTCs model we are be able to 
detect drugs transporters and we did some functional experiments to those transporters. Our 
model may be useful for drugs companies to test for nephrotoxicity of drugs and their 
molecular cause of cell deaths to renal epithelial cells.   Nephrotoxicants cause injuries by 
choosing specific cell types or, depending on the mechanism of their action, by intentionally 
injuring several cell types within the kidney[185].  
Human and rat PTCs are validated as physiologically relevant proximal tubular models in the 
kidney and demonstrated as predictive methods for the handling of renal drugs. KIM-1, NGAL 
and clusterin were increased to response to nephrotoxins drugs treatment and they can used 
as a predictive biomarkers for nephrotoxicity.  The implications of these findings should be 
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